Skip to content
Snippets Groups Projects

Compare revisions

Changes are shown as if the source revision was being merged into the target revision. Learn more about comparing revisions.

Source

Select target project
No results found

Target

Select target project
  • 2024/bielefeld-cebitec
  • l-sanfilippo/bielefeld-ce-bi-tec-temp
2 results
Show changes
Hide whitespace changes
Inline Side-by-side
Showing
with 9443 additions and 660 deletions
src/contents/Human Practices/Further Engagement/FurtherEngagement.tsx 0 → 100644
View file @ 3fd292fd
import { Section, Subesction } from "../../../components/sections";
import { useTabNavigation } from "../../../utils/TabNavigation";
import { HPCollabs } from "./Collaborations";
import { HPEducation } from "./Education";
import { HPEntrepreneur } from "./Entrepreneurship";
import { HPOutreach } from "./Outreach";
import { HPPartnerships } from "./Partnerships";
export function HPFurtherEngagement(){
useTabNavigation();
return(
<Section title="Further Engagement" id="Further Engagement">
<Subesction title="Education" id="Further Engagement1">
<HPEducation/>
</Subesction>
<Subesction title="Public Engagement" id="Further Engagement2">
<HPOutreach/>
</Subesction>
<Subesction title="Entrepreneurship" id="Further Engagement3">
<HPEntrepreneur/>
</Subesction>
<Subesction title="Collaborations" id="Further Engagement4">
<HPCollabs/>
</Subesction>
<Subesction title="Partnerships" id="Further Engagement5">
<HPPartnerships/>
</Subesction>
</Section>
)
}
\ No newline at end of file
src/contents/education.tsx → src/contents/Human Practices/Further Engagement/Outreach.tsx
View file @ 3fd292fd
import { ButtonOne } from "../../../components/Buttons";
import { H4 } from "../../../components/Headings";
import { useTabNavigation } from "../../../utils/TabNavigation";
import { useNavigation } from "../../../utils/useNavigation";
import { ButtonOne} from "../components/Buttons";
import { useEffect } from "react";
import { useLocation } from "react-router-dom";
import { useNavigation } from "../utils/useNavigation";
export function Education() {
const { goToPagesAndOpenTab/* , goToTextsAndOpenCollapsible */ } = useNavigation();
const location = useLocation();
useEffect(() => {
const params = new URLSearchParams(location.search);
const collapseId = params.get('collapseId');
const tabId = params.get('tab');
// Open the tab specified by tabId
if (tabId) {
// Hide all tabs
const tabs = document.querySelectorAll('.cycletab');
tabs.forEach((tab) => {
(tab as HTMLElement).style.display = 'none';
});
// Show the selected tab
const selectedTab = document.getElementById(tabId);
if (selectedTab) {
selectedTab.style.display = 'block';
}
}
// Scroll to the section specified by collapseId after opening the tab
if (collapseId) {
const collapseElement = document.getElementById(collapseId);
if (collapseElement) {
const elementTop = collapseElement.getBoundingClientRect().top + window.pageYOffset;
const offset = window.innerHeight / 2 - collapseElement.offsetHeight / 2;
const scrollPosition = elementTop - offset;
window.scrollTo({
top: scrollPosition,
behavior: 'smooth',
});
}
}
}, [location.search]);
return (
<>
<div>
<h2>Interviews Page</h2>
{/* <a onClick={() => goToTextsAndOpenCollapsible("symptoms-collapsible", "/description?collapseId=")}>
Go to Texts and Open Collapsible 1
</a> */}
</div>
<div className="row align-items-center" style={{marginTop: "5vh", marginBottom: "5vh"}}>
export function HPOutreach(){
const { goToPagesAndOpenTab } = useNavigation();
useTabNavigation();
return(
<div className="col">
<ButtonOne text="Overview" open="overview"></ButtonOne>
<div className="row align-items-center" >
<div className="col ">
<ButtonOne openclass="out-cycletab" text="Overview" open="out-overview"></ButtonOne>
</div>
<div className="col">
<ButtonOne text="MukoMove" open="mukomove"></ButtonOne>
</div>
<div className="col">
<ButtonOne text="Teuto ruft!" open="teutoruft"></ButtonOne>
<div className="col ">
<ButtonOne openclass="out-cycletab" text="MUKOmove" open="mukomove"></ButtonOne>
</div>
<div className="col">
<ButtonOne text="Schüler*innen Akademie" open="akademie"></ButtonOne>
<div className="col ">
<ButtonOne openclass="out-cycletab" text="Waffle Sale" open="Waffle sale"></ButtonOne>
</div>
</div>
<div id="overview" className="cycletab" style={{display: "block"}}>
<h2>Our education and outreach</h2>
<h2>If not as a special prize - then why?</h2>
</div>
<div id="akademie" className="cycletab" style={{display: "none"}}>
<h2>Student academy on the topic of synthetic biology</h2>
<div id="out-overview" className="out-cycletab" style={{display: "block"}}>
<H4 id="out-why-heading" text="Public engament as part of a integrated human practice - but why?"/>
<p>While many of our efforts in science communication were educational, we also recognized the importance of public engagement through activities
that were not focused on formal education but rather on raising awareness. Initiatives like MUKOmove and our waffle sale were essential in bringing
Cystic Fibrosis (CF) into public focus and showing a visible commitment to the cause.</p>
<p>Public enganegment and outreach serves as a reminder that science does not happen in isolation - it is rooted
in real-world problems that impact individuals and communities. Establishing presence allows diverting interest to our project and our cause which in turn
paves the way to edcuate interested people and to lay the groundwork for a deeper connection between us and our project and the general public. </p>
<H4 id="out-heading" text="Our public engagement"/>
<p>Our public engagement served both as a form of spreading awareness and to establish first contacts. By inviting other people in Bielefeld to join our team
for MUKOmove, we were able to reach a wider audience and foster connections that extended beyond our university.</p>
<p>In addition to our in-person events, we used social media as a tool to keep the community engaged and updated. We shared our progress in
MUKOmove, promoted our events, and posted educational content about Cystic Fibrosis and gene therapy. Our social media presence helped us
stay connected with a broader audience, ensuring that even those who could not attend our events could still follow along and support our mission.</p>
<p>
Through these efforts, we also made valuable connections, resulting in an interview with the "Muko Dino" <a onClick={() => goToPagesAndOpenTab('dino', '/human-practices')}>Thomas Malenke</a>. This highlighted the power
of online platforms in expanding our reach and fostering collaboration beyond our immediate community.</p>
</div>
<div id="teutoruft" className="cycletab" style={{display: "none"}}>
<h2>Educational city tour for young and old</h2>
<div className="row align-items-center">
<div className="col">
<img src="https://static.igem.wiki/teams/5247/photos/edcation-and-outreach/teutoruft-experminet.jpeg"></img>
</div>
<div className="col">
<img src="https://static.igem.wiki/teams/5247/photos/edcation-and-outreach/teutoruft-gruppe.jpeg"></img>
</div>
<div id="Waffle sale" className="out-cycletab" style={{display: "none"}}>
<div className="col">
<H4 text="Waffle Sale"></H4>
<div className="row">
<div className="col">
<p>To support our research project and raise funds for our iGEM team at Bielefeld University, we decided to organize a waffle sale in the main hall of the university. This initiative was aimed at raising awareness about our project and collecting funds for our research into Cystic Fibrosis. </p>
<p>The sale took place in Cystic Fibrosis awareness month May in the Great Hall of our University. As people passed by, we engaged them by introducing our research group and explaining our project’s objectives. We shared information about Cystic Fibrosis and why we are raising money. Our goal was to not only just to sell waffles, but also to educate the university community about our research and its’ potential impact. The response has been overwhelmingly positive. Many were genuinely interested in our work and asked for more details about our research and the goals of our project. This enthusiasm strengthened our commitment to the project and highlighted the importance of community involvement in scientific research. </p>
<p>The waffle sale was a great success, both in terms of raising funds and increasing awareness about our work within the university. It was a collaborative effort that brought our team closer together and demonstrated the power of community support in advancing scientific research. </p>
</div>
<div className="col-4">
<img src="https://static.igem.wiki/teams/5247/photos/edcation-and-outreach/screenshot-2024-09-25-202008.png" style={{objectFit: "cover", maxHeight: "50%", width: "100%"}}/>
</div>
</div>
</div>
</div>
<div id="mukomove" className="cycletab" style={{display: "none"}}>
<h2>Cystic fibrosis awareness month</h2>
<div id="mukomove" className="out-cycletab" style={{display: "none"}}>
<H4 id="cf-month" text="Cystic Fibrosis awareness month"/>
<div className="row">
<div className="full-small col-3">
<img className="max400" src="https://static.igem.wiki/teams/5247/photos/for-wiki-texts/po-mukomove/wir-plakat-mukomove.jpeg"></img>
</div>
<div className="col">
<h3>What is MUKOMOVE?</h3>
<p>As part of the cystic fibrosis awareness month May, we took part in this year's <a href="https://www.muko.info/mukomove">MUKOmove</a> from May 8th to May
<h3>What is MUKOmove?</h3>
<p>As part of the Cystic Fibrosis awareness month May, we took part in this year's <a href="https://www.muko.info/mukomove">MUKOmove</a> from May 8th to May
12th under the team name iGEM Bielefeld. MUKOmove is a participatory sports initiative organized by
<a href="https://www.muko.info/"> Mukoviszidose e.V.</a>, the German Cystic Fibrosis Association, aimed at raising awareness and funds
for cystic fibrosis research and support. This annual event encourages individuals and teams to
for Cystic Fibrosis research and support. This annual event encourages individuals and teams to
engage in various physical activities, track their movement, and share their experiences online. </p>
<button>Spenden</button>
</div>
<button onClick={() => window.location.href = "https://spenden.muko.info/"}>Donate</button>
</div>
<br/>
<div className="row">
<div className="col">
<h3>Why and in which ways were we invested in MUKOmove? </h3>
<p>We did not stop at our participation itself – we wanted to make other people from our university and city
aware of the event and collect sport hours for cystic fibrosis with them by inviting them to join our team.
Our survey about cystic fibrosis awareness and our discussions with <a onClick={() => goToPagesAndOpenTab('InvWesthoff', '/human-practices?tab=')}>Kathrin Westhoff</a>, the head of a
<p>While MUKOmove was not a scientific or educational event, it played an important role in demonstrating our presence in the broader CF
community.</p>
<p>We did not stop at our participation itself - we wanted to make other people from our university and city
aware of the event and collect sport hours for Cystic Fibrosis with them by inviting them to join our team.
Our survey about Cystic Fibrosis awareness and our discussions with <a onClick={() => goToPagesAndOpenTab('InvWesthoff', '/human-practices?tab=')}>Kathrin Westhoff</a>, the head of a
practice for physiotherapy in Gütersloh who is also treating young CF patients, showed us how little known
this illness still is. Especially the interview with the physiotherapist made us realize how important
exercise is for everyone and how it brings a community together – we wanted to establish MUKOmove in
exercise is for everyone and how it brings a community together - we wanted to establish MUKOmove in
Bielefeld. That is why we really got the publicity going by putting up posters and distributing flyers
at the university and in our city as you can see in the following picture. </p>
</div>
......@@ -122,20 +96,19 @@ export function Education() {
while the entire MUKOmove had a goal of collecting 24,000 sport hours. In cooperation with our university's
sports facilities, using their <a href="https://www.uni-bielefeld.de/einrichtungen/hochschulsport/zusatzangebote/houbi/">“HOUBI-Aktivmobil"</a> and other equipment, we organized a team event at the sports
ground of our university at the begin of MUKOmove. Everyone was warmly invited to our event on May 8th, and
it was a lot of fun to play various sport games together outside in the sun – check out in the following
it was a lot of fun to play various sport games together outside in the sun - check out in the following
video! </p>
<div className="row align-items-center">
<div className="col">
<img src="https://www.mapcom.com/wp-content/uploads/2015/07/video-placeholder.jpg"></img>
<iframe title="Bielefeld-CeBiTec: MUKOmove (2024) [English]" width="560" height="315" src="https://video.igem.org/videos/embed/dd3e6eff-95f5-47f4-a0fc-f416db88dfe4?autoplay=1" frameBorder="0" allowFullScreen={true} sandbox="allow-same-origin allow-scripts allow-popups allow-forms"></iframe>
</div>
</div>
<br/>
<h3>What did we achieve?</h3>
<p>We are happy to announce that both movement goals were surpassed: Team iGEM Bielefeld was able to collect 358 sport hours, and everyone who took part in MUKOmove together collected 36,542 sport hours! </p>
<p>The MUKOmove was therefore a complete success, and we take pride in having contributed to the goal while raising more awareness for cystic fibrosis in our region and Germany as a whole.</p>
<p>The MUKOmove was therefore a complete success, and we take pride in having contributed to the goal while raising more awareness for Cystic Fibrosis in our region and Germany as a whole.</p>
</div>
</>
</div>
</div>
);
}
\ No newline at end of file
}
\ No newline at end of file
src/contents/Human Practices/Further Engagement/Partnerships.tsx 0 → 100644
View file @ 3fd292fd
import { H4 } from "../../../components/Headings";
import { useTabNavigation } from "../../../utils/TabNavigation";
export function HPPartnerships(){
useTabNavigation();
return(
<div className="col">
<H4 text="CF Vests"></H4>
<p>CF Vests Worldwide is a dedicated charity organization committed to providing life-saving vest equipment to those in need, regardless of their financial situation. But they can't do it alone — they need your support. Help us make a difference! By donating to CFVWW, you can directly impact the lives of Cystic Fibrosis patients, giving them the chance to breathe easier and live fuller lives. Every contribution counts.</p>
<p><strong>Join us in the fight against Cystic Fibrosis.</strong> <a href="https://donorbox.org/igem"> Donate today</a> and help us bring hope, one vest at a time! Together, we can change lives.</p>
</div>
)
}
\ No newline at end of file
src/contents/Human Practices/Further Engagement/SupMaterial.tsx 0 → 100644
View file @ 3fd292fd
import { DownloadLink } from "../../../components/Buttons";
import { Section } from "../../../components/sections";
import { useTabNavigation } from "../../../utils/TabNavigation";
export function HPSupplement(){
useTabNavigation();
return(
<Section title="Supplementary Material" id="Supplementary Material">
<div className="row">
<div className="col">
<p>Click here to see our raw data of our surverys</p>
</div>
<div className="col">
<DownloadLink url="https://static.igem.wiki/teams/5247/pdfs/raw-data-survey.pdf" fileName="raw-data-survey.pdf"></DownloadLink>
</div>
</div>
</Section>
)
}
\ No newline at end of file
src/contents/Human Practices/HP svgs/hp3.tsx 0 → 100644
View file @ 3fd292fd
Source diff could not be displayed: it is too large. Options to address this: view the blob.
src/contents/Human Practices/HP svgs/hp4.tsx 0 → 100644
View file @ 3fd292fd
/* <a onClick={openElement({elementToOpen: "under-responsibility", classToHide: "understandingtab"})}> */
const HP4 = () => (
<svg
viewBox="0 0 1537.5035 475.29123"
height={475.29123}
width={1537.5035}
xmlSpace="preserve"
id="svg2"
inkscape:export-filename="Design-IHP-2.svg"
inkscape:export-xdpi={96}
inkscape:export-ydpi={96}
xmlns="http://www.w3.org/2000/svg"
>
<defs id="defs6">
<clipPath id="clipPath18" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path16"
d="M 0,2.4414e-4 H 1417.32 V 1417.3202 H 0 Z"
/>
</clipPath>
<clipPath id="clipPath28" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path26"
d="M 2.112e-5,-1.2207e-4 H 1417.32 V 1417.3199 H 2.112e-5 Z"
/>
</clipPath>
<clipPath id="clipPath40" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path38"
d="M 2.112e-5,-1.2207e-4 H 1417.32 V 1417.3199 H 2.112e-5 Z"
/>
</clipPath>
<clipPath id="clipPath52" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path50"
d="M 2.112e-5,-1.2207e-4 H 1417.32 V 1417.3199 H 2.112e-5 Z"
/>
</clipPath>
<clipPath id="clipPath64" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path62"
d="M 2.112e-5,-1.2207e-4 H 1417.32 V 1417.3199 H 2.112e-5 Z"
/>
</clipPath>
<clipPath id="clipPath76" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path74"
d="M 2.112e-5,-1.2207e-4 H 1417.32 V 1417.3199 H 2.112e-5 Z"
/>
</clipPath>
<linearGradient
id="linearGradient102"
spreadMethod="pad"
gradientUnits="userSpaceOnUse"
y2={846.35999}
x2={309}
y1={846.35999}
x1={-89.879997}
>
<stop
id="stop92"
offset={0}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop94"
offset={0.29}
style={{
stopOpacity: 1,
stopColor: "var(--ourbeige)",
}}
/>
<stop
id="stop96"
offset={0.5}
style={{
stopOpacity: 1,
stopColor: "var(--ourbeige)",
}}
/>
<stop
id="stop98"
offset={0.71}
style={{
stopOpacity: 1,
stopColor: "var(--ourbeige)",
}}
/>
<stop
id="stop100"
offset={1}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
</linearGradient>
<linearGradient
id="linearGradient120"
spreadMethod="pad"
gradientUnits="userSpaceOnUse"
y2={973.62}
x2={498}
y1={973.62}
x1={100.33}
>
<stop
id="stop110"
offset={0}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop112"
offset={0.25}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop114"
offset={0.5}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop116"
offset={0.75}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop118"
offset={1}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
</linearGradient>
<linearGradient
id="linearGradient138"
spreadMethod="pad"
gradientUnits="userSpaceOnUse"
y2={846.35999}
x2={686.88}
y1={846.35999}
x1={289.20001}
>
<stop
id="stop128"
offset={0}
style={{
stopOpacity: 1,
stopColor: "#850e78",
}}
/>
<stop
id="stop130"
offset={0.25}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop132"
offset={0.5}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop134"
offset={0.75}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop136"
offset={1}
style={{
stopOpacity: 1,
stopColor: "#850e78",
}}
/>
</linearGradient>
<linearGradient
id="linearGradient156"
spreadMethod="pad"
gradientUnits="userSpaceOnUse"
y2={973.62}
x2={875.76001}
y1={973.62}
x1={478.09}
>
<stop
id="stop146"
offset={0}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop148"
offset={0.25}
style={{
stopOpacity: 1,
stopColor: "#850e78",
}}
/>
<stop
id="stop150"
offset={0.5}
style={{
stopOpacity: 1,
stopColor: "#850e78",
}}
/>
<stop
id="stop152"
offset={0.75}
style={{
stopOpacity: 1,
stopColor: "#850e78",
}}
/>
<stop
id="stop154"
offset={1}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
</linearGradient>
<linearGradient
id="linearGradient174"
spreadMethod="pad"
gradientUnits="userSpaceOnUse"
y2={846.35999}
x2={1064.64}
y1={846.35999}
x1={666.96002}
>
<stop
id="stop164"
offset={0}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop166"
offset={0.25}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop168"
offset={0.5}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop170"
offset={0.75}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop172"
offset={1}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
</linearGradient>
<clipPath id="clipPath194" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path192"
d="M -3.0518e-5,1417.32 H 1417.32 V 2.4414e-4 L 0,1.2207e-4"
/>
</clipPath>
<linearGradient
id="linearGradient220"
spreadMethod="pad"
gradientUnits="userSpaceOnUse"
y2={972.06}
x2={1256.63}
y1={972.06}
x1={859.21002}
>
<stop
id="stop206"
offset={0}
style={{
stopOpacity: 1,
stopColor: "var(--ourbeige)",
}}
/>
<stop
id="stop208"
offset={0.055}
style={{
stopOpacity: 1,
stopColor: "var(--ourbeige)",
}}
/>
<stop
id="stop210"
offset={0.335}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop212"
offset={0.5}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop214"
offset={0.665}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop216"
offset={0.945}
style={{
stopOpacity: 1,
stopColor: "var(--ourbeige)",
}}
/>
<stop
id="stop218"
offset={1}
style={{
stopOpacity: 1,
stopColor: "var(--ourbeige)",
}}
/>
</linearGradient>
<clipPath id="clipPath234" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path232"
d="M 2.112e-5,-1.2207e-4 H 1417.32 V 1417.3199 H 2.112e-5 Z"
/>
</clipPath>
</defs>
<g transform="matrix(1.3333333,0,0,-1.3333333,-146.08,1445.2779)" id="g10">
<g id="g22">
<g clipPath="url(#clipPath28)" id="g24">
<text
id="text32"
style={{
fontVariant: "normal",
fontWeight: "bold",
fontSize: "47.304px",
fontFamily: "'18'",
fill: "#32232c",
fillOpacity: 1,
fillRule: "nonzero",
stroke: "none",
}}
transform="matrix(1,0,0,-1,163.75,731.26)"
>
<tspan id="tspan30" y={0} x="0 31.799988 60.950951">
{"ASK"}
</tspan>
</text>
</g>
</g>
<g id="g34">
<g clipPath="url(#clipPath40)" id="g36">
<text
id="text44"
style={{
fontVariant: "normal",
fontWeight: "bold",
fontSize: "47.28px",
fontFamily: "'18'",
fill: "#32232c",
fillOpacity: 1,
fillRule: "nonzero",
stroke: "none",
}}
transform="matrix(1,0,0,-1,302.02,1046.93)"
>
<tspan
id="tspan42"
y={0}
x="0 13.80576 55.175758 86.947922 119.19288 132.99864 166.37833"
>
{"IMAGINE"}
</tspan>
</text>
</g>
</g>
<g id="g46">
<g clipPath="url(#clipPath52)" id="g48">
<text
id="text56"
style={{
fontVariant: "normal",
fontWeight: "bold",
fontSize: "47.28px",
fontFamily: "'18'",
fill: "#32232c",
fillOpacity: 1,
fillRule: "nonzero",
stroke: "none",
}}
transform="matrix(1,0,0,-1,526.32,731.38)"
>
<tspan
id="tspan54"
y={0}
x="0 30.4956 56.074081 87.846237 121.22592"
>
{"PLAN "}
</tspan>
</text>
</g>
</g>
<g id="g58">
<g clipPath="url(#clipPath64)" id="g60">
<text
id="text68"
style={{
fontVariant: "normal",
fontWeight: "bold",
fontSize: "47.28px",
fontFamily: "'18'",
fill: "#32232c",
fillOpacity: 1,
fillRule: "nonzero",
stroke: "none",
}}
transform="matrix(1,0,0,-1,688.56,1046.66)"
>
<tspan
id="tspan66"
y={0}
x="0 30.92112 61.2276 87.846237 119.6184 148.93201 175.55064"
>
{"CREATE "}
</tspan>
</text>
</g>
</g>
<g id="g70">
<g clipPath="url(#clipPath76)" id="g72">
<text
id="text80"
style={{
fontVariant: "normal",
fontWeight: "bold",
fontSize: "47.28px",
fontFamily: "'18'",
fill: "#32232c",
fillOpacity: 1,
fillRule: "nonzero",
stroke: "none",
}}
transform="matrix(1,0,0,-1,835.54,727.49)"
>
<tspan
id="tspan78"
y={0}
x="0 26.618641 56.641441 87.137039 113.75568 144.06216 157.86792 199.23792 225.85657 259.23624 288.54984"
>
{"EXPERIMENT "}
</tspan>
</text>
</g>
</g>
<path
id="path82"
style={{
fill: "var(--ourbeige)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 210.72,968.52 c -39.19,0 -71.04,-31.8 -71.04,-71.01 0,-39.27 31.85,-71.07 71.04,-71.07 39.2,0 71.04,31.8 71.04,71.07 0,39.21 -31.84,71.01 -71.04,71.01 z"
/>
<path
id="path84"
style={{
fill: "var(--ourbeige)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 398.55,996.48 c -39.27,0 -71.07,-31.83 -71.07,-71.13 0,-39.24 31.8,-71.07 71.07,-71.07 39.21,0 71.01,31.83 71.01,71.07 0,39.3 -31.8,71.13 -71.01,71.13 z"
/>
<path
id="path86"
style={{
fill: "var(--ourbeige)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 586.89,966.84 c -39.21,0 -71.01,-31.8 -71.01,-71.01 0,-39.21 31.8,-71.07 71.01,-71.07 39.27,0 71.07,31.86 71.07,71.07 0,39.21 -31.8,71.01 -71.07,71.01 z"
/>
<path
id="path88"
style={{
fill: "var(--ourbeige)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 966.3182,968.84033 c -39.27,0 -71.07,-31.8 -71.07,-71.07 0,-39.21 31.8,-71.01 71.07,-71.01 39.21,0 71.01,31.8 71.01,71.01 0,39.27 -31.8,71.07 -71.01,71.07 z"
/>
<path
id="path88-6"
style={{
fill: "var(--ourbeige)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 776.43928,993.85337 c -39.27,0 -71.07,-31.8 -71.07,-71.07 0,-39.21 31.8,-71.01 71.07,-71.01 39.21,0 71.01,31.8 71.01,71.01 0,39.27 -31.8,71.07 -71.01,71.07 z"
inkscape:transform-center-x={16.555908}
inkscape:transform-center-y={189.15588}
/>
<g id="g90">
<path
id="path104"
style={{
fill: "url(#linearGradient102)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 309,893.55 c 0,2.91 -2.33,5.25 -5.25,5.25 -2.92,0 -5.25,-2.34 -5.25,-5.25 0,-49.12 -40.03,-89.13 -89.22,-89.13 -49.19,0 -89.22,40.01 -89.22,89.13 0,2.91 -2.33,5.25 -5.25,5.25 -2.91,0 -5.25,-2.34 -5.25,-5.25 0,-54.95 44.75,-99.63 99.72,-99.63 55.03,0 99.72,44.68 99.72,99.63 z"
/>
</g>
<path
id="path106"
style={{
fill: "#ebecfd",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 210.66,968.48 c 39.27,0 71.07,-31.78 71.07,-70.97 0,-39.25 -31.86,-71.03 -71.07,-71.03 -39.2,0 -71,31.78 -71,71.03 0,39.19 31.8,70.97 71,70.97 z m 0,9.4 c -44.34,0 -80.46,-36.05 -80.46,-80.37 0,-44.32 36.12,-80.43 80.46,-80.43 44.34,0 80.46,36.11 80.46,80.43 0,44.32 -36.12,80.37 -80.46,80.37 z"
/>
<g id="g108">
<path
id="path122"
style={{
fill: "url(#linearGradient120)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 309.61,936.6 c 5.14,44.38 42.89,79.07 88.65,79.07 49.14,0 89.23,-40.12 89.23,-89.29 0,-2.92 2.33,-5.26 5.26,-5.26 2.91,0 5.25,2.34 5.25,5.26 0,55.01 -44.77,99.74 -99.74,99.74 -51.3,0 -93.67,-38.95 -99.1,-88.88 1.46,0.59 3.04,0.93 4.67,0.93 2.05,0 4.03,-0.58 5.78,-1.57 z"
/>
</g>
<path
id="path124"
style={{
fill: "#ebecfd",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 398.82,996.44 c 39.2,0 71,-31.81 71,-71.09 0,-39.22 -31.8,-71.03 -71,-71.03 -39.26,0 -71.06,31.81 -71.06,71.03 -0.06,39.28 31.74,71.09 71.06,71.09 z m 0,9.4 c -44.34,0 -80.46,-36.13 -80.46,-80.49 0,-44.36 36.12,-80.43 80.46,-80.43 44.34,0 80.46,36.07 80.46,80.43 0,44.36 -36.12,80.49 -80.46,80.49 z"
/>
<g id="g126">
<path
id="path140"
style={{
fill: "url(#linearGradient138)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 488.04,882.7 c 5.37,-49.88 47.75,-88.78 99.07,-88.78 55.05,0 99.77,44.68 99.77,99.63 0,2.91 -2.33,5.25 -5.26,5.25 -2.91,0 -5.25,-2.34 -5.25,-5.25 0,-49.12 -40.11,-89.13 -89.26,-89.13 -45.77,0 -83.54,34.53 -88.68,78.92 -1.75,-0.99 -3.68,-1.52 -5.83,-1.52 -1.58,-0.05 -3.22,0.29 -4.56,0.88 z"
/>
</g>
<path
id="path142"
style={{
fill: "#ebecfd",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 586.83,966.86 c 39.28,0 71.09,-31.82 71.09,-71.06 0,-39.3 -31.81,-71.12 -71.09,-71.12 -39.22,0 -71.03,31.82 -71.03,71.12 0,39.24 31.81,71.06 71.03,71.06 z m 0,9.46 c -44.36,0 -80.43,-36.14 -80.43,-80.52 0,-44.37 36.07,-80.52 80.43,-80.52 44.36,0 80.49,36.15 80.49,80.52 0,44.38 -36.13,80.52 -80.49,80.52 z"
/>
<g id="g144">
<path
id="path158"
style={{
fill: "url(#linearGradient156)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 687.37,936.6 c 5.08,44.38 42.91,79.07 88.68,79.07 49.15,0 89.2,-40.12 89.2,-89.29 0,-2.92 2.33,-5.26 5.25,-5.26 2.92,0 5.26,2.34 5.26,5.26 0,55.01 -44.72,99.74 -99.71,99.74 -51.32,0 -93.76,-38.95 -99.13,-88.88 1.46,0.59 2.98,0.93 4.67,0.93 2.05,0 4.03,-0.58 5.78,-1.57 z"
/>
</g>
<path
id="path160"
style={{
fill: "#ebecfd",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 776.61,994.76 c 39.22,0 71.03,-31.81 71.03,-71.09 0,-39.22 -31.81,-71.03 -71.03,-71.03 -39.28,0 -71.09,31.81 -71.09,71.03 0,39.28 31.81,71.09 71.09,71.09 z m 0,9.4 c -44.36,0 -80.49,-36.13 -80.49,-80.49 0,-44.3 36.13,-80.43 80.49,-80.43 44.3,0 80.43,36.13 80.43,80.43 0,44.36 -36.02,80.49 -80.43,80.49 z"
/>
<g id="g162">
<path
id="path176"
style={{
fill: "url(#linearGradient174)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 865.8,882.7 c 5.43,-49.88 47.8,-88.78 99.1,-88.78 54.98,0 99.74,44.68 99.74,99.63 0,2.91 -2.33,5.25 -5.25,5.25 -2.92,0 -5.31,-2.34 -5.31,-5.25 0,-49.12 -40.04,-89.13 -89.18,-89.13 -45.75,0 -83.52,34.53 -88.65,78.92 -1.75,-0.99 -3.74,-1.52 -5.84,-1.52 -1.58,-0.05 -3.21,0.29 -4.61,0.88 z"
/>
</g>
<path
id="path178"
style={{
fill: "#ebecfd",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 966.36,968.48 c 39.24,0 71.06,-31.78 71.06,-70.97 0,-39.25 -31.82,-71.03 -71.06,-71.03 -39.3,0 -71.12,31.78 -71.12,71.03 0,39.19 31.82,70.97 71.12,70.97 z m 0,9.4 c -44.38,0 -80.52,-36.05 -80.52,-80.37 0,-44.32 36.14,-80.43 80.52,-80.43 44.37,0 80.52,36.11 80.52,80.43 0,44.32 -36.09,80.37 -80.52,80.37 z"
/>
<path
id="path180"
style={{
fill: "#32232c",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 227.57,916.92 v -2.46 c 0,-0.85 0.69,-1.54 1.55,-1.54 h 2.44 l -3.09,-3.1 h -4 v 4 z m -17.11,-16.38 c 0.72,0 1.42,-0.17 2.06,-0.49 l -3.15,-3.15 c -0.61,-0.61 -0.61,-1.59 0,-2.2 0.3,-0.3 0.69,-0.45 1.09,-0.45 0.39,0 0.79,0.15 1.09,0.45 l 3.16,3.16 c 0.32,-0.63 0.49,-1.34 0.49,-2.06 0,-2.52 -2.17,-4.65 -4.74,-4.65 -2.57,0 -4.74,2.13 -4.74,4.65 0,2.57 2.17,4.74 4.74,4.74 z m 0,6.19 c 2.36,-0.01 4.64,-0.79 6.51,-2.23 l -2.2,-2.21 c -1.27,0.88 -2.77,1.34 -4.31,1.35 -4.24,0 -7.83,-3.59 -7.83,-7.84 0,-2.07 0.84,-4.04 2.33,-5.48 1.53,-1.51 3.51,-2.26 5.5,-2.26 1.99,0 3.98,0.75 5.5,2.26 1.49,1.44 2.33,3.41 2.33,5.48 0,1.54 -0.47,3.04 -1.33,4.31 l 2.2,2.21 c 1.43,-1.88 2.22,-4.16 2.22,-6.52 0,-5.98 -4.89,-10.83 -10.92,-10.83 -6.02,0 -10.92,4.85 -10.92,10.83 0,5.92 5,10.93 10.92,10.93 z m 0.04,6.19 c 3.97,0 7.82,-1.38 10.88,-3.9 v -0.11 l -2.19,-2.18 c -2.59,2.08 -5.71,3.1 -8.81,3.1 -3.88,0 -7.73,-1.59 -10.5,-4.69 -4.99,-5.58 -4.75,-14.09 0.54,-19.39 2.75,-2.74 6.36,-4.13 9.97,-4.13 3.35,0 6.71,1.19 9.39,3.59 5.58,4.99 6.28,13.48 1.6,19.33 l 2.19,2.19 h 0.1 c 2.53,-3.08 3.91,-6.95 3.9,-10.93 0,-9.39 -7.68,-17.02 -17.11,-17.02 -9.43,0 -17.1,7.63 -17.1,17.02 0,9.44 7.67,17.12 17.1,17.12 0.01,0 0.03,0 0.04,0 z m -0.04,6.18 c 4.13,0 8.19,-1.09 11.77,-3.15 l -0.39,-0.39 c -0.29,-0.29 -0.46,-0.69 -0.46,-1.1 v -1.63 c -3.25,2.08 -7.02,3.18 -10.88,3.18 -0.01,0 -0.03,0 -0.04,0 -5.36,0 -10.42,-2.11 -14.25,-5.95 -3.83,-3.83 -5.94,-8.9 -5.94,-14.26 0,-5.36 2.11,-10.41 5.94,-14.21 3.94,-3.94 9.1,-5.9 14.25,-5.9 5.16,0 10.31,1.96 14.25,5.9 3.84,3.8 5.95,8.85 5.95,14.21 0.01,3.87 -1.1,7.66 -3.18,10.93 h 1.64 c 0.4,0 0.8,0.16 1.08,0.45 l 0.4,0.4 c 2.06,-3.59 3.15,-7.65 3.15,-11.78 0,-12.85 -10.45,-23.31 -23.29,-23.31 -12.84,0 -23.29,10.46 -23.29,23.31 0,12.85 10.45,23.3 23.29,23.3 z m 18.64,3.1 c -0.38,0 -0.77,-0.14 -1.08,-0.46 l -3.54,-3.54 c -4.21,2.61 -9.06,3.99 -14.02,4 -7.01,0 -13.63,-2.76 -18.63,-7.76 -5,-5 -7.75,-11.62 -7.75,-18.64 0,-7.02 2.75,-13.65 7.75,-18.65 5,-4.99 11.62,-7.75 18.63,-7.75 7.02,0 13.63,2.76 18.63,7.75 5,5 7.75,11.63 7.75,18.65 -0.01,4.96 -1.39,9.82 -3.99,14.03 l 3.54,3.54 c 0.97,0.97 0.28,2.64 -1.09,2.64 h -4.64 v 4.64 c 0,0.93 -0.76,1.55 -1.56,1.55 z"
/>
<path
id="path182"
style={{
fill: "#32232c",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 798.71,939.33 -0.75,-5.1 -4.35,4.35 z m -31.22,-8.73 v -20.42 h -13.44 v 9.64 z m 3.09,0.68 12.87,-6.64 v -14.46 h -12.87 z m -18.08,25 c -0.85,0 -1.54,-0.7 -1.54,-1.56 v -46.09 c 0,-0.86 0.69,-1.55 1.54,-1.55 h 47.98 c 0.85,0 1.54,0.69 1.54,1.55 0,0.85 -0.69,1.55 -1.54,1.55 h -13.95 v 14.77 l 8.16,8.18 3.26,-3.27 c 0.31,-0.31 0.7,-0.45 1.08,-0.45 0.72,0 1.41,0.5 1.54,1.32 l 1.49,10.21 c 0.14,0.95 -0.6,1.77 -1.52,1.77 -0.07,0 -0.15,-0.01 -0.23,-0.02 l -10.19,-1.49 c -1.25,-0.19 -1.76,-1.72 -0.87,-2.63 l 3.26,-3.26 -7.81,-7.83 -14.96,7.72 c -0.04,0.01 -0.07,0.03 -0.09,0.04 l -0.04,0.02 -0.11,0.04 h -0.04 c -0.03,0.01 -0.06,0.02 -0.09,0.03 l -0.05,0.01 c -0.04,0.01 -0.09,0.01 -0.13,0.02 h -0.34 c -0.04,0 -0.08,-0.01 -0.11,-0.01 l -0.05,-0.02 c -0.03,0 -0.06,-0.01 -0.08,-0.02 l -0.05,-0.01 c -0.04,-0.02 -0.08,-0.03 -0.12,-0.04 l -0.05,-0.03 -0.07,-0.03 -0.05,-0.03 c -0.03,-0.02 -0.05,-0.03 -0.08,-0.05 l -0.04,-0.02 c -0.03,-0.02 -0.06,-0.04 -0.09,-0.07 l -0.01,-0.02 -14,-11.22 v 30.93 c 0,0.86 -0.69,1.56 -1.55,1.56 z"
/>
<path
id="path184"
style={{
fill: "#32232c",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 593.01,919.12 c 4.34,0 8.69,-1.67 12,-4.99 6.62,-6.64 6.62,-17.4 0,-24.05 -3.27,-3.26 -7.61,-4.98 -12.02,-4.98 -2.45,0 -4.91,0.52 -7.22,1.61 -0.06,0.02 -0.11,0.06 -0.17,0.08 -1.71,0.83 -3.26,1.94 -4.6,3.29 -6.61,6.63 -6.61,17.42 0,24.05 3.31,3.32 7.66,4.99 12.01,4.99 z m -17.08,-27.57 c 1.64,-2.67 3.88,-4.91 6.54,-6.56 L 581,883.51 c -0.3,-0.3 -0.7,-0.45 -1.09,-0.45 -0.39,0 -0.79,0.15 -1.09,0.45 l -4.37,4.38 c -0.6,0.6 -0.6,1.58 0,2.19 z m -2.56,-6.95 2.18,-2.19 -2.18,-2.18 -2.19,2.18 z m -4.38,-4.37 2.18,-2.19 -5.07,-5.09 c -0.3,-0.3 -0.69,-0.45 -1.09,-0.45 -0.39,0 -0.79,0.15 -1.1,0.46 -0.6,0.6 -0.6,1.58 0,2.18 z M 593,922.2 c -5.14,0 -10.28,-1.96 -14.18,-5.88 -5.9,-5.9 -7.35,-14.59 -4.37,-21.87 l -2.19,-2.19 c -1.38,-1.39 -1.74,-3.5 -0.9,-5.29 l -9.63,-9.64 c -1.81,-1.81 -1.81,-4.75 0,-6.57 0.91,-0.91 2.09,-1.36 3.27,-1.36 1.19,0 2.38,0.45 3.28,1.36 l 9.63,9.65 c 0.63,-0.3 1.31,-0.44 1.99,-0.44 1.2,0 2.39,0.46 3.28,1.35 l 2.18,2.18 c 2.48,-1.02 5.07,-1.51 7.62,-1.51 6.55,0 12.9,3.22 16.71,8.96 5.31,7.97 4.27,18.6 -2.49,25.37 -3.92,3.92 -9.06,5.88 -14.2,5.88 z"
/>
<path
id="path186"
style={{
fill: "#32232c",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 593.05,912.87 c 2.81,0 5.57,-1.09 7.64,-3.16 4.21,-4.21 4.21,-11.04 0,-15.26 -2.07,-2.06 -4.83,-3.16 -7.63,-3.16 -1.4,0 -2.81,0.27 -4.15,0.83 -4.03,1.67 -6.66,5.6 -6.66,9.96 0,4.37 2.63,8.3 6.66,9.97 1.34,0.55 2.74,0.82 4.14,0.82 z m 0.03,3.09 c -0.01,0 -0.02,0 -0.03,0 -6.63,-0.01 -12.32,-4.68 -13.6,-11.16 -1.29,-6.49 2.19,-12.98 8.31,-15.5 1.72,-0.71 3.53,-1.06 5.3,-1.06 4.53,0 8.9,2.22 11.54,6.17 3.68,5.49 2.95,12.81 -1.72,17.49 -2.6,2.6 -6.13,4.06 -9.8,4.06 z"
/>
<g id="g188">
<g clipPath="url(#clipPath194)" id="g190">
<path
id="path196"
style={{
fill: "#32232c",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 419.68,945.85 -34.83,-34.83 -6.9,6.9 2.37,2.37 3.5,-3.5 c 0.62,-0.62 1.65,-0.62 2.27,0 0.62,0.61 0.62,1.64 0,2.26 l -3.51,3.51 2.37,2.37 1.14,-1.14 c 0.62,-0.62 1.65,-0.62 2.27,0 0.62,0.62 0.62,1.65 0,2.27 l -1.14,1.14 2.37,2.36 3.51,-3.5 c 0.61,-0.62 1.64,-0.62 2.26,0 0.62,0.62 0.62,1.65 0,2.26 l -3.5,3.51 2.37,2.37 1.13,-1.13 c 0.62,-0.62 1.65,-0.62 2.27,-0.01 0.62,0.62 0.62,1.66 0,2.27 l -1.14,1.14 2.27,2.27 3.51,-3.51 c 0.62,-0.62 1.65,-0.62 2.37,0.1 0.61,0.62 0.62,1.65 0,2.27 l -3.51,3.51 2.37,2.36 1.14,-1.13 c 0.61,-0.62 1.65,-0.62 2.27,0 0.61,0.62 0.61,1.65 -0.01,2.27 l -1.13,1.13 2.37,2.37 3.5,-3.5 c 0.62,-0.62 1.65,-0.62 2.27,0 0.62,0.62 0.62,1.64 0,2.26 l -3.51,3.51 2.38,2.37 z m -5.77,10.09 c -0.62,0.62 -1.65,0.62 -2.37,-0.1 l -36.89,-36.89 c -0.72,-0.72 -0.72,-1.75 -0.1,-2.37 l 9.17,-9.17 c 0.61,-0.62 1.65,-0.62 2.37,0.1 l 36.89,36.89 c 0.72,0.72 0.72,1.75 0.1,2.37 z"
/>
</g>
</g>
<path
id="path198"
style={{
fill: "#32232c",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 966.19,913.05 c 9.46,0 17.22,-7.78 17.22,-17.39 0,-9.47 -7.76,-17.25 -17.22,-17.25 -9.6,0 -17.36,7.78 -17.36,17.25 0,9.61 7.76,17.39 17.36,17.39 z m 0,11.31 c -1.13,0 -1.98,-0.85 -1.98,-1.98 v -5.66 c -4.37,-0.28 -8.46,-2.12 -11.71,-4.8 l -3.95,4.1 c -0.36,0.35 -0.85,0.53 -1.34,0.53 -0.49,0 -0.99,-0.18 -1.35,-0.53 -0.7,-0.71 -0.7,-1.98 0,-2.69 l 4.1,-3.96 c -2.68,-3.25 -4.52,-7.35 -4.8,-11.73 h -5.64 c -1.13,0 -1.84,-0.85 -1.84,-1.7 0,-1.13 0.99,-1.98 1.84,-1.98 h 5.64 c 0.28,-4.38 2.12,-8.48 4.8,-11.73 l -4.1,-3.96 c -0.7,-0.71 -0.7,-1.98 0,-2.69 0.29,-0.42 0.86,-0.56 1.28,-0.56 0.28,0 0.84,0.14 1.13,0.56 l 4.09,4.1 c 3.24,-2.68 7.19,-4.52 11.71,-4.8 v -5.66 c 0,-0.99 0.85,-1.98 1.84,-1.98 1.13,0 1.83,0.99 1.83,1.98 v 5.66 c 4.38,0.28 8.47,2.12 11.58,4.8 l 4.09,-4.1 c 0.42,-0.42 0.85,-0.56 1.27,-0.56 0.56,0 0.84,0.14 1.27,0.56 0.7,0.71 0.7,1.98 0,2.69 l -4.09,3.96 c 2.68,3.25 4.37,7.35 4.79,11.73 h 5.65 c 0.99,0 1.83,0.85 1.83,1.98 0.43,0.85 -0.42,1.7 -1.55,1.7 h -5.64 c -0.29,4.38 -2.12,8.48 -4.8,11.73 l 4.09,3.96 c 0.71,0.71 0.71,1.98 0,2.69 -0.35,0.35 -0.84,0.53 -1.34,0.53 -0.49,0 -0.99,-0.18 -1.34,-0.53 l -3.95,-4.1 c -3.25,2.68 -7.34,4.52 -11.72,4.8 v 5.66 c 0,1.13 -0.84,1.98 -1.69,1.98 z"
/>
<path
id="path200"
style={{
fill: "#32232c",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 964.15,905.69 v -3.95 c -0.42,-0.14 -0.7,-0.14 -1.12,-0.28 l -2.54,2.54 c 0.99,0.7 2.25,1.27 3.66,1.69 z m 3.67,-0.28 c 1.41,-0.14 2.69,-0.71 3.67,-1.56 l -2.54,-2.67 c -0.42,0.13 -0.7,0.42 -1.13,0.42 z m -10.02,-4.1 2.69,-2.54 c -0.29,-0.42 -0.43,-0.7 -0.43,-1.12 h -3.81 c 0.28,1.41 0.85,2.68 1.55,3.66 z m 16.37,0 c 0.71,-0.98 1.28,-2.25 1.56,-3.66 h -3.81 c -0.15,0.42 -0.15,0.7 -0.43,1.12 z m -8.04,-2.96 c 0.71,0 1.13,-0.28 1.69,-0.7 0.57,-0.57 0.71,-0.99 0.71,-1.7 0,-0.7 -0.28,-1.41 -0.71,-1.83 -0.56,-0.57 -0.98,-0.71 -1.69,-0.71 -0.7,0 -1.27,0.42 -1.83,0.71 -0.57,0.56 -0.71,1.13 -0.71,1.83 0,0.71 0.43,1.13 0.71,1.7 0.56,0.56 1.13,0.7 1.83,0.7 z m -5.93,-4.37 c 0.29,-0.43 0.29,-0.71 0.43,-1.13 l -2.68,-2.54 c -0.85,0.98 -1.42,2.26 -1.56,3.67 z m 15.53,0 c -0.28,-1.41 -0.85,-2.69 -1.56,-3.67 l -2.68,2.54 c 0.28,0.42 0.43,0.7 0.43,1.13 z m -12.7,-3.67 c 0.42,-0.28 0.7,-0.43 1.12,-0.43 v -3.8 c -1.41,0.13 -2.67,0.7 -3.66,1.55 z m 5.92,0 2.54,-2.68 c -0.98,-0.71 -2.26,-1.27 -3.67,-1.55 v 3.8 c 0.43,0.15 0.71,0.15 1.13,0.43 z m -2.82,19.05 c -7.62,0 -13.69,-6.21 -13.69,-13.69 0,-3.67 1.41,-7.05 3.95,-9.46 1.56,-1.97 5.51,-4.09 9.74,-4.09 7.34,0 13.55,6.07 13.55,13.55 0,7.62 -6.21,13.69 -13.55,13.69 z"
/>
<path
id="path202"
style={{
fill: "var(--ourbeige)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 1157.61,993.24 c -39.3,0 -71.13,-31.83 -71.13,-71.13 0,-39.24 31.83,-71.07 71.13,-71.07 39.24,0 71.06,31.83 71.06,71.07 0,39.3 -31.82,71.13 -71.06,71.13 z"
/>
<g
id="g204"
style={{
strokeWidth: 0.99975002,
strokeDasharray: "none",
}}
>
<path
id="path222"
style={{
fill: "url(#linearGradient220)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
strokeWidth: 0.99975002,
strokeDasharray: "none",
}}
d="m 1068.37,935.04 c 5.07,44.38 42.88,79.07 88.62,79.07 49.12,0 89.14,-40.12 89.14,-89.29 0,-2.92 2.34,-5.26 5.26,-5.26 2.91,0 5.25,2.34 5.25,5.26 0,55.01 -44.69,99.74 -99.65,99.74 -51.28,0 -93.7,-38.95 -99.07,-88.88 1.46,0.59 2.98,0.93 4.67,0.93 2.04,0 4.03,-0.58 5.78,-1.57 z"
/>
</g>
<path
id="path224"
style={{
fill: "#ebecfd",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 1157.61,993.2 c 39.22,0 71.03,-31.81 71.03,-71.09 0,-39.22 -31.81,-71.03 -71.03,-71.03 -39.28,0 -71.09,31.81 -71.09,71.03 0,39.28 31.81,71.09 71.09,71.09 z m 0,9.4 c -44.36,0 -80.49,-36.13 -80.49,-80.49 0,-44.3 36.13,-80.43 80.49,-80.43 44.3,0 80.42,36.13 80.42,80.43 0,44.36 -36.01,80.49 -80.42,80.49 z"
/>
<path
id="path226"
style={{
fill: "#32232c",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 1179.71,937.81 -0.75,-5.09 -4.35,4.34 z m -31.22,-8.71 v -20.37 h -13.44 v 9.62 z m 3.09,0.68 12.87,-6.62 v -14.43 h -12.87 z m -18.08,24.94 c -0.85,0 -1.54,-0.7 -1.54,-1.55 v -45.98 c 0,-0.86 0.69,-1.55 1.54,-1.55 h 47.98 c 0.85,0 1.54,0.69 1.54,1.55 0,0.85 -0.69,1.54 -1.54,1.54 h -13.95 v 14.73 l 8.16,8.16 3.26,-3.25 c 0.31,-0.31 0.7,-0.46 1.08,-0.46 0.72,0 1.41,0.5 1.54,1.32 l 1.49,10.19 c 0.14,0.95 -0.6,1.76 -1.52,1.76 -0.07,0 -0.15,0 -0.23,-0.01 l -10.19,-1.49 c -1.25,-0.19 -1.76,-1.72 -0.87,-2.62 l 3.26,-3.26 -7.81,-7.81 -14.96,7.7 c -0.04,0.02 -0.07,0.03 -0.09,0.04 l -0.04,0.02 -0.11,0.04 -0.04,0.01 c -0.03,0 -0.06,0.01 -0.09,0.02 l -0.05,0.01 c -0.04,0.01 -0.09,0.02 -0.13,0.02 h -0.34 c -0.04,0 -0.08,-0.01 -0.11,-0.01 l -0.05,-0.02 c -0.03,0 -0.06,-0.01 -0.08,-0.02 l -0.05,-0.01 c -0.04,-0.02 -0.08,-0.03 -0.12,-0.04 l -0.05,-0.03 -0.07,-0.03 -0.05,-0.03 c -0.03,-0.01 -0.05,-0.03 -0.08,-0.05 l -0.04,-0.02 c -0.03,-0.02 -0.06,-0.04 -0.09,-0.07 l -0.01,-0.01 -14,-11.2 v 30.86 c 0,0.85 -0.69,1.55 -1.55,1.55 z"
/>
<g id="g228">
<g clipPath="url(#clipPath234)" id="g230">
<text
id="text238"
style={{
fontVariant: "normal",
fontWeight: "bold",
fontSize: "47.304px",
fontFamily: "'18'",
fill: "#32232c",
fillOpacity: 1,
fillRule: "nonzero",
stroke: "none",
}}
transform="matrix(1,0,0,-1,1054.32,1048.85)"
>
<tspan
id="tspan236"
y={0}
x="0 13.812768 55.20377 85.714851 116.03671 148.62917 179.51868 206.15083"
>
{"IMPROVE "}
</tspan>
</text>
</g>
</g>
</g>
</svg>
);
export default HP4;
src/contents/Human Practices/HP svgs/mendelows.tsx 0 → 100644
View file @ 3fd292fd
export const WholeMendelow = () => (
<svg
viewBox="-1500 0 9000 6000"
xmlns="http://www.w3.org/2000/svg"
xmlnsXlink="http://www.w3.org/1999/xlink"
xmlSpace="preserve"
overflow="hidden"
>
<g transform="translate(-339 -829)">
<g>
<path
d="M28.6458-2.9618e-06 28.6462 3347.24-28.6455 3347.24-28.6458 2.9618e-06ZM85.9378 3318.59 0.000360892 3490.47-85.9372 3318.59Z"
fill="#32232C"
fillRule="nonzero"
fillOpacity={1}
transform="matrix(1 0 0 -1 871.5 5049.97)"
/>
<path
d="M1286 1623.84C1286 1444.44 1431.44 1299 1610.84 1299L2910.16 1299C3089.56 1299 3235 1444.44 3235 1623.84L3235 2923.16C3235 3102.56 3089.56 3248 2910.16 3248L1610.84 3248C1431.44 3248 1286 3102.56 1286 2923.16Z"
fill="#B85BD1"
fillRule="evenodd"
fillOpacity={1}
/>
<text
fill="var(--ourbeige)"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={400}
fontStretch="normal"
fontSize={147}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 1442.34 2089)"
>
{"High Power, Low Interest"}
</text>
<text
fill="var(--ourbeige)"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={238}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 1439.48 2548)"
>
{"Keep "}
</text>
<text
fill="var(--ourbeige)"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={238}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 2088.02 2548)"
>
{"Satisfied"}
</text>
<path
d="M3386 1623.84C3386 1444.44 3531.44 1299 3710.84 1299L5010.16 1299C5189.56 1299 5335 1444.44 5335 1623.84L5335 2923.16C5335 3102.56 5189.56 3248 5010.16 3248L3710.84 3248C3531.44 3248 3386 3102.56 3386 2923.16Z"
fill="#850E78"
fillRule="evenodd"
fillOpacity={1}
/>
<text
fill="var(--ourbeige)"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={400}
fontStretch="normal"
fontSize={147}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3525.83 2089)"
>
{"High Power, High Interest"}
</text>
<text
fill="var(--ourbeige)"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={238}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3711.75 2548)"
>
{"Keep Close"}
</text>
<path
d="M1286 3743.84C1286 3564.44 1431.44 3419 1610.84 3419L2910.16 3419C3089.56 3419 3235 3564.44 3235 3743.84L3235 5043.16C3235 5222.56 3089.56 5368 2910.16 5368L1610.84 5368C1431.44 5368 1286 5222.56 1286 5043.16Z"
fill="var(--darkerbeige)"
fillRule="evenodd"
fillOpacity={1}
/>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={400}
fontStretch="normal"
fontSize={147}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 1458.67 4208)"
>
{"Low Power, Low Interest"}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={238}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 1492.2 4667)"
>
{"Keep Minimal"}
</text>
<path
d="M3386 3743.84C3386 3564.44 3531.44 3419 3710.84 3419L5010.16 3419C5189.56 3419 5335 3564.44 5335 3743.84L5335 5043.16C5335 5222.56 5189.56 5368 5010.16 5368L3710.84 5368C3531.44 5368 3386 5222.56 3386 5043.16Z"
fill="#A0A7F3"
fillRule="evenodd"
fillOpacity={1}
/>
<text
fill="var(--ourbeige)"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={400}
fontStretch="normal"
fontSize={147}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3542.16 4208)"
>
{"High Power, Low Interest"}
</text>
<text
fill="var(--ourbeige)"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={238}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3526.12 4667)"
>
{"Keep "}
</text>
<text
fill="var(--ourbeige)"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={238}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 4174.66 4667)"
>
{"Informed"}
</text>
<path
d="M28.6458-2.9618e-06 28.6462 3347.24-28.6455 3347.24-28.6458 2.9618e-06ZM85.9378 3318.59 0.000360892 3490.47-85.9372 3318.59Z"
fill="#32232C"
fillRule="nonzero"
fillOpacity={1}
transform="matrix(6.12323e-17 1 1 -6.12323e-17 1641.5 5804.5)"
/>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={165}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(-1.83697e-16 -1 1 -1.83697e-16 665.153 4092)"
>
{"POWER "}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={165}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(-1.83697e-16 -1 1 -1.83697e-16 665.153 3423)"
>
{"OF IMPACT"}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={165}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 2368.38 6113)"
>
{"INTEREST "}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={165}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3230.04 6113)"
>
{"FOR PROJECT"}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="italic"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={183}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 654.587 5871)"
>
{"LOW"}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="italic"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={183}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 5684.95 5856)"
>
{"HIGH"}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Arial,Arial_MSFontService,sans-serif"
fontStyle="italic"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={183}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 638.277 1067)"
>
{"HIGH"}
</text>
</g>
</g>
</svg>
);
src/contents/Human Practices/HP svgs/stakeholder-management.tsx 0 → 100644
View file @ 3fd292fd
export function StakeholderManagement(){
return(
<svg
viewBox="0 0 4700 2500"
xmlns="http://www.w3.org/2000/svg"
xmlnsXlink="http://www.w3.org/1999/xlink"
xmlSpace="preserve"
overflow="hidden"
>
<g transform="translate(-1040 -2021)">
<g>
<path
d="M0 0.042729 0 717.078 430.957 1148 430.957 0.042729Z"
fill="#7E84C1"
fillRule="evenodd"
fillOpacity={1}
transform="matrix(-1 0 0 1 4153 3108)"
/>
<path
d="M430.965 0 0 431 1147.96 431 1147.96 0Z"
fill="#8F47A2"
fillRule="evenodd"
fillOpacity={1}
transform="matrix(-1 0 0 1 4154 2189)"
/>
<path
d="M0.0427325 0 0.0427325 1147.96 431 1147.96 431 430.965 0.0427325 0Z"
fill="#5E0A54"
fillRule="evenodd"
fillOpacity={1}
transform="matrix(-1 0 0 1 2518 2189)"
/>
<path
d="M0.042729 0.0427325 0.042729 431 717.078 431 1148 0.0427325Z"
fill="#080607"
fillRule="evenodd"
fillOpacity={1}
transform="matrix(-1 0 0 1 3235 3825)"
/>
<path
d="M595.489 0 164.511 430.858 164.511 918.873 0 918.873 380 1380.96 760 918.873 595.489 918.873 595.489 0Z"
stroke="#B85BD1"
strokeWidth={3.4375}
strokeLinecap="butt"
strokeLinejoin="round"
strokeMiterlimit={10}
strokeOpacity={1}
fill="#B85BD1"
fillRule="evenodd"
fillOpacity={1}
transform="matrix(-1 0 0 1 4318.5 2189.5)"
/>
<path
d="M462.127 0 0.0427184 380 462.127 760 462.127 595.489 1381 595.489 950.185 164.511 462.127 164.511 462.127 0Z"
stroke="#850E78"
strokeWidth={3.4375}
strokeLinecap="butt"
strokeLinejoin="round"
strokeMiterlimit={10}
strokeOpacity={1}
fill="#850E78"
fillRule="evenodd"
fillOpacity={1}
transform="matrix(-1 0 0 1 3468.5 2025.5)"
/>
<path
d="M380 0.0427184 0.0427302 462.127 164.554 462.127 164.554 1381 595.489 950.185 595.489 462.127 760 462.127 380 0.0427184Z"
fill="#32232C"
fillRule="evenodd"
fillOpacity={1}
transform="matrix(-1 0 0 1 2682 2875)"
/>
<path
d="M918.872 0.0427302 918.872 164.554 0 164.554 430.815 595.489 918.872 595.489 918.872 760 1380.96 380 918.872 0.0427302Z"
fill="#A0A7F3"
fillRule="evenodd"
fillOpacity={1}
transform="matrix(-1 0 0 1 4153 3661)"
/>
<text
fill="#A0A7F3"
fillOpacity={1}
fontFamily="Fira Sans,Fira Sans_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={147}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 4190.15 4224)"
>
{"IMPLEMENTATION"}
</text>
<text
fill="#B85BD1"
fillOpacity={1}
fontFamily="Fira Sans,Fira Sans_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={147}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 4378.25 2327)"
>
{"REGULATION & "}
</text>
<text
fill="#B85BD1"
fillOpacity={1}
fontFamily="Fira Sans,Fira Sans_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={147}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 4880.13 2503)"
>
{"SAFETY"}
</text>
<text
fill="#5E0A54"
fillOpacity={1}
fontFamily="Fira Sans,Fira Sans_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={147}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 1130.82 2342)"
>
{"PERCEPTION"}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Fira Sans,Fira Sans_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={147}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 1130.82 4202)"
>
{"IMPACT"}
</text>
</g>
</g>
</svg>
);
}
\ No newline at end of file
src/contents/Human Practices/HP svgs/swots.tsx 0 → 100644
View file @ 3fd292fd
export function SWOTone(){
return(
<svg
viewBox="0 0 5500 2500"
xmlns="http://www.w3.org/2000/svg"
xmlnsXlink="http://www.w3.org/1999/xlink"
xmlSpace="preserve"
overflow="hidden"
>
<g transform="translate(-435 -3575)">
<g>
<path
d="M3222 5305.3 3351.91 5305.3 3351.91 5632.92 3236.22 5632.92 3226.44 5601.43C3223.53 5587.19 3222 5572.46 3222 5557.36ZM3554.96 5223.35 3708.52 5223.35 3708.52 5632.92 3554.96 5632.92ZM3910.16 5043.62 4063.84 5043.62 4063.84 5632.92 3910.16 5632.92ZM4383.51 3704.32C4434.88 3704.32 4478.82 3714.55 4515.84 3733.18L4522.83 3737.9 4529.56 3759.57C4532.47 3773.81 4534 3788.54 4534 3803.64L4534 4415.42 4521.94 4422.93C4484.84 4442.71 4440.1 4453.85 4386.72 4453.85 4190.88 4453.85 4096.17 4290.14 4096.17 4073.46 4096.17 3858.4 4182.85 3704.32 4383.51 3704.32ZM3440.67 3585 4102.31 3585 4070 3605.25C3927.34 3705.87 3848.96 3877.66 3848.96 4078.28 3848.96 4396.07 4030.35 4648.05 4378.69 4648.05 4423.64 4648.05 4465.85 4643.91 4505.31 4636.07L4534 4628.79 4534 5557.36C4534 5678.11 4436.1 5776 4315.33 5776L3440.67 5776C3365.19 5776 3298.64 5737.76 3259.35 5679.61L3250.62 5663.53 4213.26 5663.53C4224.51 5663.53 4231.61 5657.47 4231.61 5647.61 4231.61 5640.32 4223.09 5632.92 4213.26 5632.92L4099.01 5632.92 4099.01 5028.94C4099.01 5019.18 4092.02 5013.02 4082.19 5013.02L3894.65 5013.02C3884.82 5013.02 3877.72 5019.18 3877.72 5028.94L3877.72 5632.92 3743.81 5632.92 3743.81 5207.43C3743.81 5198.91 3736.7 5192.74 3725.46 5192.74L3539.45 5192.74C3528.08 5192.74 3521.1 5198.91 3521.1 5207.43L3521.1 5632.92 3387.19 5632.92 3387.19 5290.62C3387.19 5280.76 3380.09 5274.7 3370.26 5274.7L3222 5274.7 3222 5211.5 3273.45 5203.47C3332.59 5193.14 3404.21 5177.15 3482.97 5152.38 3600.07 5115.72 3711.37 5066.83 3811.53 5008.09 3821.36 5004.49 3822.78 4994.63 3817.1 4987.34 3813.43 4982.62 3808.1 4979.95 3802.42 4979.95 3799.34 4979.95 3796.14 4980.67 3793.18 4982.41 3694.44 5041.16 3585.98 5087.58 3470.31 5123.11 3393.67 5146.95 3324.16 5162.36 3266.84 5172.37L3222 5179.4 3222 5144.99 3261.42 5138.72C3318.08 5128.72 3386.82 5113.42 3461.9 5090.04 3628.25 5037.46 3867.89 4932.29 4063.84 4720.73 4074.61 4711.38 4064.55 4696.29 4049.99 4696.29 4049.4 4696.29 4048.92 4696.29 4048.33 4696.29L3991.97 4702.45C3990.2 4702.76 3988.54 4702.96 3987 4702.96 3978.24 4702.96 3971.96 4697.42 3970.78 4690.23 3966.52 4680.37 3976.46 4670.61 3987.71 4669.38L4138.55 4652.33C4139.26 4652.23 4139.97 4652.23 4140.68 4652.23 4151.22 4652.23 4161.05 4660.24 4161.05 4669.38L4161.05 4798.99C4161.05 4808.85 4152.64 4816.14 4141.39 4816.14 4130.03 4816.14 4121.62 4808.85 4121.62 4798.99L4121.62 4759.86C4121.62 4753.8 4117.36 4747.64 4111.79 4745.28 4110.02 4744.97 4108.24 4744.76 4106.35 4744.76 4100.43 4744.76 4094.15 4746.41 4092.02 4750.1 4027.14 4821.07 3951.01 4883.41 3869.31 4938.46 3862.21 4943.28 3860.79 4953.14 3866.47 4959.2 3870.02 4963.1 3875.82 4965.47 3881.39 4965.47 3884.7 4965.47 3887.78 4964.65 3890.39 4962.9 3960.95 4915.14 4028.56 4860.2 4087.76 4802.69 4090.6 4828.36 4113.09 4847.98 4142.69 4847.98 4172.41 4847.98 4197.75 4827.13 4197.75 4800.22L4197.75 4670.61C4194.91 4657.16 4187.8 4644.94 4175.14 4636.41 4164.72 4628.3 4152.17 4623.58 4139.5 4623.58 4136.77 4623.58 4134.17 4623.78 4131.45 4624.19L3980.61 4640.11C3951.01 4643.7 3929.93 4668.15 3934.07 4693.82 3936.8 4717.96 3961.78 4735.62 3989.37 4735.62 3991.14 4735.62 3992.92 4735.62 3994.69 4735.42L4007.36 4732.95C3822.78 4918.84 3604.22 5014.25 3449.23 5061.9 3376.28 5084.39 3309.66 5099.3 3254.81 5109.15L3222 5114.5 3222 3803.64C3222 3682.89 3319.9 3585 3440.67 3585Z"
fill="#C8CBF1"
fillRule="evenodd"
fillOpacity={1}
/>
<path
d="M5410.55 5364.83C5405.66 5364.83 5400.29 5366.4 5395.27 5369.41 5388.23 5375.65 5388.23 5385.52 5395.27 5394.25L5420.93 5415.25 5395.27 5437.5C5388.23 5443.73 5388.23 5453.61 5395.27 5462.24 5399.57 5464.73 5405.3 5465.98 5409.48 5465.98 5415.2 5465.98 5420.93 5464.73 5423.68 5462.24L5449.34 5439.99 5473.44 5462.24C5477.74 5464.73 5483.35 5465.98 5487.64 5465.98 5493.37 5465.98 5498.98 5464.73 5501.85 5462.24 5509.01 5456.1 5509.01 5444.98 5501.85 5437.5L5477.74 5415.25 5501.85 5394.25C5509.01 5388.02 5509.01 5376.89 5501.85 5369.41 5498.27 5366.4 5493.73 5364.83 5488.72 5364.83 5483.71 5364.83 5478.46 5366.4 5473.44 5369.41L5449.34 5390.51 5423.68 5369.41C5420.22 5366.4 5415.56 5364.83 5410.55 5364.83ZM4888.08 5329.8C4919.34 5329.8 4946.31 5353.4 4946.31 5381.88 4946.31 5409.01 4919.34 5432.61 4888.08 5432.61 4855.38 5432.61 4829.84 5409.01 4829.84 5381.88 4829.84 5353.4 4855.38 5329.8 4888.08 5329.8ZM5071.86 5137.08C5066.73 5137.08 5061.36 5138.64 5057.18 5141.76 5050.02 5147.89 5050.02 5159.01 5057.18 5166.5L5081.29 5187.49 5057.18 5209.84C5050.02 5215.98 5050.02 5227.1 5057.18 5234.58 5059.93 5237.08 5065.65 5239.47 5071.38 5239.47 5075.56 5239.47 5081.29 5237.08 5085.58 5234.58L5109.69 5212.23 5135.23 5234.58C5138.09 5237.08 5143.82 5239.47 5149.43 5239.47 5153.73 5239.47 5159.46 5237.08 5163.63 5234.58 5170.79 5228.35 5170.79 5217.22 5163.63 5209.84L5138.09 5187.49 5163.63 5166.5C5170.79 5160.26 5170.79 5149.14 5163.63 5141.76 5160.17 5138.64 5155.16 5137.08 5150.03 5137.08 5144.9 5137.08 5139.53 5138.64 5135.23 5141.76L5109.69 5162.75 5085.58 5141.76C5082 5138.64 5076.99 5137.08 5071.86 5137.08ZM5383.94 5115.77C5383.94 5115.77 5381.07 5115.77 5381.07 5117.02L5329.99 5140.51C5321.4 5144.25 5315.67 5154.13 5321.4 5162.76 5325.58 5169.2 5332.14 5172.84 5339.78 5172.84 5342.53 5172.84 5345.39 5172.42 5348.37 5171.38L5362.57 5165.25C5337.03 5239.47 5291.57 5295.19 5229.03 5329.8 5166.74 5364.94 5097.28 5372.42 5046.92 5372.42 5022.69 5372.42 5002.76 5370.66 4990.35 5369.41 4983.19 5328.66 4943.45 5297.68 4895.12 5297.68 4841.18 5297.68 4797.14 5336.04 4797.14 5383.03 4797.14 5428.87 4841.18 5468.47 4895.12 5468.47 4940.59 5468.47 4980.45 5439.99 4990.35 5402.88 5004.55 5404.13 5024.48 5406.62 5050.02 5406.62 5103.96 5406.62 5180.7 5396.64 5250.39 5358.29 5319.97 5319.93 5369.73 5260.57 5398.14 5180.12L5401 5185C5405.3 5191.24 5412.34 5193.73 5419.5 5193.73 5422.24 5193.73 5423.68 5193.73 5427.97 5192.49 5429.4 5187.5 5433.7 5177.62 5427.97 5167.75L5401 5123.15C5401 5123.15 5401 5121.9 5399.57 5121.9L5395.27 5118.27 5393.84 5117.02C5393.84 5117.02 5392.41 5117.02 5392.41 5115.77ZM4730.9 5090.09C4725.65 5090.09 4720.4 5091.65 4716.1 5094.67 4708.94 5100.9 4708.94 5112.03 4716.1 5119.41L4740.21 5141.76 4716.1 5162.75C4708.94 5168.99 4708.94 5180.11 4716.1 5187.49 4718.97 5191.24 4724.58 5192.48 4730.31 5192.48 4734.6 5192.48 4740.21 5191.24 4744.51 5187.49L4768.73 5166.5 4794.27 5187.49C4797.14 5191.24 4802.75 5192.48 4808.47 5192.48 4812.77 5192.48 4818.38 5191.24 4822.68 5187.49 4829.84 5181.36 4829.84 5171.38 4822.68 5162.75L4797.14 5141.76 4822.68 5119.41C4829.84 5113.27 4829.84 5103.4 4822.68 5094.67 4819.1 5091.65 4814.2 5090.09 4808.95 5090.09 4803.82 5090.09 4798.57 5091.65 4794.27 5094.67L4768.73 5117.02 4744.51 5094.67C4740.93 5091.65 4736.03 5090.09 4730.9 5090.09ZM5356.96 4896.64 5614.14 4896.64C5653.88 4896.64 5683.72 4925.13 5683.72 4957.35L5683.72 5576.16 5679.42 5576.16C5679.42 5610.78 5648.27 5636.77 5611.28 5636.77L4629.41 5636.77 4618.44 5601.43 4616.39 5581.05 5264.59 5581.05C5274.5 5581.05 5284.52 5573.67 5284.52 5563.79 5284.52 5555.06 5274.5 5546.43 5264.59 5546.43L4620.87 5546.43 4620.87 4988.22 4845.35 4988.22C4849.65 5014.21 4875.31 5032.82 4907.89 5032.82L5293 5032.82C5322.83 5032.82 5349.8 5012.96 5355.53 4988.22L5578.58 4988.22 5578.58 5546.43 5361.14 5546.43C5351.24 5546.43 5342.76 5555.06 5342.76 5563.79 5342.76 5573.67 5351.24 5581.05 5361.14 5581.05L5598.51 5581.05C5608.41 5581.05 5617.01 5573.67 5617.01 5563.79L5617.01 4970.97C5617.01 4962.24 5608.41 4954.86 5598.51 4954.86L5356.96 4954.86ZM4614 4896.64 4844.04 4896.64 4844.04 4954.86 4614 4954.86ZM5096.92 4875.65C5115.42 4875.65 5129.62 4888.02 5129.62 4902.88 5129.62 4918.99 5115.42 4931.36 5096.92 4931.36 5079.86 4931.36 5065.66 4918.99 5065.66 4902.88 5065.66 4888.02 5079.86 4875.65 5096.92 4875.65ZM5096.92 4839.79C5058.5 4839.79 5024.48 4868.16 5024.48 4902.88 5024.48 4937.5 5057.18 4967.23 5096.92 4967.23 5136.66 4967.23 5169.36 4938.75 5169.36 4902.88 5167.93 4868.16 5136.66 4839.79 5096.92 4839.79ZM5058.49 4694.98 5129.62 4694.98C5170.79 4694.98 5203.49 4723.36 5203.49 4759.33L5203.49 4797.68C5203.49 4827.41 5231.9 4852.15 5266.03 4852.15L5284.52 4852.15C5295.86 4852.15 5307.2 4862.03 5307.2 4871.9L5307.2 4979.6C5307.2 4989.47 5295.86 4999.45 5284.52 4999.45L4897.98 4999.45C4886.64 4999.45 4875.31 4989.47 4875.31 4979.6L4880.91 4871.9C4880.91 4862.03 4890.82 4852.15 4903.71 4852.15L4922.09 4852.15C4954.79 4852.15 4983.19 4827.41 4983.19 4797.68L4983.19 4759.33C4983.19 4723.36 5017.32 4694.98 5058.49 4694.98ZM4832.67 3585 5122.63 3585 5122.63 3721.97 5459.73 3721.97 5459.73 4632 5698.92 4632 5698.92 3721.97 5909.88 3721.97 5921.56 3759.57C5924.47 3773.81 5926 3788.54 5926 3803.64L5926 5557.36C5926 5678.11 5828.1 5776 5707.33 5776L4832.67 5776C4757.19 5776 4690.64 5737.76 4651.35 5679.61L4648.23 5673.88 5611.28 5673.88C5670.95 5673.88 5720.71 5630.63 5720.71 5577.41L5720.71 4958.6C5719.28 4905.38 5669.52 4863.28 5608.41 4863.28L5351.24 4863.28C5345.51 4837.29 5321.4 4818.68 5288.7 4818.68L5271.64 4818.68C5258.87 4818.68 5248.96 4808.81 5248.96 4797.68L5248.96 4759.33C5248.96 4703.61 5196.33 4659.02 5132.48 4659.02L5061.36 4659.02C4997.39 4659.02 4946.31 4703.61 4946.31 4759.33L4946.31 4797.68C4946.31 4808.81 4936.29 4818.68 4923.52 4818.68L4905.14 4818.68C4875.31 4818.68 4848.21 4838.54 4844.04 4863.28L4614 4863.28 4614 3803.64C4614 3682.89 4711.9 3585 4832.67 3585Z"
fill="#EEF9FF"
fillRule="evenodd"
fillOpacity={1}
/>
<path
d="M731.094 5666.23 879.805 5776 657.671 5776C642.575 5776 627.836 5774.47 613.601 5771.56L595.09 5765.81ZM461.894 5652.98 541.539 5652.98 526.425 5726.63 526.721 5731.49 503.047 5711.96C493.155 5702.07 484.205 5691.24 476.345 5679.61ZM439 5521.79 568.997 5521.79 549.731 5611.65 446.615 5611.65 443.443 5601.43C440.529 5587.19 439 5572.46 439 5557.36ZM1044.21 5303.71C1034.64 5303.71 1026.44 5312.5 1026.44 5324.38 1026.44 5334.66 1034.64 5344.93 1044.21 5344.93L1167.89 5344.93C1178.85 5344.93 1187.16 5334.66 1187.16 5324.38 1187.16 5312.5 1178.85 5303.71 1167.89 5303.71ZM758.553 5194.68C747.592 5194.68 739.285 5203.46 739.285 5215.22 739.285 5227.1 747.592 5235.89 758.553 5235.89L1167.89 5235.89C1178.85 5235.89 1187.16 5227.1 1187.16 5215.22 1187.16 5203.46 1178.85 5194.68 1167.89 5194.68ZM961.834 4973.62C952.258 4973.62 943.952 4982.41 943.952 4994.29 943.952 5006.05 952.258 5014.84 961.834 5014.84L1167.89 5014.84C1178.85 5014.84 1187.15 5006.05 1187.15 4994.29 1187.15 4982.41 1178.85 4973.62 1167.89 4973.62ZM552.498 4863.1C541.538 4863.1 533.231 4871.89 533.231 4883.77 533.231 4895.53 541.538 4904.32 552.498 4904.32L1167.89 4904.32C1178.84 4904.32 1187.15 4895.53 1187.15 4883.77 1187.15 4871.89 1178.84 4863.1 1167.89 4863.1ZM1353.29 4860.13 1375.33 4860.13C1409.71 4860.13 1439.82 4889.59 1439.82 4927.96L1439.82 5545.31C1438.55 5582.19 1408.32 5613.13 1373.94 5613.13L1046.98 5613.13C1041.56 5613.13 1034.64 5617.59 1030.48 5620.56 1027.83 5626.37 1026.44 5632.32 1027.83 5636.77L1057.36 5776 946.695 5776 765.475 5642.59 930.224 5521.79 1251.65 5521.79C1309.33 5521.79 1353.29 5473.15 1353.29 5412.75ZM439 4727.45 1251.65 4727.45C1286.03 4727.45 1316.26 4757.04 1316.26 4795.28L1316.26 5412.75C1316.26 5449.64 1288.8 5480.58 1251.65 5480.58L924.802 5480.58C920.649 5480.58 917.88 5481.94 913.726 5483.42L566.229 5738.38C563.46 5738.38 563.46 5736.9 563.46 5736.9L614.339 5504.09C615.723 5498.15 614.339 5490.85 610.185 5487.88 606.031 5481.94 601.994 5480.58 595.071 5480.58L439 5480.58 439 5344.93 964.606 5344.93C974.182 5344.93 982.489 5334.66 982.489 5324.38 982.489 5312.5 974.182 5303.71 964.606 5303.71L439 5303.71 439 5235.89 634.874 5235.89C644.565 5235.89 652.756 5227.1 652.756 5215.22 655.525 5203.46 645.949 5194.68 634.874 5194.68L439 5194.68 439 5125.37 1167.89 5125.37C1178.85 5125.37 1187.16 5116.58 1187.16 5104.7 1187.16 5092.94 1178.85 5084.15 1167.89 5084.15L439 5084.15 439 5014.84 882.23 5014.84C891.805 5014.84 899.997 5006.05 899.997 4994.29 899.997 4982.41 891.805 4973.62 882.23 4973.62L439 4973.62 439 4904.32 471.509 4904.32C481.085 4904.32 490.66 4895.53 490.66 4883.77 490.66 4871.89 481.085 4863.1 471.509 4863.1L439 4863.1ZM1577.16 3686.66C1666.45 3686.66 1714.36 3715.5 1740.87 3753.98L1747.12 3765.14 1751 3803.64 1751 3983.75 1705.1 3969.63C1686.94 3964.49 1667.86 3959.51 1647.79 3954.69 1468 3914.57 1421.45 3882.47 1421.45 3805.43 1421.45 3726.79 1479.24 3686.66 1577.16 3686.66ZM657.671 3585 1301.72 3585 1282.39 3599.19C1213.57 3655.77 1177.45 3736.42 1177.45 3832.72 1177.45 3981.98 1251.29 4092.72 1553.08 4163.34 1647.79 4185.01 1708.39 4205.48 1745.31 4231.96L1751 4237.09 1751 4433.26 1726.81 4447.81C1698.41 4461.07 1660.63 4468.29 1612.47 4468.29 1484.05 4468.29 1405.4 4418.54 1379.71 4307.79L1138.92 4307.79C1164.61 4510.02 1313.9 4648.05 1594.82 4648.05 1649.6 4648.05 1699.47 4643.14 1744.34 4633.84L1751 4632.19 1751 5557.36C1751 5678.11 1653.1 5776 1532.33 5776L1096.62 5776 1070.4 5652.98 1373.94 5652.98C1430.24 5652.98 1475.58 5605.83 1475.58 5545.31L1475.58 4927.96C1475.58 4868.92 1428.86 4818.92 1373.94 4818.92L1351.91 4818.92 1351.91 4795.28C1351.91 4734.88 1307.95 4686.24 1250.26 4686.24L439 4686.24 439 3803.64C439 3682.89 536.902 3585 657.671 3585Z"
fill="#BF63B7"
fillRule="evenodd"
fillOpacity={1}
/>
<path
d="M2612.68 5483.31C2603.02 5483.31 2594.58 5490.5 2594.58 5501.19 2594.58 5510.68 2601.8 5517.88 2612.68 5517.88L2724.12 5517.88C2733.78 5517.88 2742.22 5510.68 2742.22 5501.19 2742.22 5490.5 2733.78 5483.31 2724.12 5483.31ZM2350.03 5483.31C2341.49 5483.31 2331.83 5490.5 2331.83 5501.19 2331.83 5510.68 2340.26 5517.88 2350.03 5517.88L2462.59 5517.88C2471.03 5517.88 2480.69 5510.68 2480.69 5501.19 2480.69 5490.5 2473.47 5483.31 2462.59 5483.31ZM2089.72 5483.31C2081.17 5483.31 2071.51 5490.5 2071.51 5501.19 2071.51 5510.68 2079.95 5517.88 2089.72 5517.88L2202.28 5517.88C2210.72 5517.88 2220.48 5510.68 2220.48 5501.19 2220.48 5490.5 2211.94 5483.31 2202.28 5483.31ZM2612.68 5335.84C2603.02 5335.84 2594.58 5342.94 2594.58 5353.63 2594.58 5364.42 2601.8 5371.51 2612.68 5371.51L2724.12 5371.51C2733.78 5371.51 2742.22 5364.42 2742.22 5353.63 2742.22 5342.94 2733.78 5335.84 2724.12 5335.84ZM2089.72 5335.84C2081.17 5335.84 2071.51 5342.94 2071.51 5353.63 2071.51 5364.42 2079.95 5371.51 2089.72 5371.51L2202.28 5371.51C2210.72 5371.51 2220.48 5364.42 2220.48 5353.63 2220.48 5342.94 2211.94 5335.84 2202.28 5335.84ZM2462.08 5298.68C2457.71 5298.68 2453.44 5300.78 2450.49 5304.87L2388.77 5365.62 2363.25 5340.64C2359.08 5336.44 2354.5 5334.35 2350.23 5334.35 2346.06 5334.35 2342.1 5336.44 2339.05 5340.64 2330.61 5347.73 2330.61 5358.42 2339.05 5364.42L2376.57 5401.28C2379.01 5403.68 2383.89 5405.98 2388.77 5405.98 2393.55 5405.98 2397.21 5403.68 2400.87 5401.28L2474.69 5328.65C2481.91 5322.76 2481.91 5310.87 2474.69 5304.87 2471.03 5300.78 2466.46 5298.68 2462.08 5298.68ZM2350.03 5189.48C2341.49 5189.48 2331.83 5197.87 2331.83 5207.36 2331.83 5218.05 2340.26 5225.25 2350.03 5225.25L2462.59 5225.25C2471.03 5225.25 2480.69 5218.05 2480.69 5207.36 2480.69 5197.87 2473.47 5189.48 2462.59 5189.48ZM2723.61 5152.01C2719.24 5152.01 2714.97 5153.81 2711.92 5157.41L2650.2 5218.05 2624.78 5193.07C2621.22 5189.48 2616.64 5187.78 2612.27 5187.78 2607.9 5187.78 2603.63 5189.48 2600.58 5193.07 2593.36 5200.27 2593.36 5210.96 2600.58 5216.85L2638.1 5253.72C2641.76 5257.32 2645.42 5258.51 2650.2 5258.51 2655.08 5258.51 2659.96 5257.32 2662.3 5253.72L2736.22 5181.18C2744.66 5175.29 2744.66 5164.5 2736.22 5157.41 2732.56 5153.81 2727.99 5152.01 2723.61 5152.01ZM2201.77 5152.01C2197.4 5152.01 2193.23 5153.81 2190.18 5157.41L2128.46 5218.05 2103.04 5193.07C2098.76 5189.48 2094.19 5187.78 2090.02 5187.78 2085.75 5187.78 2081.78 5189.48 2078.83 5193.07 2070.29 5200.27 2070.29 5210.96 2078.83 5216.85L2116.36 5253.72C2118.7 5257.32 2123.58 5258.51 2128.46 5258.51 2133.24 5258.51 2136.9 5257.32 2140.56 5253.72L2214.38 5181.18C2220.48 5175.29 2220.48 5164.5 2214.38 5157.41 2210.72 5153.81 2206.25 5152.01 2201.77 5152.01ZM2612.68 5043.21C2603.02 5043.21 2594.58 5050.3 2594.58 5061.09 2594.58 5070.58 2601.8 5078.88 2612.68 5078.88L2724.12 5078.88C2733.78 5078.88 2742.22 5070.58 2742.22 5061.09 2742.22 5050.3 2733.78 5043.21 2724.12 5043.21ZM2089.72 5043.21C2081.17 5043.21 2071.51 5050.3 2071.51 5061.09 2071.51 5070.58 2079.95 5078.88 2089.72 5078.88L2202.28 5078.88C2210.72 5078.88 2220.48 5070.58 2220.48 5061.09 2220.48 5050.3 2211.94 5043.21 2202.28 5043.21ZM2462.08 5005.75C2457.71 5005.75 2453.44 5007.54 2450.49 5011.04L2388.77 5072.98 2363.25 5046.81C2359.08 5043.21 2354.5 5041.41 2350.23 5041.41 2346.06 5041.41 2342.1 5043.21 2339.05 5046.81 2330.61 5055.1 2330.61 5064.59 2339.05 5070.59L2376.57 5108.65C2379.01 5111.05 2383.89 5112.25 2388.77 5112.25 2393.55 5112.25 2397.21 5111.05 2400.87 5108.65L2474.69 5034.92C2481.91 5027.73 2481.91 5017.03 2474.69 5011.04 2471.03 5007.54 2466.46 5005.75 2462.08 5005.75ZM1903.23 4823.11 2651.42 4823.11 2651.42 4824.31C2651.42 4843.39 2668.4 4859.97 2687.72 4859.97L2726.47 4859.97C2745.89 4859.97 2762.87 4843.39 2762.87 4824.31L2762.87 4823.11 2800.39 4823.11C2820.93 4823.11 2837.91 4838.59 2837.91 4859.97L2837.91 5592.81C2837.91 5611.79 2819.71 5629.68 2799.17 5629.68L1843.21 5629.68 1834.44 5601.43C1831.53 5587.19 1830 5572.46 1830 5557.36L1830 5524.36 1854.83 5548.75C1857.27 5551.15 1862.05 5552.35 1866.93 5552.35 1870.59 5552.35 1875.37 5551.15 1879.03 5548.75L1952.85 5475.02C1960.17 5467.83 1960.17 5457.13 1952.85 5451.24 1948.68 5447.64 1944.11 5445.84 1939.84 5445.84 1935.67 5445.84 1931.7 5447.64 1928.65 5451.24L1866.93 5513.08 1840.29 5486.91 1830 5482.51 1830 5371.51 1940.75 5371.51C1949.29 5371.51 1958.95 5364.42 1958.95 5353.63 1958.95 5342.94 1949.29 5335.84 1940.75 5335.84L1830 5335.84 1830 5225.25 1940.75 5225.25C1949.29 5225.25 1958.95 5218.05 1958.95 5207.36 1958.95 5197.87 1949.29 5189.48 1940.75 5189.48L1830 5189.48 1830 5078.88 1940.75 5078.88C1949.29 5078.88 1958.95 5070.58 1958.95 5061.09 1958.95 5050.3 1949.29 5043.21 1940.75 5043.21L1830 5043.21 1830 4931.41 2780.97 4931.41C2789.4 4931.41 2799.17 4923.02 2799.17 4913.52 2799.17 4902.83 2789.4 4895.74 2780.97 4895.74L1830 4895.74 1830 4859.97 1866.93 4859.97C1886.25 4859.97 1903.23 4843.39 1903.23 4824.31ZM2722.91 4746.98C2722.91 4746.98 2724.13 4746.98 2724.13 4748.17L2724.13 4820.71C2724.13 4820.71 2724.13 4823.11 2722.91 4823.11L2685.39 4823.11C2685.39 4823.11 2684.16 4823.11 2684.16 4820.71L2684.16 4748.17 2685.39 4748.17ZM1864.49 4746.98C1864.49 4746.98 1865.71 4746.98 1865.71 4748.17L1865.71 4820.71C1865.71 4820.71 1865.71 4823.11 1864.49 4823.11L1830 4823.11 1830 4748.08ZM3111.08 3693.22 3124.82 3718.53C3135.88 3744.69 3142 3773.45 3142 3803.64L3142 3812.87 3113.96 3704.22ZM2483.82 3585 2829.44 3585 2821.67 3616.49C2757.49 3871.49 2670.59 4188.7 2634.07 4367.06L2632.46 4367.06C2620.42 4252.7 2578.75 4046.66 2487.62 3603.45ZM2048.67 3585 2232.24 3585 2496.01 4617.44 2743.22 4617.44C2802.62 4394.34 2902.14 4021.99 2942.27 3824.57L2943.88 3824.57C2982.41 4013.96 3080.33 4371.87 3138.12 4617.44L3142 4617.44 3142 5557.36C3142 5678.11 3044.1 5776 2923.33 5776L2048.67 5776C1973.19 5776 1906.64 5737.76 1867.35 5679.61L1858.95 5664.15 2797.95 5664.15C2839.13 5664.15 2872.99 5632.07 2872.99 5591.61L2872.99 4858.77C2872.99 4818.41 2839.13 4785.04 2799.17 4785.04L2760.43 4785.04 2760.43 4748.17C2760.43 4729.19 2744.67 4712.51 2724.13 4712.51L2686.5 4712.51C2667.18 4712.51 2650.2 4729.19 2650.2 4748.17L2650.2 4785.04 1900.79 4785.04 1900.79 4748.17C1900.79 4729.19 1883.91 4712.51 1864.49 4712.51L1830 4712.51 1830 3803.64C1830 3682.89 1927.9 3585 2048.67 3585Z"
fill="#C7A0CE"
fillRule="evenodd"
fillOpacity={1}
/>
<path
d="M1577.15 3686.63C1666.44 3686.63 1714.35 3715.54 1740.86 3754.12L1751 3772.27 1751 3783.89C1751 3849.12 1698.25 3902 1633.17 3902L1481.15 3902 1467.19 3894.41C1433.08 3871.68 1421.44 3844.33 1421.44 3805.71 1421.44 3726.86 1479.23 3686.63 1577.15 3686.63ZM556.827 3579 1312.74 3579 1282.39 3598.93C1213.56 3655.65 1177.44 3736.51 1177.44 3833.06 1177.44 3851.77 1178.6 3869.87 1181.2 3887.37L1184.81 3902 556.827 3902C491.753 3902 439 3849.12 439 3783.89L439 3697.11C439 3631.88 491.753 3579 556.827 3579Z"
fill="#BF63B7"
fillRule="evenodd"
fillOpacity={1}
/>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={128}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 711.748 3776)"
>
{"STRENGTHS"}
</text>
<path
d="M2942.27 3842.51 2943.88 3842.51C2946.29 3854.36 2948.93 3866.87 2951.78 3879.96L2956.24 3900 2929.99 3900 2934.08 3881.53C2937.03 3867.89 2939.77 3854.86 2942.27 3842.51ZM3078.2 3586.83 3079.08 3587.1C3116.06 3602.75 3142 3639.38 3142 3682.08L3142 3796.92 3138.16 3815.93 3113.96 3722.07C3104.42 3685.46 3095.21 3650.52 3086.58 3618.1ZM2478.94 3579 2835.44 3579 2835.04 3580.61C2813.42 3668.21 2788.23 3765.58 2762.8 3863.57L2753.35 3900 2544.63 3900 2536.52 3860.03C2522.09 3789.14 2505.85 3709.92 2487.62 3621.21ZM1933.02 3579 2226.18 3579 2308.12 3900 1933.02 3900C1876.12 3900 1830 3853.85 1830 3796.92L1830 3682.08C1830 3625.15 1876.12 3579 1933.02 3579Z"
fill="#C7A0CE"
fillRule="evenodd"
fillOpacity={1}
/>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={128}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 2129.21 3776)"
>
{"WEAKNESS"}
</text>
<path
d="M4383.51 3707.47C4434.88 3707.47 4478.82 3717.68 4515.84 3736.28L4534 3746.91 4534 3819.64C4534 3877.83 4486.73 3925 4428.42 3925L4113.8 3925 4134.18 3865.01C4177.21 3767.55 4258.1 3707.47 4383.51 3707.47ZM3327.58 3581 4114.12 3581 4070 3608.59C3970.14 3678.89 3901.77 3784 3869.74 3909.42L3866.49 3925 3327.58 3925C3269.27 3925 3222 3877.83 3222 3819.64L3222 3686.36C3222 3628.17 3269.27 3581 3327.58 3581Z"
fill="#C8CBF1"
fillRule="evenodd"
fillOpacity={1}
/>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={128}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3363.33 3789)"
>
{"OPPORTUNITIES"}
</text>
<path
d="M5698.92 3721.98 5926 3721.98 5926 3834.97C5926 3884.69 5885.61 3925 5835.78 3925L5698.92 3925ZM4704.22 3581 5122.63 3581 5122.63 3721.98 5459.73 3721.98 5459.73 3925 4704.22 3925C4654.39 3925 4614 3884.69 4614 3834.97L4614 3671.03C4614 3621.31 4654.39 3581 4704.22 3581Z"
fill="#EEF9FF"
fillRule="evenodd"
fillOpacity={1}
/>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={128}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 4979.88 3789)"
>
{"THREATS"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 649.554 4959)"
>
{"PreCyse"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 1142.83 4959)"
>
{"ut"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 1256.27 4959)"
>
{"i"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 1288.93 4959)"
>
{"lizes"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 549.866 5102)"
>
{"novel technology to "}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 556.168 5245)"
>
{"cure gene mutation "}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 640.685 5388)"
>
{"of Cystic Fibrosis"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 1981.06 4953)"
>
{"Gene "}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 2301.32 4953)"
>
{"editing"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 2717.83 4953)"
>
{"need"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 1939.54 5096)"
>
{"conteract"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 2502.71 5096)"
>
{"off"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 2649.95 5096)"
>
{"-"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 2695.79 5096)"
>
{"target "}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 2021.74 5239)"
>
{"effects"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 2429.08 5239)"
>
{"& "}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 2551.11 5239)"
>
{"require"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 2013.44 5382)"
>
{"safety"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 2380.11 5382)"
>
{"evaluation"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3379.9 4949)"
>
{"Technology "}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 4054.23 4949)"
>
{"might"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3306 5092)"
>
{"enable"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3707.61 5092)"
>
{"directions"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 4294.85 5092)"
>
{"for"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3341.22 5235)"
>
{"treatments"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3981.17 5235)"
>
{"of"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 4118.1 5235)"
>
{"other"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3413.71 5378)"
>
{"genetic"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3856 5378)"
>
{"diseases"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 4830 4949)"
>
{"Requirments"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 5569.64 4949)"
>
{"on "}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 4702.82 5092)"
>
{"regulatory"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 5277.45 5092)"
>
{", "}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 5338.18 5092)"
>
{"ethical"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 5743.23 5092)"
>
{"& "}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 4748.65 5235)"
>
{"legal "}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 5045.99 5235)"
>
{"requirements"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 4830.85 5378)"
>
{"offer"}
</text>
<text
fill="#000000"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={700}
fontStretch="normal"
fontSize={119}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 5119.6 5378)"
>
{"limitations"}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={400}
fontStretch="normal"
fontSize={92}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 623.457 4361)"
>
{"Internal positive factors "}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={400}
fontStretch="normal"
fontSize={92}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 699.082 4471)"
>
{"provide advantages"}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={400}
fontStretch="normal"
fontSize={92}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 1998.52 4360)"
>
{"Internal negative factors "}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={400}
fontStretch="normal"
fontSize={92}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 2053.79 4470)"
>
{"provide disadvantage"}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={400}
fontStretch="normal"
fontSize={92}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3397.35 4360)"
>
{"External positive factors "}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={400}
fontStretch="normal"
fontSize={92}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 3435.46 4470)"
>
{"enable new directions"}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={400}
fontStretch="normal"
fontSize={92}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 4772.42 4360)"
>
{"External negative factors "}
</text>
<text
fill="#32232C"
fillOpacity={1}
fontFamily="Acumin Pro,Acumin Pro_MSFontService,sans-serif"
fontStyle="normal"
fontVariant="normal"
fontWeight={400}
fontStretch="normal"
fontSize={92}
textAnchor="start"
direction="ltr"
writingMode="lr-tb"
unicodeBidi="normal"
textDecoration="none"
transform="matrix(1 0 0 1 4776.16 4470)"
>
{"impact endanger project"}
</text>
</g>
</g>
</svg>
);
};
src/contents/Human Practices/HP svgs/understanding.tsx 0 → 100644
View file @ 3fd292fd
import { openElement } from "../../../utils/openElement";
export const HPUnderstanding = () => (
<svg
viewBox="0 0 853.05645 556.00848"
height={200.00848}
width={853.05646}
xmlSpace="preserve"
id="svg2"
xmlnsXlink="http://www.w3.org/1999/xlink"
xmlns="http://www.w3.org/2000/svg"
>
<metadata id="metadata8">
</metadata>
<defs id="defs6">
<clipPath id="clipPath30" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path28"
d="M 2.112e-5,-1.2207e-4 H 1417.32 V 1417.3199 H 2.112e-5 Z"
/>
</clipPath>
<clipPath id="clipPath46" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path44"
d="M 2.112e-5,-1.2207e-4 H 1417.32 V 1417.3199 H 2.112e-5 Z"
/>
</clipPath>
<clipPath id="clipPath66" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path64"
d="M 2.112e-5,-1.2207e-4 H 1417.32 V 1417.3199 H 2.112e-5 Z"
/>
</clipPath>
<clipPath id="clipPath90" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path88"
d="M 599.4,830.52 H 672 V 903 h -72.6 z"
/>
</clipPath>
<mask
id="mask94"
height={1}
width={1}
y={0}
x={0}
maskUnits="userSpaceOnUse"
>
<image
id="image96"
xlinkHref="data:image/png;base64,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"
preserveAspectRatio="none"
/* style={{
imageRendering: "optimizeSpeed",
}}*/
height={1}
width={1}
/>
</mask>
<clipPath id="clipPath106" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path104"
d="m 711.84,714.6 h 68.04 v 68.04 h -68.04 z"
/>
</clipPath>
<mask
id="mask110"
height={1}
width={1}
y={0}
x={0}
maskUnits="userSpaceOnUse"
>
<image
id="image112"
xlinkHref="data:image/png;base64,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"
preserveAspectRatio="none"
/* style={{
imageRendering: "optimizeSpeed",
}}*/
height={1}
width={1}
/>
</mask>
<clipPath id="clipPath122" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path120"
d="m 596.4,602.16 h 73.68 v 73.68 H 596.4 Z"
/>
</clipPath>
<mask
id="mask126"
height={1}
width={1}
y={0}
x={0}
maskUnits="userSpaceOnUse"
>
<image
id="image128"
xlinkHref="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAMwAAADMCAAAAAAaSRMuAAAAAXNCSVQI5gpbmQAACilJREFUeJztnX9wFdUVx+++/DCBiCISfozYTGOZTqWFkf6QcSxSOkUyotDSUUcxDHWmWhRqf9ApaCEmpskQbHAgYxxnChHL1NoUDU6h0GqR1FKCDYxJq0BqIejwSKCEEJKX997pHy/JO/eeu7t3n9m92+n9/EV2z12+3+zde3fvnrNhzGAwGAwGg8FgMBgMBoPBYDAYDAbDCFZmzcbO+vxNEwvyWOxy18n2loujqyljMjCTM/9r82bmoA3Q/tb+P14aNUnBYc2q7gUJV+rnRHRr80jkS2/LnKRouz1Ltz4vTDlsbwUA4PSnMrwEg8fa7GwFAGD7/8jJmXTW3QtAdIZunSosuaTiBaD3Ed1K3VmTUPMCEK/SrdWNclUrAJCs0a3WmXUevAAkq3XrdeL+pEzypa6uHpvOVx7eQa2oTxQ70NGw8BrGGBsz7/njVyRu1ofVTaRbUNpfPwbvz60gZgE2hPTm5g1B59Y8MSJ3Le1ulTqkuvJZXuSHxbKgqcdEM8mNQQtV4KpTnMbGa+RhY+qJm03BClXhbk7hi1fZxWVVhN9NHndiGm29MGY9HfqetpC7Xmz6WAqrkripDNeYthuLu8k51qohk2tZmOabaVjZVtfwzWSIDtPs+SjS1U/mF0qtaAbK/RepymtIVr1Kg2riJjR3nZGetKiBMe7xjFnhHaFnI1Edak0kI/Sz/opUBV8yDYptJG7C8bS2BUm6U7WRpKet8VOkKr9DghwnTA6LjAKJJT6KVOVAWo+nteRaMt9I77WD5d20mi5PDTeL9wJXrvZJojptmZphNeKp+aU/Cj3wXlpMj7eW9K7zDl8UegB1s6TSnJmGjNDv57g38pU/IzHzPLa1ygQ3D/siUZ1GpOV5r40tYRn0g2w/JKqDJ83jnltH6ng3D/ig0AOPIClXcj03zz3KmXnTB4UeuAVrqfDePp9bHkxOHH2FXkCPANDn/dSwZdyp0bwwuAtrWZvBAbjFncOjrs8T+KKBxFTvB1iBD6A5+eEGrpscc5s4C6eL6wQR7k3oF/3SqUYT56beaa2loOwkwOCBb/JbubWqZ3zV6soCzgxU2L/onzY8DtdxK3/LcfODvut1JLeTd/O0nZv8v43E7MAxhfhhwPvEO7os5M1ApY2bJ1DMKzgminZ0BiLZnhzxvZnN6sTfcUwT6mn4LuBcMJrt+YxgJrlZFhWJc0GN6XPTjDafD0y1DdargptErSRqnBC0c8TNQbT1QoC65WR3CUKhml43lpiN0jDc01rQxu5glcuYeVl0Ixmh94ox24bcdKBtZwNWLuPRuKiUjtCLxJAhNzkDaNOp4LVTqshbJOqmTgyBBosx9lW85X0N2imbiBvS0yI7iJudFv+wCnu0iCcovHexXiExjRG89AbwhA7pEmiSFhmhrSYS01TM/XiDDuUSstaLQhNk9ow0ijHA5Q1/pEO4lKwNotBkjXjdWDuJG8yftAiXEqkkowC567QanMys0KLbho3uI3Rkm72X8w75HRqgI3SZBzcvadFsD3VTLmaUROx6WmK2FskO0J5WJy6n2Y0Cr2sR7MjPicij+UKIRUdoAEjeqkWvIxHxTQVA3zIxhs6eAC8IMfN+9mpLx7/b9tctz2A5brSg8w3AqRX8lVNMa2xik9K7r6/4Zxe+Ee89tWdBwC6GyZKln5/dvbwwtTtn7pY2SUDysaHmeeuODUr2n9v9FT12qmVJ25CMHm0+2NIxINsHAMlVjDE2fssFm/0Af/22Fjd0hFYguYrlr+t3DGm+XYebZzNyU/Evt5DEc2M1uKEZjKPEhc9pcFPhlxtYpCFL9Tt+mYEfB2/G+rJfZpI6aqOmHHIXNpjRSKEjE9JaZj9ppFRtm/xYRm60ZEJOrOpxkPTmXMbYquDOzScueZ30/fuKpDv699WmnvlX/0L6n5xsbT9xNpY3cfrNsyQHgI0/+aTKMiJy155O8bffe6RswkgAydkE6G64GR3hCy9FaYi+urWitc0d0Z7+eDzWd76zfXsJFpJ3gio9IbyVzq2iNa1hyrwf4Ueyi6JLfKJj79H1hXDVeDDGWL68jvi0mFNg0WLQ8NWt0efsFG0kBXWpmHMbumoi6yMbM9BCMqUXEzchybwfZoXUCAAAvHOtGLwk5G6apT6G3CicmzD1tFzHzwi0kOtmEXETorq1B5y8ALSTPKlvkNWO8NStvYVl9dG7zk4y38yPiTEbwuKGywTcyx4k56aLVLLNp+vZOpRL4G6qFzCrlCg9USC2KSE1HuGoWxuLtZ+LMMa+S9y0kjHtHjIKhKJu7Q4s6Q+MMcbodXNIYb55KnDplJVY0XOpbfRpTWH2jC0NWjqFSx9YPbSRujlErhvS0y5ofFcwBPeVgHuHt9Ke9nvSkowCulMiGXsBy1k8spmMAolppCmZb1YGKVwGV611f3r7ckEovEzbfl28F5hAY3h8vvHhcjLQ66btDwIfKFn+339Xkt9QN1qqMqQE/2a34D0P8z3ttKy1eNepuT5yAtayn9v1Pc7NG9Lmwgit+9TgjMhuvk8/jtzYvYou5czEJweg2IEzWEwJv2912s0Ru/b8u+2H/JbrDPcVwb3CzseHe9EZ2xkxrxUf4IDPal3gFs0ui7eU95wBAIj/ZYr9AYq4U+MQGAAFXOJtk7jbunPHvpoixyO8jA9wn1861eA+4jR4nfcDjMVzpzR1fwTfVwtewz9kZ1AT3IenIM2JUeP4j581ef/t4fTv//ig0Au/4swAyet0xcK/jkI/JKozQ8i9L/fsBi+KaC7BY2KeI8mEdAOPISXu4b5SLBZ5eD03v0Ft73UKDGDt8+RPhQ1PPuPNDS7u0r4emPUP4dTY1a3ZgJ/wHLO4gliVTswXt/zAefITuB792+OnPPxgjnhqpHVrduCvd8/0TaMyVildcVW/bo6jZurfJfIRmtHlUFksgAr4wlC0xmTZdraVxQKF6Kzu81ekMjQTUtHNi6hJaF6mK9StycjBc+7dvqtUJbPvBd6G4uOhuP5TKNStEXJx8vCuAESqolK3JlKKwxe7RQdJFqmKoHVrPNNxAntsXEA61VCpW8OM45YQMvlWjK/QaiKHJ4Lc17lI/e+bROgIvclulaOA+4YPhPGvJ1A3v5V/xOnTR7ioAf2fFZRAe1r0NtrVsr/Fr+skwzNhcpDvBQK0T+KfrLJnijnGrZrEuhGRVHole9akE0/G15I6r6jC8qGeP+WT9dR6ydZ498UzH18cf2PhtdeRB+DBW98NQFdmSOvWnCjVrdgRed2aHT/ULdcFL7VRYffC2JMkS86GWLj7WIqlLgUrQ0Rv0S1UiakfuFtJtur+zKsyK928DIR03pcy4deOXqpCeT9mT/FW8vGkIWJrw3fP78rkhw5QJ/Fdiz0/V4bkLxNOmTtn9oyRpZfoscPvvJ3B68uQmGGMMVZ4Y+HVkcHejz8My19ONRgMBoPBYDAYDAaDwWAwGAwGw/8f/wVlW0owGRS7WQAAAABJRU5ErkJggg=="
preserveAspectRatio="none"
/* style={{
imageRendering: "optimizeSpeed",
}}*/
height={1}
width={1}
/>
</mask>
<clipPath id="clipPath138" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path136"
d="M 0,1417.32 H 1417.32 V 3.6621e-4 L 0,2.4414e-4"
/>
</clipPath>
<linearGradient
id="linearGradient166"
spreadMethod="pad"
gradientUnits="userSpaceOnUse"
y2={860.03998}
x2={986.34998}
y1={404.47}
x1={948.63}
>
<stop
id="stop140"
offset={0}
style={{
stopOpacity: 1,
stopColor: "#850e78",
}}
/>
<stop
id="stop142"
offset={0.033333}
style={{
stopOpacity: 1,
stopColor: "#850e78",
}}
/>
<stop
id="stop144"
offset={0.07}
style={{
stopOpacity: 1,
stopColor: "#850e78",
}}
/>
<stop
id="stop146"
offset={0.27667}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
<stop
id="stop148"
offset={0.33333}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
<stop
id="stop150"
offset={0.39}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
<stop
id="stop152"
offset={0.59667}
style={{
stopOpacity: 1,
stopColor: "#850e78",
}}
/>
<stop
id="stop154"
offset={0.63333}
style={{
stopOpacity: 1,
stopColor: "#850e78",
}}
/>
<stop
id="stop156"
offset={0.66667}
style={{
stopOpacity: 1,
stopColor: "#850e78",
}}
/>
<stop
id="stop158"
offset={0.7}
style={{
stopOpacity: 1,
stopColor: "#850e78",
}}
/>
<stop
id="stop160"
offset={0.73667}
style={{
stopOpacity: 1,
stopColor: "#850e78",
}}
/>
<stop
id="stop162"
offset={0.94333}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
<stop
id="stop164"
offset={1}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
</linearGradient>
<clipPath id="clipPath176" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path174"
d="M -6.1035e-5,1417.32 H 1417.32 V 2.4414e-4 L -9.1553e-5,1.2207e-4"
/>
</clipPath>
<linearGradient
id="linearGradient204"
spreadMethod="pad"
gradientUnits="userSpaceOnUse"
y2={970.92999}
x2={388.42999}
y1={517.84003}
x1={425.95001}
>
<stop
id="stop178"
offset={0}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop180"
offset={0.033333}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop182"
offset={0.07}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop184"
offset={0.27667}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
<stop
id="stop186"
offset={0.33333}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
<stop
id="stop188"
offset={0.39}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
<stop
id="stop190"
offset={0.59667}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop192"
offset={0.63333}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop194"
offset={0.66667}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop196"
offset={0.7}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop198"
offset={0.73667}
style={{
stopOpacity: 1,
stopColor: "#b85bd1",
}}
/>
<stop
id="stop200"
offset={0.94333}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
<stop
id="stop202"
offset={1}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
</linearGradient>
<clipPath id="clipPath214" clipPathUnits="userSpaceOnUse">
<path
style={{
clipRule: "evenodd",
}}
id="path212"
d="M 0,1417.32 H 1417.32 V 3.6621e-4 L 1.2207e-4,2.4414e-4"
/>
</clipPath>
<linearGradient
id="linearGradient242"
spreadMethod="pad"
gradientUnits="userSpaceOnUse"
y2={1082.73}
x2={987.71997}
y1={627.15002}
x1={950}
>
<stop
id="stop216"
offset={0}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop218"
offset={0.033333}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop220"
offset={0.07}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop222"
offset={0.27667}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
<stop
id="stop224"
offset={0.33333}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
<stop
id="stop226"
offset={0.39}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
<stop
id="stop228"
offset={0.59667}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop230"
offset={0.63333}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop232"
offset={0.66667}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop234"
offset={0.7}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop236"
offset={0.73667}
style={{
stopOpacity: 1,
stopColor: "#a0a7f3",
}}
/>
<stop
id="stop238"
offset={0.94333}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
<stop
id="stop240"
offset={1}
style={{
stopOpacity: 1,
stopColor: "#32232c",
}}
/>
</linearGradient>
</defs>
<g transform="matrix(1.3333333,0,0,-1.3333333,-490.85172,1245.44)" id="g10">
<a onClick={openElement({elementToOpen: "under-responsive", classToHide: "understandingtab"})}>
<path
id="path22"
style={{
fill: "#850e78",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 628.2,711.36 c 36.9,0 66.8,-31.58 66.8,-70.54 0,-38.96 -29.9,-70.58 -66.8,-70.58 h 308.44 c 36.9,0 66.8,31.62 66.8,70.58 0,38.96 -29.9,70.54 -66.8,70.54 z"
/>
</a>
<g id="g24">
<g clipPath="url(#clipPath30)" id="g26">
<text
id="text34"
style={{
fontVariant: "normal",
fontWeight: "bold",
fontSize: "21.96px",
fontFamily: "Arial",
/* writingMode: "lr-tb",*/
fill: "var(--ourbeige)",
fillOpacity: 1,
fillRule: "nonzero",
stroke: "none",
}}
transform="matrix(1,0,0,-1,765.84,632.57)"
>
<a onClick={openElement({elementToOpen: "under-responsive", classToHide: "understandingtab"})}>
<tspan
id="tspan32"
y={0}
x="0 15.85512 30.502439 45.149761 59.797081 76.794121 92.649239 107.29656 113.40144 128.04877"
>
{"RESPONSIVE"}
</tspan>
</a>
</text>
</g>
</g>
<path
id="path36"
style={{
fill: "#850e78",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 628.78,711.36 c -36.91,0 -66.82,-31.58 -66.82,-70.54 0,-38.96 29.91,-70.58 66.82,-70.58 36.9,0 66.86,31.62 66.86,70.58 0,38.96 -29.96,70.54 -66.86,70.54 z"
/>
<a onClick={openElement({elementToOpen: "under-reflection", classToHide: "understandingtab"})}>
<path
id="path38"
style={{
fill: "#a0a7f3",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 628.2,934.08 c 36.9,0 66.8,-31.55 66.8,-70.48 0,-38.92 -29.9,-70.52 -66.8,-70.52 h 308.44 c 36.9,0 66.8,31.6 66.8,70.52 0,38.93 -29.9,70.48 -66.8,70.48 z"
/>
</a>
<g id="g40">
<g clipPath="url(#clipPath46)" id="g42">
<text
id="text50"
style={{
fontVariant: "normal",
fontWeight: "bold",
fontSize: "21.96px",
fontFamily: "Arial",
/* writingMode: "lr-tb",*/
fill: "var(--ourbeige)",
fillOpacity: 1,
fillRule: "nonzero",
stroke: "none",
}}
transform="matrix(1,0,0,-1,767.04,855.38)"
>
<a onClick={openElement({elementToOpen: "under-reflection", classToHide: "understandingtab"})}>
<tspan
id="tspan48"
y={0}
x="0 15.85512 30.502439 43.919998 57.337559 71.984879 87.839996 101.25756 107.36244 124.44732"
>
{"REFLECTION"}
</tspan>
</a>
</text>
</g>
</g>
<path
id="path52"
style={{
fill: "#a0a7f3",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 628.78,934.08 c -36.91,0 -66.82,-31.55 -66.82,-70.48 0,-38.92 29.91,-70.52 66.82,-70.52 36.9,0 66.86,31.6 66.86,70.52 0,38.93 -29.96,70.48 -66.86,70.48 z"
/>
<path
id="path54"
style={{
fill: "#a0a7f3",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 561.96,863.1 c 0,38.94 31.56,70.5 70.5,70.5 38.94,0 70.5,-31.56 70.5,-70.5 0,-38.94 -31.56,-70.5 -70.5,-70.5 -38.94,0 -70.5,31.56 -70.5,70.5 z"
/>
<path
id="path56"
style={{
fill: "#850e78",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 561.96,640.98 c 0,38.94 31.56,70.5 70.5,70.5 38.94,0 70.5,-31.56 70.5,-70.5 0,-38.94 -31.56,-70.5 -70.5,-70.5 -38.94,0 -70.5,31.56 -70.5,70.5 z"
/>
<a onClick={openElement({elementToOpen: "under-responsibility", classToHide: "understandingtab"})}>
<path
id="path58"
style={{
fill: "#b85bd1",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 439.33,823.08 c -36.92,0 -66.85,-31.58 -66.85,-70.54 0,-38.96 29.93,-70.58 66.85,-70.58 h 308.63 c -36.93,0 -66.85,31.62 -66.85,70.58 0,38.96 29.92,70.54 66.85,70.54 z"
/>
</a>
<g id="g60">
<g clipPath="url(#clipPath66)" id="g62">
<text
id="text70"
style={{
fontVariant: "normal",
fontWeight: "bold",
fontSize: "21.96px",
fontFamily: "Arial",
/* writingMode: "lr-tb",*/
fill: "var(--ourbeige)",
fillOpacity: 1,
fillRule: "nonzero",
stroke: "none",
}}
transform="matrix(1,0,0,-1,447.5,744.31)"
>
<a onClick={openElement({elementToOpen: "under-responsibility", classToHide: "understandingtab"})}>
<tspan
id="tspan68"
y={0}
x="0 15.85512 30.502439 45.149761 59.797081 76.794121 92.649239 107.29656 113.40144 129.25656 135.36143 148.77901 154.88388 168.30144"
>
{"RESPONSIBILITY"}
</tspan>
</a>
</text>
</g>
</g>
<path
id="path72"
style={{
fill: "#b85bd1",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 747.34,823.08 c -36.91,0 -66.82,-31.58 -66.82,-70.54 0,-38.96 29.91,-70.58 66.82,-70.58 36.95,0 66.86,31.62 66.86,70.58 0,38.96 -29.91,70.54 -66.86,70.54 z"
/>
<path
id="path74"
style={{
fill: "#b85bd1",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 673.2,752.7 c 0,38.94 31.56,70.5 70.5,70.5 38.94,0 70.5,-31.56 70.5,-70.5 0,-38.94 -31.56,-70.5 -70.5,-70.5 -38.94,0 -70.5,31.56 -70.5,70.5 z"
/>
<path
id="path76"
style={{
fill: "var(--ourbeige)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 632.53,909.84 c -25.55,0 -46.26,-20.71 -46.3,-46.23 0,-24.73 20.2,-45.58 44.92,-46.32 h 0.6 c 17.84,-0.27 34.95,-6.92 47.59,-19.56 l 0.6,-0.6 c 11.66,-11.67 17.61,-27.63 17.47,-44.15 v -0.46 -0.23 c 0.05,-17.11 -5.99,-33.63 -18.07,-45.67 l -1.53,-1.52 c -11.25,-11.31 -26.48,-18.11 -42.38,-18.11 -0.52,0 -1.04,0.01 -1.56,0.02 -0.46,0.02 -0.92,0.03 -1.39,0.03 -0.46,0 -0.92,-0.01 -1.38,-0.03 -23.89,-0.69 -43.76,-20.25 -44.83,-44.15 -1.15,-26.48 19.97,-48.35 46.21,-48.35 h 0.23 0.38 c 14.44,0 28.44,-5.21 38.69,-15.45 l 5.76,-5.77 c 12.77,-12.78 19.36,-30.17 19.87,-48.26 0.05,-2.03 0.23,-4.1 0.56,-6.18 3.13,-20.07 -43.61679,138.77795 -0.34671,32.67417 -46.70726,93.91764 11.46655,-2.19219 13.43655,-2.19219 27.53,0 18.60722,-10.36809 15.02722,17.88191 -2.58,20.21 11.65815,39.29636 24.68294,4.78611 -2.08,0.32 -4.11,0.46 -6.14,0.5 -18.25,0.42 -35.87,6.97 -48.78,19.94 l -2.08,2.03 c -11.12,11.16 -16.51,26.7 -15.17,42.39 0.09,1.29 0.14,2.58 0.14,3.92 v 0.23 c -0.09,17.03 5.99,33.54 18.03,45.58 l 1.57,1.57 c 11.3,11.31 26.53,18.11 42.43,18.11 0.52,0 1.04,-0.01 1.56,-0.02 h 2.72 c 23.89,0.74 43.77,20.3 44.78,44.2 1.15,26.48 -19.97,48.34 -46.21,48.34 -0.37,0 -0.78,0 -1.15,-0.04 -0.52,-0.02 -1.04,-0.02 -1.55,-0.02 -15.96,0 -31.33,6.2 -42.63,17.5 -12.73,12.69 -19.32,29.94 -19.55,47.89 v 0.6 c -0.6,24.77 -21.45,45.07 -46.21,45.12 z"
/>
<a onClick={openElement({elementToOpen: "under-responsive", classToHide: "understandingtab"})}>
<path
id="path78"
style={{
fill: "#850e78",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 633.24,581.1 c 0,31.18 28.8,56.46 64.32,56.46 35.52,0 64.32,-25.28 64.32,-56.46 0,-31.18 -28.8,-56.46 -64.32,-56.46 -35.52,0 -64.32,25.28 -64.32,56.46 z"
/>
</a>
<path
id="path80"
style={{
fill: "var(--ourbeige)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 587.04,639.66 c 0,25.28 20.87,45.78 46.62,45.78 25.75,0 46.62,-20.5 46.62,-45.78 0,-25.28 -20.87,-45.78 -46.62,-45.78 -25.75,0 -46.62,20.5 -46.62,45.78 z"
/>
<g id="g84">
<g clipPath="url(#clipPath90)" id="g86">
<g transform="matrix(72.6,0,0,72.48,599.4,830.52)" id="g92">
<image
id="image98"
mask="url(#mask94)"
xlinkHref="data:image/png;base64,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"
transform="matrix(1,0,0,-1,0,1)"
preserveAspectRatio="none"
/* style={{
imageRendering: "optimizeSpeed",
}} */
height={1}
width={1}
/>
</g>
</g>
</g>
<g id="g100">
<g clipPath="url(#clipPath106)" id="g102">
<g transform="matrix(68.04,0,0,68.04,711.84,714.6)" id="g108">
<image
id="image114"
mask="url(#mask110)"
xlinkHref="data:image/png;base64,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"
transform="matrix(1,0,0,-1,0,1)"
preserveAspectRatio="none"
/* style={{
imageRendering: "optimizeSpeed",
}} */
height={1}
width={1}
/>
</g>
</g>
</g>
<g id="g116">
<g clipPath="url(#clipPath122)" id="g118">
<g transform="matrix(73.68,0,0,73.68,596.4,602.16)" id="g124">
<image
id="image130"
mask="url(#mask126)"
xlinkHref="data:image/png;base64,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"
transform="matrix(1,0,0,-1,0,1)"
preserveAspectRatio="none"
/* style={{
imageRendering: "optimizeSpeed",
}} */
height={1}
width={1}
/>
</g>
</g>
</g>
<g id="g132">
<g clipPath="url(#clipPath138)" id="g134">
<path
id="path168"
style={{
fill: "url(#linearGradient166)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 935.26,711.07 c 39.15,0.36 71.07,-31.67 71.29,-71.52 0.2,-33.45 -22.21,-62.71 -54.13,-70.71 l -0.84,-11.72 -20.76,13.66 23.02,17.92 -0.84,-11.69 c 33.54,9.88 52.97,45.6 43.4,79.79 -7.78,27.78 -32.76,46.81 -61.1,46.54 z"
/>
</g>
</g>
<g id="g170">
<g clipPath="url(#clipPath176)" id="g172">
<path
id="path206"
style={{
fill: "url(#linearGradient204)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 439.43,822.8 c -39.14,0.3 -71.06,-31.56 -71.29,-71.16 -0.19,-33.28 22.27,-62.36 54.23,-70.23 l 0.84,-11.73 20.64,13.72 -22.89,17.86 0.83,-11.7 c -33.55,9.72 -53.04,45.14 -43.52,79.11 7.74,27.65 32.74,46.63 61.12,46.4 z"
/>
</g>
</g>
<g id="g208">
<g clipPath="url(#clipPath214)" id="g210">
<path
id="path244"
style={{
fill: "url(#linearGradient242)",
fillOpacity: 1,
fillRule: "evenodd",
stroke: "none",
}}
d="m 936.64,933.76 c 39.14,0.35 71.06,-31.67 71.29,-71.52 0.19,-33.45 -22.21,-62.71 -54.13,-70.71 l -0.84,-11.72 -20.77,13.65 23.02,17.93 -0.83,-11.69 c 33.54,9.88 52.97,45.6 43.4,79.79 -7.78,27.78 -32.76,46.81 -61.1,46.54 z"
/>
</g>
</g>
</g>
</svg>
);
src/contents/Human Practices/HP-abstract.tsx 0 → 100644
View file @ 3fd292fd
import { Section } from "../../components/sections"
import { useTabNavigation } from "../../utils/TabNavigation";
export function HPAbstract(){
useTabNavigation();
return(
<Section title="Abstract" id="Abstract">
<p>As the iGEM Bielefeld-CeBiTec team, we adopted a human-centered approach and provided a comprehensive framework of <strong>seven reglementations</strong> for future iGEM teams, establishing <strong>seven frameworks</strong> that were validated through our project. Our methodology was shaped by over <strong>80 interviews with stakeholders and institutions</strong> , creating a comprehensive and multidimensional perspective on the complex challenge of gene therapy for Cystic Fibrosis (CF). Through <strong>33 key interviews</strong> , we navigated <strong>seven thematic areas</strong> simultaneously, incorporating <strong>five iterative feedback loops</strong> to ensure the project’s refinement at every stage.
</p>
<p> Our approach offers future iGEM teams and the synthetic biology community a valuable blueprint for responsible and ethical project development. By actively engaging with CF patients, clinicians, researchers, and regulatory bodies, we ensured that real-world needs and societal values were central to our project's evolution. Our efforts culminated in a thoughtful, scientifically sound solution, setting new standards for accessibility, patient focus, and regulatory compliance. Future teams can leverage our documented methodologies to further their own impact, ensuring that innovation remains aligned with the needs of those it serves.
</p>
</Section>
)
}
\ No newline at end of file
src/contents/Human Practices/IHP.tsx 0 → 100644
View file @ 3fd292fd
import { ButtonOne, ButtonOneWithScroll } from "../../components/Buttons";
import { H4, H5 } from "../../components/Headings";
import { HPTimeline } from "../../components/HP-timeline";
import PreCyse from "../../components/precyse";
import { Section, Subesction } from "../../components/sections";
import { useNavigation } from "../../utils";
import { useTabNavigation } from "../../utils/TabNavigation";
import { HPconclusion } from "./Conclisuin";
import { HPFeedback } from "./Feedback";
import { HP3new } from "./HP svgs/hp3";
import {WholeMendelow} from "./HP svgs/mendelows";
import { StakeholderManagement } from "./HP svgs/stakeholder-management";
import { SWOTone } from "./HP svgs/swots";
import { HPUnderstanding } from "./HP svgs/understanding";
export function HPIntegrated(){
const { goToPageWithTabAndScroll} = useNavigation();
useTabNavigation();
return(
<Section title="Integrated Human Practices" id="Integrated Human Practices">
<Subesction title="Framework" id="Integrated Human Practices1">
<p>Our team has defined a framework for managing interactions with stakeholders during each step of the project:
</p>
<ol>
<li> <b>Stakeholder Management Framework </b>- To identify stakeholders and define how potential stakeholders fit our project.</li>
<li><b>Power-Interest Matrix </b>- According to Mendelow to identify and evaluate the priorities of potential stakeholders.</li>
<li><b>SWOT analysis</b> - Assessment of the strengths, weaknesses, opportunities and threats of the various groups previously identified as potential stakeholders.</li>
<li><b>AREA Framework</b> - To structure and optimize project-related decisions.</li>
<li><b>Third-Party Feedback Templates </b>- To introduce the stakeholders, summarize the interactions and implement the output in our project.</li>
<li><b>Feedback-Cycle</b> - To structure interactions with stakeholders for efficient and informative design and maximization of potential.</li>
<li><b>Cycle of Reflection</b> - According to Gibbs demonstrate the response and implementation as a part of our feedback cycle.</li>
</ol>
<div className="row align-items-center">
<div className="col">
<ButtonOneWithScroll text="Stakeholder Management" scrollId="stakeH" open="stakemamange" openclass="framecycletab"></ButtonOneWithScroll>
</div>
<div className="col">
<ButtonOneWithScroll text="Mendelow Analysis" open="mendelow" scrollId="mendelowH" openclass="framecycletab"></ButtonOneWithScroll>
</div>
<div className="col">
<ButtonOneWithScroll text="SWOT analysis" scrollId="swotH" open="swot" openclass="framecycletab"></ButtonOneWithScroll>
</div>
</div>
<div className="row align-items-center">
<div className="col">
<ButtonOneWithScroll scrollId="areaH" text="AREA Framework" open="area" openclass="framecycletab"></ButtonOneWithScroll>
</div>
<div className="col">
<ButtonOneWithScroll scrollId="thirdH" text="Third Party Feedback" open="thirdparty" openclass="framecycletab"></ButtonOneWithScroll>
</div>
<div className="col">
<ButtonOneWithScroll scrollId="feedH" text="Feedback-Cycle" open="feedcycle" openclass="framecycletab"></ButtonOneWithScroll>
</div>
<div className="col">
<ButtonOneWithScroll scrollId="gibsonH" text="Gibbs' Cycle" open="gibson" openclass="framecycletab"></ButtonOneWithScroll>
</div>
</div>
<div className="col framecycletab" id="stakemamange" style={{display: "block"}}>
<br/>
<div className="align-items-center">
<StakeholderManagement/>
</div>
<H4 text="Stakeholder Management Framework" id="stakeH"/>
<p>To clearly communicate to our stakeholders how they can support the <PreCyse/> project and the specific areas requiring
their input, we developed a stakeholder management framework highlighting four key areas. Starting at the bottom right of the
figure and moving clockwise, the first area needing feedback is <b>implementation</b>. It is crucial for our team to ensure that the project
has all necessary components for realistic application in healthcare settings, focusing on the gene therapy treatment for Cystic Fibrosis.
This includes both the technical design and the appropriate business model to ensure successful implementation.
</p>
<p>The second key area is <b>sustainability and social impact.</b> We seek to understand how our project aligns with current healthcare initiatives and facilities in Germany and Europe, but also in the globally, and how it interacts with social efforts related to CF awareness and gene therapy strategies.
</p>
<p>Next, we want to shape the <b>public perception</b> of our project, which is based on synthetic biology to tackle a major healthcare challenge. We ask stakeholders about their knowledge and opinions on our gene therapeutic approach and its potential application to improve CF treatments.
</p>
<p>The final area involves <b>regulatory and safety considerations</b>. Given the stringent regulations governing healthcare in Germany, which vary by municipality, it is essential to consult with stakeholders familiar with these regulations to ensure our project complies with all necessary safety standards.
</p>
</div>
<div className="col framecycletab" id="mendelow" style={{display: "none"}}>
<H4 text="Power-Interest Matrix according to Mendelow" id="mendelowH"/>
<p>Using the Mendelow Power-Interest Matrix, we classified the potential stakeholders associated with our project in terms of their power (the ability to provide important feedback on our project design and influence our project development) and interest in our project. The matrix consists of four quadrants arranged in descending order according to their priority level in the project:
</p>
<ul>
<li>High Power, High Interest (Key Players)</li>
<li>High Power, Low Interest (Keep Satisfied)</li>
<li>Low Power, High Interest (Keep Informed)</li>
<li>Low Power, Low Interest (Minimal Effort)</li>
</ul>
<p>This categorization helps to develop appropriate communication and management strategies for the different stakeholder groups and to ensure that their needs and influences are considered during the project.
</p>
<WholeMendelow/>
<div className="row">
<div className="col">
<a onClick={() => goToPageWithTabAndScroll({path: "", tabId: "mendelow-one", scrollToId: "keyplayersH" })}>
<img src="https://static.igem.wiki/teams/5247/scientific-figures/mendelow-1-aktuell.svg"/>
</a>
</div>
<div className="col">
<a onClick={() => goToPageWithTabAndScroll({path: "", tabId: "mendelow-two", scrollToId: "keepH" })}>
<img src="https://static.igem.wiki/teams/5247/scientific-figures/mendelow-2.svg"/>
</a>
</div>
<div className="col">
<a onClick={() => goToPageWithTabAndScroll({path: "", tabId: "mendelow-three", scrollToId: "informedH" })}>
<img src="https://static.igem.wiki/teams/5247/scientific-figures/mendelow-3-1.svg"/>
</a>
</div>
<div className="col">
<a onClick={() => goToPageWithTabAndScroll({path: "", tabId: "mendelow-four", scrollToId: "minimalH" })}>
<img src="https://static.igem.wiki/teams/5247/scientific-figures/mendelow-4.svg"/>
</a>
</div>
</div>
<p style={{ textAlign: "center", marginTop: "10px", fontStyle: "italic" }}>
Click on the images above to learn more about each category.
</p>
{/* TABS */}
<div className="mendelowtab" id="mendelow-one" style={{display: "none"}}>
<H4 text="Key Players" id="keyplayersH"/>
<H5 text="High Power, High Interest - Priority Level 4"/>
<p>
Close support and extensive feedback are necessary to successfully implement <PreCyse/>.
Target groups include experts and physicians with expertise in gene therapy and treatment
strategies for Cystic Fibrosis. The project has a reasonable, responsible, and future-oriented
significance for the world. Furthermore, scientific-technological knowledge and biosafety are
crucial. Collaboration with specialists in the field of gene therapy, Cystic Fibrosis, and different
treatment strategies ensures the quality and effectiveness of the solutions developed.
</p>
<p><b>Scientific community and research institutions</b></p>
<p>
This group includes researchers, scientists, and research institutions specializing in gene editing
and gene therapy. They have a high interest in the success of prime editing technology and have
the power to significantly influence the project, be it through collaborations, scientific support,
or critical reviews of the research results.
</p>
<p><b>Regulatory authorities (e.g. FDA, EMA)</b></p>
<p>
Regulatory agencies have both the power and the interest to ensure that gene therapy is safe and
effective. They are crucial for the approval and authorization of the therapy for clinical use.
</p>
</div>
<div className="mendelowtab" id="mendelow-two" style={{display: "none"}}>
<H4 text=" Keep Satisfied" id="keepH"/>
<H5 text="High Power, Low Interest - Priority Level 3"/>
<p>
In order to successfully implement <PreCyse/>, all concerns must be fully considered, even if they
may differ from the project interests. CF specialists, bioethics specialists, and regulatory experts
provide important information. Their input is beneficial to the implementation of our project.
These categories of experts help to ensure that the project is ethical and compliant with the law.
Their expertise ensures that all relevant aspects are covered.
</p>
<p><b>Government and public health authorities</b></p>
<p>
Although these stakeholders have some interest in new therapies that improve population health,
their day-to-day interest may not be specifically focused on the iGEM project. However, they have
the power to influence the project through funding, political support, or regulatory action.
</p>
<p><b>Pharmaceutical companies and industries</b></p>
<p>
Large pharmaceutical companies have the power to significantly support the project through
investment or strategic partnerships. However, their interest may be low for the time being until
the project has proven that it is commercially promising.
</p>
</div>
<div className="mendelowtab" id="mendelow-three" style={{display: "none"}}>
<H4 text="Keep Informed" id="informedH"/>
<H5 text="KEEP INFORMED - Low Power, High Interest - Priority Level 2"/>
<p> <b>Potential users of <PreCyse/></b> </p>
<p>
are important for understanding the needs, even if their expertise
may not be sufficient to solve all the problems that arise in the project. It is therefore important to
keep them informed. These users include stakeholders as their needs coincide with the project.
Their feedback can provide valuable insights. This collaboration helps to better tailor the project
to user needs.
</p>
<p><b>Patients and patient organizations</b></p>
<p>
Patients suffering from Cystic Fibrosis and the organizations that support them have a high interest in
new therapies that could improve their quality of life. However, their power to influence the project
is limited.
</p>
<p> <b>Academic community and students</b></p>
<p>
This group includes universities, professors, and students who are interested in the latest research
in gene therapy. Although they do not have the direct power to influence the project, they can
support and promote the project through research and academic publications.
</p>
</div>
<div className="mendelowtab" id="mendelow-four" style={{display: "none"}}>
<H4 text="Minimal Effort" id="minimalH"/>
<H5 text="Low Power, Low Interest - Priority Level 1" />
<p><b>Stakeholders who are regularly monitored</b></p>
<p>
may not be interested in the project and do not provide feedback. However, this can change over time.
Stakeholders in this category are involved in the right situation. For example, the public of Bielefeld is
essential for understanding the background information about the awareness of gene therapy or Cystic Fibrosis.
Their involvement occurs when it is relevant and other groups of people cannot meet their needs.
</p>
<p><b>General public of Bielefeld</b></p>
<p>
The public may have little interest and power in relation to the specific iGEM project. While a certain level
of education and awareness of the topic is important, intensive involvement of this group is generally not necessary.
</p>
<p><b>Media</b></p>
<p>
The media may have an interest in scientific breakthroughs and new technologies, but they tend to have little
power in terms of directly influencing the project. Nevertheless, strategic communication with the media can
be important to manage public perception.
</p>
</div>
</div>
<div className="col framecycletab" id="swot" style={{display: "none"}}>
<H4 text="SWOT Analyses" id="swotH"/>
<p>A <b>SWOT</b> analysis is a strategic tool used to evaluate the <b>S</b>trengths, <b>W</b>eaknesses, <b>O</b>pportunities, and <b>T</b>hreats of an
organization. In the context of our Human Practice approach, this analysis helps us identify internal strengths and weaknesses of our project, such as
technical capabilities and resource limitations, while also examining external opportunities, like potential collaborations, and threats, such as regulatory
challenges or public perception.
</p>
<SWOTone/>
<div className="row align-items-center">
<div className="col ">
<ButtonOne text="Patients" open="swot&subTab=pats" openclass="subcycletab"></ButtonOne>
</div>
<div className="col ">
<ButtonOne text="Industry" open="swot&subTab=inds" openclass="subcycletab"></ButtonOne>
</div>
<div className="col ">
<ButtonOne text="Academia" open="swot&subTab=acs" openclass="subcycletab"></ButtonOne>
</div>
<div className="col ">
<ButtonOne text="Healthcare" open="swot&subTab=healths" openclass="subcycletab"></ButtonOne>
</div>
</div>
<div className="row align-items-center">
< div className="col ">
<ButtonOne text="Government" open="swot&subTab=govs" openclass="subcycletab"></ButtonOne>
</div>
<div className="col ">
<ButtonOne text="Community" open="swot&subTab=comms" openclass="subcycletab"></ButtonOne>
</div>
<div className="col ">
<ButtonOne text="The Public" open="swot&subTab=pubs" openclass="subcycletab"></ButtonOne>
</div>
<div className="col ">
<ButtonOne text="Business" open="swot&subTab=busi" openclass="subcycletab"></ButtonOne>
</div>
</div>
<div className="col subcycletab" id="pats" style={{display: "block"}}>
<H5 text="Patient Advocacy and Support Groups"/>
<table cellPadding={10} cellSpacing={0} >
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
<th>Opportunities</th>
<th>Threats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong support network for patients </td>
<td>Limited funding and resources </td>
<td>Increased patient engagement and support for new therapies</td>
<td>Potential opposition from groups skeptical of new treatments</td>
</tr>
<tr>
<td>Influential in policy advocacy</td>
<td>Potential resistance to new technologies</td>
<td>Advocacy can drive policy changes</td>
<td>Misinformation or miscommunication about new therapies</td>
</tr>
<tr>
<td>Personal connection to patient communities</td>
<td>Dependence on donations and grants</td>
<td>Enhancing awareness and education</td>
<td>Competing priorities among advocacy groups</td>
</tr>
</tbody>
</table>
</div>
<div className="col subcycletab" id="inds" style={{display: "none"}}>
<H5 text="Pharmaceutical Companies" />
<table cellPadding={10} cellSpacing={0}>
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
<th>Opportunities</th>
<th>Threats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resources for large-scale production and distribution</td>
<td>Focus on profitability may conflict with patient affordability</td>
<td>Potential for developing new treatment modalities</td>
<td>High cost and risk associated with new therapy development</td>
</tr>
<tr>
<td>Experience with regulatory processes</td>
<td>Long development timelines</td>
<td>Market expansion and competitive advantage</td>
<td>Stringent regulatory and compliance requirements</td>
</tr>
<tr>
<td>Strong research and development capabilities</td>
<td>Potential for high pricing</td>
<td>Partnerships with research institutions</td>
<td>Potential public backlash over high treatment costs</td>
</tr>
</tbody>
</table>
<H5 text="Bioengineering and Biotechnology Departments "/>
<table cellPadding={10} cellSpacing={0}>
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
<th>Opportunities</th>
<th>Threats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agile and innovative, can quickly adapt to new technologies</td>
<td>Focused on niche markets and cutting-edge solutions</td>
<td>Opportunity for rapid growth and partnership with larger firms</td>
<td>High risk of failure and market volatility</td>
</tr>
<tr>
<td>Strong entrepreneurial spirit</td>
<td></td>
<td>Potential to disrupt existing markets with innovative solutions</td>
<td>Intense competition and fast-paced industry changes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Opportunities for collaboration and acquisition</td>
<td>Regulatory and market entry barriers</td>
</tr>
</tbody>
</table>
</div>
<div className="col subcycletab" id="acs" style={{display: "none"}}>
<H5 text="Genetic Research Institutions "/>
<table cellPadding={10} cellSpacing={0}>
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
<th>Opportunities</th>
<th>Threats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expertise in genetic disorders and advanced research capabilities</td>
<td>May have limited practical experience with therapy delivery</td>
<td>Collaboration can lead to breakthroughs in gene editing</td>
<td>High competition for funding and research grants</td>
</tr>
<tr>
<td>Access to state-of-the-art research facilities</td>
<td>Potential disconnect between research and clinical application</td>
<td>Potential for groundbreaking research and new discoveries</td>
<td>Rapid technological changes requiring constant adaptation</td>
</tr>
<tr>
<td>Strong track record of innovation</td>
<td>High operational costs</td>
<td>Collaborative research opportunities</td>
<td>Ethical and regulatory challenges</td>
</tr>
</tbody>
</table>
<H5 text="Universities and Academic Researchers "/>
<table cellPadding={10} cellSpacing={0}>
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
<th>Opportunities</th>
<th>Threats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong research foundation and innovation capabilities</td>
<td>May have limited resources for commercialization</td>
<td>Established research infrastructure</td>
<td>Funding limitations and bureaucratic challenges</td>
</tr>
<tr>
<td>Access to a diverse pool of academic talent</td>
<td>Limited industry connections</td>
<td>High competition for academic grants</td>
<td>Intellectual property and technology transfer issues</td>
</tr>
<tr>
<td>Potential for groundbreaking research and new discoveries</td>
<td>Collaboration with industry for applied research</td>
<td>Opportunities for interdisciplinary research</td>
<td>Balancing academic research with practical applications</td>
</tr>
</tbody>
</table>
</div>
<div className="col subcycletab" id="healths" style={{display: "none"}}>
<H5 text="Pulmonologists and Respiratory Specialists"/>
<table cellPadding={10} cellSpacing={0}>
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
<th>Opportunities</th>
<th>Threats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deep understanding of CF and its complications</td>
<td>May lack expertise in gene editing and new delivery systems</td>
<td>Can provide valuable insights for therapy optimization</td>
<td>Resistance to adopt new and unproven therapies</td>
</tr>
<tr>
<td>Direct patient care experience</td>
<td>Limited time and resources for research involvement</td>
<td>Opportunities for clinical trials and patient feedback</td>
<td>Potential liability issues with new treatments</td>
</tr>
<tr>
<td>Established patient trust and rapport</td>
<td>Risk of slow adoption of new technologies</td>
<td>Enhanced treatment protocols through collaboration</td>
<td>Competition from alternative therapies</td>
</tr>
</tbody>
</table>
<H5 text="Specialized Clinics and Hospitals"/>
<table cellPadding={10} cellSpacing={0}>
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
<th>Opportunities</th>
<th>Threats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct access to patient population</td>
<td>May lack expertise in gene therapy and new delivery systems</td>
<td>Clinical trials and real-world application of new therapies</td>
<td>High cost and complexity of integrating new therapies</td>
</tr>
<tr>
<td>Ability to conduct clinical trials</td>
<td>High operational costs</td>
<td>Opportunities for improving patient care and outcomes</td>
<td>Resistance from clinical staff to adopt new technologies</td>
</tr>
<tr>
<td>Experienced medical staff and infrastructure</td>
<td>Potential liability and ethical concerns</td>
<td>Collaboration with research institutions for therapy development</td>
<td>Competition for patients and clinical trial participation</td>
</tr>
</tbody>
</table>
<H5 text="Healthcare Networks"/>
<table cellPadding={10} cellSpacing={0}>
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
<th>Opportunities</th>
<th>Threats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Broad reach and influence</td>
<td>Variability in network capabilities and resources</td>
<td>Established relationships with patient communities</td>
<td>Organizational resistance to change</td>
</tr>
<tr>
<td>Potential for large-scale impact on patient care</td>
<td>Ability to implement new therapies widely</td>
<td>Standardizing care across multiple facilities</td>
<td>Economic pressures and budget constraints</td>
</tr>
<tr>
<td>Leveraging network for large-scale clinical trials</td>
<td>Complex coordination required</td>
<td>Potential disparities in care quality</td>
<td>Variability in regulatory compliance across regions</td>
</tr>
</tbody>
</table>
</div>
<div className="col subcycletab" id="govs" style={{display: "none"}}>
<H5 text="Bioethics Committees "/>
<table cellPadding={10} cellSpacing={0}>
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
<th>Opportunities</th>
<th>Threats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure ethical standards are met</td>
<td>May be conservative and slow to approve new technologies</td>
<td>Establishing ethical frameworks for new therapies</td>
<td>Ethical dilemmas and public perception issues</td>
</tr>
<tr>
<td>Provide guidance on complex issues</td>
<td>Potential for conflicting opinions within the committee</td>
<td>Enhancing public trust through ethical oversight</td>
<td>Rapid advancements outpacing ethical guidelines</td>
</tr>
<tr>
<td>Enhance credibility and acceptance of new therapies</td>
<td>Limited authority to enforce decisions</td>
<td>Collaboration with regulatory agencies for comprehensive oversight</td>
<td>Misalignment with fast-paced technological advancements</td>
</tr>
</tbody>
</table>
<H5 text="Legal Experts"/>
<table cellPadding={10} cellSpacing={0}>
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
<th>Opportunities</th>
<th>Threats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Navigate complex legal landscapes</td>
<td>High costs for legal services</td>
<td>Development of comprehensive legal frameworks for new therapies</td>
<td>Legal challenges and liability issues</td>
</tr>
<tr>
<td>Ensure compliance with regulations</td>
<td>Potential for lengthy legal processes</td>
<td>Protecting intellectual property and ensuring regulatory compliance</td>
<td>Rapidly changing legal environments and regulations</td>
</tr>
<tr>
<td>Expertise in healthcare law and genetic research regulations</td>
<td>Risk of stifling innovation with overly cautious advice</td>
<td>Advising on best practices for ethical and legal standards</td>
<td>Potential for litigation and legal disputes</td>
</tr>
</tbody>
</table>
</div>
<div className="col subcycletab" id="comms" style={{display: "none"}}>
<H5 text="Patient and Community Outreach Programs"/>
<table cellPadding={10} cellSpacing={0}>
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
<th>Opportunities</th>
<th>Threats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase awareness and education</td>
<td>Limited reach and resources</td>
<td>Foster connections between patients, researchers, and healthcare providers</td>
<td>Public skepticism and resistance to new technologies</td>
</tr>
<tr>
<td>Build public support</td>
<td>Potential misinformation</td>
<td>Dependence on volunteer efforts</td>
<td>Competing messages and priorities among various community groups</td>
</tr>
<tr>
<td>Enhanced public engagement and support for new therapies</td>
<td>Opportunities for community-driven advocacy</td>
<td>Raising funds and resources through public engagement</td>
<td>Miscommunication leading to misinformation</td>
</tr>
</tbody>
</table>
</div>
<div className="col subcycletab" id="pubs" style={{display: "none"}}>
<H5 text="Educational Institutions"/>
<table cellPadding={10} cellSpacing={0}>
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
<th>Opportunities</th>
<th>Threats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Educate future scientists and healthcare professionals</td>
<td>Limited funding and resources for large-scale projects</td>
<td>Opportunity to foster new talent and innovation</td>
<td>Funding constraints and academic pressures</td>
</tr>
<tr>
<td>Promote research and innovation</td>
<td>Potential for academic bureaucracy</td>
<td>Collaboration with industry and research institutions</td>
<td>Balancing academic objectives with practical applications</td>
</tr>
<tr>
<td>Established infrastructure for education and research</td>
<td>High competition for research grants</td>
<td>Opportunities for interdisciplinary education and research</td>
<td>Risk of brain drain to more lucrative industries</td>
</tr>
</tbody>
</table>
</div>
<div className="col subcycletab" id="busi" style={{display: "none"}}>
<H5 text="Funding Agencies and Venture Capitalists"/>
<table cellPadding={10} cellSpacing={0}>
<thead>
<tr>
<th>Strengths</th>
<th>Weaknesses</th>
<th>Opportunities</th>
<th>Threats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provide crucial financial support</td>
<td>Focus on ROI may limit funding for high-risk projects</td>
<td>Extensive networks and industry connections</td>
<td>Economic downturns affecting investment capacity</td>
</tr>
<tr>
<td>Drive innovation through investment</td>
<td>High competition for funding</td>
<td>Risk aversion may limit innovative but uncertain projects</td>
<td>Potential for high financial losses</td>
</tr>
<tr>
<td>Potential for high returns and impact on healthcare</td>
<td>Supporting transformative technologies</td>
<td>Identifying and nurturing breakthrough technologies</td>
<td>Changes in economic and policy environments</td>
</tr>
</tbody>
</table>
</div>
</div>
<div className="col framecycletab" id="thirdparty" style={{display: "none"}}>
<H4 text="The Third-Party Feedback Template" id="thirdH"/>
<p>To drive stakeholder interactions for the <PreCyse/> project, our team implemented the “Third-Party Feedback Template”. This template helps us introduce individuals to our stakeholders and demonstrate their significance to our project. There are three main sections in this template. First, we address the important question of who our stakeholders are, introducing their backgrounds and explaining why we reached out to them. Next, we summarize the conversations and knowledge exchanged during our interactions. Finally, we share our reflections from these stakeholder conversations and how these interactions have guided the next steps of our project. </p>
<div className="col-4">
<div className="" >
<HPUnderstanding/>
</div>
</div>
<div className="col">
<div className="col understandingtab" id="under-reflection" style={{display: "block"}}>
<div><p>The reflection component of the template is essential in evaluating how stakeholder interactions have shaped the <PreCyse/> project. After summarizing conversations with stakeholders, we analyze the feedback they provided. This reflection process allows our team to carefully consider the insights shared and assess their relevance to our project's goals. By reflecting on this input, we gain a clearer understanding of how external perspectives align or differ from our initial assumptions, fostering an environment of continuous learning and improvement. This stage ensures that we approach the next steps with a deeper awareness of both our project’s impact and the expectations of our stakeholders.</p></div>
</div>
<div className="col understandingtab" id="under-responsibility" style={{display: "none"}}>
<div><p>Responsibility is embedded in how we engage with stakeholders and respond to the trust they place in our team. By thoughtfully selecting who we reach out to, we demonstrate responsibility in choosing the most relevant and impactful individuals for our project. Additionally, it is our duty to honor the contributions of stakeholders by effectively integrating their feedback into our decision-making process. The template allows us to document these contributions, emphasizing our commitment to not only listen but also act responsibly based on their input. Our responsibility extends to ensuring that stakeholder interests are respected and that their input is actively contributing to the ethical and sustainable development of the <PreCyse/> project.</p></div>
</div>
<div className="col understandingtab" id="under-responsive" style={{display: "none"}}>
<div><p>Responsiveness is about how we adapt and move forward based on the knowledge and perspectives shared by our stakeholders. After gathering feedback, we assess how it aligns with our project’s objectives and adjust our strategies accordingly. This ensures that stakeholder contributions are not only heard but also acted upon in a timely and constructive manner. The final section of the template emphasizes how these interactions have guided the future steps of the project. Being responsive is crucial for maintaining dynamic and evolving relationships with our stakeholders, demonstrating that we value their input and are willing to incorporate it into our ongoing development.</p></div>
</div>
</div>
</div>
<div className="col framecycletab" id="area" style={{display: "none"}}>
<H4 text="AREA Framework" id="areaH"/>
<p>The AREA Framework Analysis is a model that helps structure and optimize decision-making in complex projects, especially when multiple stakeholders are involved. Click on the cycle to find out more about each aspect.
</p>
<div id="hp3-wrapper">
<div className="col">
<HP3new/>
</div>
</div>
<H5 text="Agenda"/>
<p>
The central goal of the <PreCyse/> project is to develop an innovative gene therapy solution for Cystic Fibrosis (CF) that is not only technically effective but also socially acceptable and ethically justifiable. The primary questions include:
</p>
<ul>
<li>How can the project improve the lives of CF patients?</li>
<li>How can the project ensure that the proposed therapy meets ethical and regulatory standards?</li>
<li>How can the solution be integrated into current healthcare initiatives?</li>
<li>How does the project influence, and how is it influenced by, the perceptions of stakeholders, particularly patients, regulatory authorities, and the scientific community?</li>
</ul>
<p>
Here, the need is defined to develop a holistic understanding of the project’s impacts, considering both technological aspects and human perspectives.
</p>
<H5 text="Research"/>
<p>
To gain a comprehensive understanding of the needs and expectations, the <PreCyse/> team employed various methods to collect data from relevant stakeholders, including:
</p>
<p>
<b>Surveys of CF patients and their families:</b> These provided insights into the specific challenges and needs that CF patients face in daily life. Critical questions regarding safety, accessibility, and the long-term application of gene technology were addressed.
</p>
<p>
<b>Expert consultations with researchers and physicians:</b> Scientists and doctors working in gene therapy provided essential technical feedback and helped assess the feasibility and effectiveness of the proposed therapy.
</p>
<p>
<b>Regulatory authorities:</b> Feedback from agencies like the FDA and EMA played a central role in assessing safety requirements and regulatory challenges that need to be addressed before clinical application. This research phase was critical to ensuring that the technical solution aligned with patient needs and regulatory standards.
</p>
<H5 text="Evaluation"/>
<p>Based on the research phase results, a detailed assessment of the strengths, weaknesses, opportunities, and threats (SWOT analysis) was conducted (see above). The evaluation helped the team reflect on the gathered insights and focus on key challenges to ensure long-term feasibility and acceptance.
</p>
<H5 text="Agenda"/>
<p>
Based on the analysis, several measures were taken to ensure that the <PreCyse/> project is not only scientifically advanced but also socially and regulatorily acceptable:
</p>
<p>
<b>Integrated feedback loops:</b> Stakeholders were continuously involved, and their feedback was directly incorporated into the adaptation and improvement of the project design. An example of this is the application of Gibbs' Reflection Cycle to ensure that all feedback is thoroughly analyzed and incorporated into future decisions.
</p>
<p>
<b>Regulatory and ethical adjustments:</b> By working closely with regulatory authorities and ethics committees, measures were taken to ensure that the project complies with regulatory requirements and remains ethically justifiable.
</p>
<p>
<b>Safety considerations:</b> The safety of the therapy was a key concern in stakeholder interactions. Specific safety protocols were developed to minimize risks for patients.
</p>
<p>
<b>Public awareness:</b> To increase public awareness of the potential and safety of gene technologies, targeted communication measures were taken to address misunderstandings and improve acceptance of the technology.
</p>
</div>
<div className="col framecycletab" id="feedcycle" style={{display: "none"}}>
<H4 text="The Feedback Cycle of our IHP Approach" id="feedH"/>
<p>To foster productive conversations and ensure our team maximizes each stakeholder interaction for the <PreCyse/> project, we developed a feedback cycle that outlines a structured approach for our meetings. The first step in our cycle involves listening to each stakeholder's experiences, personal stories, or insights. Our team then follows up by asking relevant questions to dive deeper into the shared information or to introduce new topics or directions in the conversation. Towards the end of the meeting, we ask clarifying questions and reiterate key points to ensure our understanding is accurate and that the stakeholder has no additional input. Finally, we explore new directions and ideas inspired by the stakeholder interaction, encouraging our team to pursue innovative and novel concepts.
</p>
<div>
<img src="https://static.igem.wiki/teams/5247/photos/hp/cycle2.svg"/>
</div>
</div>
<div className="col framecycletab" id="gibson" style={{display: "none"}}>
<H4 text="Cycle of Reflections according to Gibbs" id="gibsonH"/>
<p>For the <PreCyse/> project to impact the world, it needs to work with all types of stakeholders. Therefore, we are optimizing Gibbs' Reflection Cycle to demonstrate our inclusive response to the challenges we encountered during our iGEM journey. The cycle includes the impetus for our engagement, the unbiased two-way communication with stakeholders, our thorough analysis of the feedback and our actions to implement the stakeholder inputs into our project.
</p>
<div style={{height: "20%"}}>
<img src="https://static.igem.wiki/teams/5247/scientific-figures/gibbsreflection.svg" style={{height: "20%"}}/>
</div>
<p>
<b>Impetus:</b> When developing a systematic approach to a recurring problem, it's easy to get distracted by multiple points of view. We need to prioritize quality over quantity. This section presents the successive impetus that drives the continuous implementation of Human Practices activities.
</p>
<p>
<b>Two-way communication:</b> For our solution to be human-centered, the two-way communication method is to communicate to stakeholders the values we are incorporating into our project design. We make sure they understand the project clearly so that they can articulate their concerns and suggestions precisely.
</p>
<p>
<b>Analysis:</b> The two-way communication with our stakeholders is carefully analyzed. In this section, stakeholder feedback is processed and turned into constructive guidance for project implementation, allowing us to consider what work should be prioritized to best address stakeholder concerns.
</p>
<p>
<b>Implementation:</b> Implementation shows our measures for evaluating and refining the project. These actions are fully integrated into the project designs and other parts of our project to ensure that our project and activities are good, responsible and engaging for the world.
</p>
<p>
In the areas of <b>Communication & Implementation</b>, <b>Necessity & Relevance</b>, <b>Science & Technology</b>, <b>Ethics & Regulation</b>, our Human Practice activities are conducted with X groups of stakeholders throughout our iGEM journey. In doing so, we explore the contexts that define projects, idealize solutions and evaluate outcomes for our human practice approach.
</p>
</div>
</Subesction>
<Subesction title="Timeline" id="Integrated Human Practices2">
<HPTimeline/>
</Subesction>
<Subesction title="Implementation & Feedback" id="Integrated Human Practices3">
<HPFeedback/>
</Subesction>
<Subesction title="Conclusion" id="Integrated Human Practices4">
<HPconclusion/>
</Subesction>
</Section>
)
}
\ No newline at end of file
src/contents/Human Practices/Introduction.tsx 0 → 100644
View file @ 3fd292fd
import { ButtonOne } from "../../components/Buttons";
import { H5 } from "../../components/Headings";
import PreCyse from "../../components/precyse";
import { BlockQuoteB } from "../../components/Quotes";
import { Section } from "../../components/sections";
import { useNavigation } from "../../utils";
import { useTabNavigation } from "../../utils/TabNavigation";
export function HPIntroduction(){
const {goToPageAndScroll} = useNavigation();
useTabNavigation();
return(
<Section title="Introduction" id="Introduction">
<H5 text="- Connecting our project to real life -"/>
<BlockQuoteB text="Science and everyday life cannot and should not be separated." cite="Rosalind Franklin"/>
<div className="row align-items-center">
<div className="col ">
<ButtonOne openclass="intro-cycletab" text="Our Understanding of HP" open="understanding"></ButtonOne>
</div>
<div className="col ">
<ButtonOne openclass="intro-cycletab" text="Our Mission & Vision" open="mission"></ButtonOne>
</div>
<div className="col ">
<ButtonOne openclass="intro-cycletab" text="Our Approach" open="approach"></ButtonOne>
</div>
<div className="col ">
<ButtonOne openclass="intro-cycletab" text="Our Target Groups" open="targets"></ButtonOne>
</div>
</div>
<br/>
<div className="col intro-cycletab" id="understanding" style={{display: "block"}}>
<p>This year, we at iGEM Bielefeld-CeBiTec have consciously chosen a <b>human-centered project design</b>. At the heart of our iGEM project is
one key pillar: <b>Human Practice</b>. Our goal is to understand the impact of our project on society, the scientific community and the world
as whole. This is not just about the technical effectiveness of our parts, but also about how the solution is embraced in everyday
practice, and the potential long-term impact it could have for Cystic Fibrosis patients and their families all over the world.
</p>
<p>With our human-centered approach, we aim to address fundamental iGEM Human Practice questions and beyond:
</p>
<p style={{textAlign: "center"}}> <b>How does our project affect the world around us?</b></p>
<p style={{textAlign: "center"}}> <b>How does the world around us influence our project? </b></p>
<p>From the very beginning, it was our priority to identify various stakeholders and meet people affected by Cystic Fibrosis early on to <b>actively involve</b> them throughout the planning and development process. This collaborative approach allowed us to ensure that our project
addresses real needs and contributes to solutions for as many different people as possible. Without the critical advice, varied perspectives
and input from our stakeholders, it would have been impossible to identify and reflect on all aspects of our project. We made every
effort to <b>deeply understand</b> their values and backgrounds, allowing us to integrate their feedback into our solutions.
</p>
</div>
<div className="col intro-cycletab" id="mission" style={{display: "none"}}>
<p>We view Human Practice as an opportunity to <b>go beyond practical lab work and traditional science</b> and to learn about
the needs of people affected by Cystic Fibrosis. It’s a chance for us to creatively engage with different aspects of our project
while developing an awareness of the responsibilities that come with it.
</p>
<p>
As part of our <PreCyse/> project, we performed intensive brainstorming sessions and expert consultations. We conducted comprehensive
<a onClick={() => goToPageAndScroll("our-surveys-on--Cystic Fibrosis-and-gene-therapy", "/human-practices")}> surveys</a> among the public and people with Cystic Fibrosis and their relatives. We focused on critical aspects such as the <b>needs of our
target groups, safety, ethics, design, implementation, and business</b> — each guided by the core values of our team. Based on these interactions
and the recommendations of the Human Practice committee, we have developed an optimal strategy for our project, ensuring that our work is not
only innovative but also mindful of its broader impact on society.
</p>
</div>
<div className="col intro-cycletab" id="approach" style={{display: "none"}}>
<p>It was important to us as a team to not only offer technical solutions, but to show that our project can contribute to the larger context of ongoing initiatives and movements to optimize health care. We wanted to really understand the feedback and insights of the stakeholders to gain a better understanding of how our project fits into the overall picture of living with Cystic Fibrosis, the current state of research and how it can be used to reduce the health care gap.
</p>
<p><b>Our strategy includes:</b></p>
<ul>
<li>Identifying key target groups</li>
<li>Establishing meaningful and lasting communication with stakeholders</li>
<li>Effectively engaging with the diverse backgrounds of those involved</li>
<li>Understand the ethical, social and scientific values that inspired our project</li>
<li>Integrating feedback and adapting our approach to align with stakeholder goals</li>
<li>Designing and incorporating representative surveys</li>
<li>Reflect on how these values have been incorporated into our project</li>
</ul>
<p><b>With this approach and the support of our stakeholders, our ultimate goals are to:</b></p>
<ul>
<li>Improve care for Cystic Fibrosis patients</li>
<li>Optimize the availability of essential medications</li>
</ul>
</div>
<div className="col intro-cycletab" id="targets" style={{display: "none"}}>
<p>Our target groups are composed of <b>academic and clinical experts</b> to build a bridge between research and practical application.
In addition, engaging with CF <b>patients</b> across different age groups and countries and their relatives leads to an awareness of
the special needs and demands of our project and to an understanding of the limitations and challenges in everyday CF life. The
integration of regulatory ethics serves to evaluate how our project might be implemented in German and international <b>government </b>
regulations for gene therapeutics. The exchange with <b>companies</b> contributes to understanding the chances and challenges in business of
establishing a start-up and what it takes to get our idea on the market for real life application. The continuous exchange between the
different groups contributes significantly to the successful implementation of the project. First-hand information from our target groups
and the matching and merging of the information is therefore essential for defining and achieving our goals.
</p>
</div>
</Section>
)
}
\ No newline at end of file
src/contents/Human Practices/Overwiev.tsx 0 → 100644
View file @ 3fd292fd
import { BlockQuoteB } from "../../components/Quotes";
import { useTabNavigation } from "../../utils/TabNavigation";
export function HPOverview(){
useTabNavigation();
return(
<div className="col">
<section id="OverviewH">
<h2 id="Overview"></h2>
<img src="https://static.igem.wiki/teams/5247/ihp-schaubild.webp" alt="Stakeholder Overview"></img>
<strong>Figure: Visualization of the Human-Centric Approach by iGEM Bielefeld-CeBiTec 2024</strong><p>Our project has been supported by over 80 individuals and institutions, enhancing our integrative human practices. We are deeply grateful for the invaluable feedback and the collective effort of everyone who has contributed to our vision of safe and precise gene therapy through PreCyse. Thank you for your support!
</p>
<span id="hp-quote"><BlockQuoteB
text="Human Practices is the study of how your work affects the world, and how the world affects your work."
cite="- Peter Carr, Director of Judging"
/> </span>
<p>In the development of our project, we embraced a holistic and human-centric approach, putting people at the core of our efforts. Our goal was to foster interdisciplinary collaboration and open dialogue, ensuring that diverse perspectives shaped the trajectory of our work. Over the course of this journey, we have engaged with more than 80 individuals and institutions, who have significantly influenced our project.
The strength of our approach lies in its interdisciplinary nature. We have brought together representatives from a wide range of categories, each playing a vital role in shaping the direction and success of our initiative. These categories include: </p>
<ol>
<li>
<strong>Patients:</strong> At the heart of any healthcare-related project, patients provide invaluable insights. Their lived experiences, needs, and challenges have guided our efforts to develop solutions that are truly patient-centered.
</li>
<li>
<strong>Healthcare Institutions:</strong> Collaborating with hospitals, clinics, and other healthcare providers allowed us to understand the practical implications of our work and to ensure that our solutions are aligned with the realities of healthcare delivery.
</li>
<li>
<strong>Academia – Research and Science:</strong> By partnering with researchers and scientists from leading academic institutions, we were able to base our work on the latest scientific knowledge and methodologies. Their contributions ensured that our approach is both innovative and evidence-based.
</li>
<li>
<strong>Industry – Entrepreneurship and Business:</strong> Engaging with industry professionals and entrepreneurs enabled us to explore the commercial potential of our project. Their expertise in innovation, business models, and scalability helped us to envision how our solutions could be brought to market and widely implemented.
</li>
<li>
<strong>Government – Biosafety and Ethics:</strong> Regulatory bodies and ethics committees played a crucial role in ensuring that our project adheres to the highest standards of safety, ethics, and compliance. Their oversight has been instrumental in maintaining the integrity and social responsibility of our work.
</li>
<li>
<strong>Local and International Communities:</strong> Our outreach to both local and global communities allowed us to understand the broader societal impacts of our project. These interactions helped us to address diverse cultural, social, and economic factors, ensuring that our solutions are accessible and relevant to different populations.
</li>
<li>
<strong>Public Organizations:</strong> Partnering with non-governmental organizations and public institutions enabled us to align our project with public health goals and contribute to social good. Their mission-driven focus helped us to maintain a sense of purpose and responsibility in all our endeavors.
</li>
</ol>
<p>By engaging with these diverse stakeholders, we have built a project that is not only comprehensive but also adaptable to the multifaceted needs of society. The insights and feedback from patients, healthcare professionals, researchers, businesses, governments, communities, and public organizations have ensured that our human-centric approach remains dynamic, inclusive, and impactful.
In summary, our project reflects the power of collaboration across sectors, disciplines, and geographies. The collective input of more than 80 individuals and institutions has enabled us to create a well-rounded and robust framework that addresses the challenges we set out to solve. We are proud of the interdisciplinary nature of our work and are committed to continuing this inclusive approach as we move forward. </p>
</section>
</div>
)
}
\ No newline at end of file
src/contents/Human Practices/human-practices.tsx 0 → 100644
View file @ 3fd292fd
/*
- seitwärts
- mit Farben und Text anzeigen wozu die gehören
- bei show more unten drunter Tabs öffnen
- wenn man auf die Person klickt soll es Infos über die Person anzeigen
- kann mn die Karten nach Links und nach rechts ausweiten zb für Mehr infos für die Person?
- Filter mit HalbkreisDing als Tabsteuerung | Einteilung nach Bereich (Academia, Insustry, ..., und auch nach Delivery und Mechanism)
- DNA Strang als Timeline?
*/
/* <br/>
<h3>Name</h3>
<hr/>
<div className="row">
<div className="col-2">
<div className="t-tag Tag">
Beruf
</div>
</div>
<div className="col">Original language: German</div>
</div>
<div className="row">
<div className="col">
<BlockQuoteB text="Quote" cite="."></BlockQuoteB>
</div>
<div className="col-3">
<img className="middle sechpro" src="https://static.igem.wiki/teams/5247/placeholders/placehilderperson.jpeg"/>
</div>
</div>
<h4>Aim of contact</h4>
<p></p>
<h4>Insights</h4>
<p></p>
<h4>Clarification</h4>
<p></p>
<h4>Implementation</h4>
<p></p> */
/*
<h4>Aim of contact</h4>
<p></p>
<h4>Insights</h4>
<p></p>
<h4>Clarification</h4>
<p></p>
<h4>Implementation</h4>
<p></p>
*/
import { openElement } from "../../utils/openElement";
import { HPOverview } from "./Overwiev";
import { HPIntroduction } from "./Introduction";
import { HPIntegrated } from "./IHP";
import { HPFurtherEngagement } from "./Further Engagement/FurtherEngagement";
import { HPSupplement } from "./Further Engagement/SupMaterial";
import { useTabNavigation } from "../../utils/TabNavigation";
import { HPAbstract } from "./HP-abstract";
export function HumanPractices() {
useTabNavigation();
openElement({buttonClass: "tabbutton", elementToOpen: "All", classToHide: "timelinecardtabs", });
return (
<div className="col">
<HPAbstract/>
<HPOverview/>
<HPIntroduction/>
<HPIntegrated/>
<HPFurtherEngagement/>
<HPSupplement/>
</div>
);
}
src/contents/attributions.tsx
View file @ 3fd292fd
import { useEffect } from "react";
import { BackUp } from "../components/Buttons";
import { H2 } from "../components/Headings";
import { BlockQuoteB } from "../components/Quotes";
export function Attributions() {
const teamID = import.meta.env.VITE_TEAM_ID;
......@@ -25,14 +28,24 @@ export function Attributions() {
<>
<div className="row mt-4">
<div className="col">
<H2 text="One iGEM project - Million people behind"/>
<BlockQuoteB text="With a lot of responsibility comes a bigger workload and even more people working together" cite="former iGEMer"/>
<p>We would like to thank everyone who supported our team and provided assistance, resources or useful tips in order to fulfill our project.</p>
<p>The following overview lists all team members, who have been instrumental in our iGEM project. We are proud of our work and look forward to what awaits us after the iGEM competition.</p>
<p>We would like to thank our principal investigators, instructor and supervisors for guiding us along the way and helping to shape our project.</p>
<p>We contributed all external partners that have influenced the project below. We would like to thank all iGEM teams, former iGEM team members of the university of Bielefeld or external team members, contractors, technicians, laboratory students, post-docs and collaborators for their support in any form. </p>
<p>We would also like to thank our sponsors, who have supported us with their generous donations. First and foremost, Bielefeld University, and particularly Prof. Dr. Alfred Pühler, who revived iGEM and allows us to participate in this year's competition. Additionally, we are thankful for the support and feedback of the steering committee.</p>
<p>In addition to cooperation and collaborative work, time management focuses on efficient operation of every iGEM project. The following list of our project timeline serves as an orientation and gives an overview of the temporal staggering of the project. We would like to thank all participants for the coordination of our activities</p>
</div>
<br/>
</div>
<iframe
style={{ width: "100%" }}
id="igem-attribution-form"
src={`https://teams.igem.org/wiki/${teamID}/attributions`}
/>
<BackUp/>
</>
);
}
src/contents/collaborations.tsx deleted 100644 → 0
View file @ 5f3933d7
import { useEffect } from "react";
import { useLocation } from "react-router-dom";
import { openFromOtherPage } from "../components/Buttons";
export function Collaborations() {
const location = useLocation();
useEffect(() => {
const params = new URLSearchParams(location.search);
const collapseId = params.get('collapseId');
const tabId = params.get('tab');
// Scroll to the section specified by collapseId
if (collapseId) {
const collapseElement = document.getElementById(collapseId);
if (collapseElement) {
const elementTop = collapseElement.getBoundingClientRect().top + window.pageYOffset;
const offset = window.innerHeight / 2 - collapseElement.offsetHeight / 2;
const scrollPosition = elementTop - offset;
window.scrollTo({
top: scrollPosition,
behavior: 'smooth',
});
}
}
// Open the tab specified by tabId
if (tabId) {
openFromOtherPage(tabId)({ currentTarget: document.getElementById(tabId)! });
}
}, [location.search]);
return (
<>
<div className="row mt-4">
<div className="col">
</div>
</div>
</>
);
}
\ No newline at end of file
src/contents/contribution.tsx deleted 100644 → 0
View file @ 5f3933d7
import { useEffect } from "react";
import { useLocation } from "react-router-dom";
import { openFromOtherPage } from "../components/Buttons";
export function Contribution() {
const location = useLocation();
useEffect(() => {
const params = new URLSearchParams(location.search);
const collapseId = params.get('collapseId');
const tabId = params.get('tab');
// Scroll to the section specified by collapseId
if (collapseId) {
const collapseElement = document.getElementById(collapseId);
if (collapseElement) {
const elementTop = collapseElement.getBoundingClientRect().top + window.pageYOffset;
const offset = window.innerHeight / 2 - collapseElement.offsetHeight / 2;
const scrollPosition = elementTop - offset;
window.scrollTo({
top: scrollPosition,
behavior: 'smooth',
});
}
}
// Open the tab specified by tabId
if (tabId) {
openFromOtherPage(tabId)({ currentTarget: document.getElementById(tabId)! });
}
}, [location.search]);
return (
<>
<div className="row mt-4">
<div className="col">
</div>
</div>
</>
);
}
src/contents/description.tsx
View file @ 3fd292fd
import { useLocation } from "react-router-dom";
import { InfoBox } from "../components/Boxes";
import { TabButtonRow } from "../components/Buttons";
import Collapsible from "../components/Collapsible";
import { SupScrollLink } from "../components/goto";
import { H2} from "../components/headings";
import { LoremMedium, LoremShort } from "../components/loremipsum";
import { Circle } from "../components/Shapes";
import { Complex } from "../components/svgs";
import { SupScrollLink } from "../components/ScrollLink";
import { H4 } from "../components/Headings";
import { ButtonRowTabs } from "../components/Tabs";
import { useEffect } from "react";
/* import PieChart from './Graph.tsx'; */
export function Description() {
const location = useLocation();
useEffect(() => {
const params = new URLSearchParams(location.search);
const collapseId = params.get('collapseId');
const tabId = params.get('tab');
// Open the tab specified by tabId
if (tabId) {
// Hide all tabs
const tabs = document.querySelectorAll('.enginneeringtab');
tabs.forEach((tab) => {
(tab as HTMLElement).style.display = 'none';
});
// Show the selected tab
const selectedTab = document.getElementById(tabId);
if (selectedTab) {
selectedTab.style.display = 'block';
}
}
// Scroll to the section specified by collapseId after opening the tab
if (collapseId) {
const collapseElement = document.getElementById(collapseId);
if (collapseElement) {
const elementTop = collapseElement.getBoundingClientRect().top + window.pageYOffset;
const offset = window.innerHeight / 2 - collapseElement.offsetHeight / 2;
const scrollPosition = elementTop - offset;
window.scrollTo({
top: scrollPosition,
behavior: 'smooth',
});
}
}
}, [location.search]);
return (
<div className="row mt-4">
<div className="col">
<div className="col">
<section id="Abstract" className="section">
<H2 text="Abstract"/>
<p>We are proud to introduce our next-generation prime editing technology <a href="#" className="underline--magical">PreCyse</a>. We aim to develop an innovative gene therapy against cystic fibrosis, tackling the most common mutation ΔF508 of the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene. We optimize lipid nanoparticles for the efficient and cell-specific delivery of our therapeutic mRNA. Current treatment strategies are limited in terms of speed, precision and effectiveness, often failing to achieve long-lasting improvements. In addition, high costs and limited accessibility of pharmaceuticals contribute to adverse prognosis of many patients. We want to develop a monthly applied which represents a cure that is more advanced and user-friendly compared to other medications due to its longer lasting time, lowering the frequency of use. </p>
</section>
</div>
<div className="col">
<section className="section">
<div id="Cystic-Fibrosis"><H2 text="Cystic Fibrosis"/></div>
<div id="CF1"><h3>General</h3> </div>
<div className="row align-items-center">
<div className="col">
<p data-aos="zoom-y-out" >Cystic fibrosis (CF) is the most common life-limiting genetic disorder in the Caucasian population. In Europe, CF affecting about 1 in 3,000 newborns
<SupScrollLink label="1"/>.</p>
<p> It is caused by mutations in the CFTR gene, which controls ions and water movement in cells. This leads to thick mucus, clogging airways, and frequent infections. The defective CFTR protein impacts the respiratory and digestive systems, causing chronic lung infections, breathing difficulties, and malnutrition. CF's severity varies, but it reduces life quality and expectancy. There are over 1,700 CFTR mutations; the ΔF508 mutation is most common, present in 70% of cases. It prevents proper protein folding, affecting its function. </p>
<p><LoremMedium/></p>
</div>
<div className="row-if-small col-2 ">
<Circle text="1:3000 newborns worldwide"/>
<Circle text="x:y newborns in Germany"/>
<Circle text="kosten"/>
</div>
{/* <Linear
xAxis={[{ data: [1, 2, 3, 5, 8, 10] }]}
series={[
{
data: [2, 5.5, 2, 8.5, 1.5, 5],
},
]}
width={500}
height={300}
/> */}
</div>
<div className="col">
<img src="https://static.igem.wiki/teams/5247/charts-maps/cfper10-000.png"></img>
</div>
<div id="CF2"><h3>CFTR</h3> </div>
<div className="rowalign-items-center">
<div className="full-small col-2">
<img src="https://static.igem.wiki/teams/5247/placeholders/placehilderperson.jpeg"/>
<img src="https://static.igem.wiki/teams/5247/placeholders/placehilderperson.jpeg"/>
</div>
<div className="col">
<p>Text about CFTR <LoremMedium/></p>
</div>
</div>
<div id="CF3"><h3>ΔF508</h3> </div>
<p>A multitude of mutations in the CFTR gene, exceeding 1,000, are responsible for the development of cystic
fibrosis. The most prevalent variant is F508del, observed in approximately 70% of affected individuals of
Caucasian descent in Canada, Northern Europe, and the United States<SupScrollLink label="14"/>. It is estimated that around 90% of
the European population and people of European heritage with cystic fibrosis carry at least one F508del
variant <SupScrollLink label="15"/><sup>,</sup><SupScrollLink label="16"/>. Analyses have demonstrated that the F508del mutation originated in Western Europe at least
5,000 years ago <SupScrollLink label="15"/>. </p>
<p>It is a deletion of the three nucleotides "CTT" at position 508, which removes the phenylalanine residue
without causing a frameshift. This deletion leads to defects in the kinetic and thermodynamic folding
of the NBD1 domain <SupScrollLink label="16"/>. However, this not only leads to misfolding of CFTR but also to defects in
trafficking and premature degradation, resulting in reduced surface expression of CFTR <SupScrollLink label="17"/>. </p>
<img src="https://static.igem.wiki/teams/5247/charts-maps/cfper10-000.png"/>
<div id="CF4"><h3>Symptoms</h3> </div>
<p>Text about symptoms</p>
<Collapsible id="symptoms-collapsible" title="How the symptoms affect different parts of the body" > Child </Collapsible>
<div id="CF5"><h3>Diagnosis</h3> </div>
<p>About the ways one can be diagnosed <LoremMedium/></p>
<div className="row align-items-center">
<div className="col" >
<img src="https://static.igem.wiki/teams/5247/placeholders/placehilderperson.jpeg"/>
</div>
<div className="col" >
How newbornscreening affected the numbers.
<LoremMedium/>
</div>
</div>
<div id="CF6"><h3>Treatment</h3> </div>
<img src="https://static.igem.wiki/teams/5247/placeholders/placehilderperson.jpeg"/>
<Collapsible id="drugs-collapsible" title="Different types of drugs" >
<TabButtonRow data={medibuttonrowdata} opentype="meditabs" closing=""/>
<ButtonRowTabs data={medibuttonrowdata} cla="meditabs"/>
</Collapsible>
<p>Why we still need other options</p>
<img src="https://static.igem.wiki/teams/5247/charts-maps/cfper10-000.png"/>
</section>
</div>
<div className="col">
<section className="section">
<div id="Our-motivation"><H2 text="Our motivation"></H2></div>
<p>We chose to focus on CF and specifically the ΔF508 mutation due to its prevalence and the severe impact it has on patients' lives. Additionally, our team includes members who have close friends affected by this condition, giving us a personal connection and a strong motivation to find a solution. By targeting the ΔF508 mutation, we aim to develop a therapy that could potentially, not only benefit many CF patients and make a significant improvement in their lives, but also can serve as a template, which research groups can use to target other genetic diseases. </p>
<div className="row align-items-center">
<div className="col" >
</div>
<div className="col" >
<img className="img" src="https://static.igem.wiki/teams/5247/placeholders/placehilderperson.jpeg"/>
</div>
</div>
<p>Max</p>
</section>
</div>
<div className="col">
<section className="section">
<div id="Approach"><H2 text="Approach"></H2></div>
<p>To correct the mutation, we are utilizing Prime Editing technologies. Prime Editing is a genome editing technique that allows precise DNA modifications without causing double-strand breaks<SupScrollLink label="2"/>. Structurally, the Prime Editing complex consists of a Cas9 endonuclease fused to a reverse transcriptase (RT) and guided by a pegRNA, which directs the complex to the target site in the genome. </p>
<InfoBox title="Prime Editing" id="prime-editing">
<details>
<summary>Prime editing is a new method of gene editing based on an RNA-Protein complex. It was developed by a group of researchers revolving around Professor David Liu from Harvard University in 2019. <SupScrollLink label="9"/></summary>
<p>Details</p>
<LoremMedium/>
</details>
</InfoBox>
<div className="row">
<div className="col">
<p>However, the Prime Editing complex is relatively large, posing challenges for therapeutic delivery<SupScrollLink label="3"/>. Additionally, Prime Editing has been shown to be relatively inefficient in terms of gene editing rates, which could limit its therapeutic utility<SupScrollLink label="4"/>. Our project aims to enhance the Prime Editing approach by miniaturizing its components. Fanzor, a recently discovered eukaryotic endonuclease, performs functions similar to Cas9, a crucial part of the Prime Editing complex, but is significantly smaller. We aim to substitute Cas9 with Fanzor. </p>
<p>Additionally, we plan to replace the reverse transcriptase in the Prime Editing complex with a smaller RT variant. Furthermore, MCP proteins will be added to the Prime Editing complex to increase its stability<SupScrollLink label="5"/>. </p>
</div>
<div className="img-right img-half col"><Complex></Complex></div>
</div>
<Collapsible id="fanzorcas-collapsible" title="Cas vs. Fanzor"> child </Collapsible>
<p>The pegRNA is optimized via an extension by a stem loop, which stabilizes the RNA by protecting it from RNases and serves as a binding site for the MCP, which also supports the secondary RNA structure. Additionally, the pegRNA contains a riboswitch, a sodium ion-controlled regulator that switches off the complex. This represents a major biosafety feature in that the complex is switched off after successful DNA editing and the subsequent increased influx of chloride ions into the cell. The pegRNA is combined with an optimized sgRNA resulting in higher on-target effect. Overall, its optimization leads to a longer shelf life and an increase in the biosafety of the complex. </p>
<InfoBox title="Riboswitch" id="riboswitch">
About the Riboswitch
</InfoBox>
</section>
</div>
<div className="col">
<section className="section">
<div id="Delivery"> <H2 text="Delivery"></H2> </div>
<img className="img-left img-half spin" src="https://static.igem.wiki/teams/5247/scientific-figures/lnp.png" height={"200vw"}/>
<div>
<p>We chose LNPs as the delivery system of our Next-Generation Prime Editing Technology. Because of their large capacity and less immunogenic side effects compared to other delivery systems like Adeno-associated Viruses (AVV)<SupScrollLink label="6"/>. Our aim is to optimize the LNP formulation to improve delivery to lung tissue via inhalation. Because of our collaborations, we are able to test and optimize different delivery systems to improve our organ specific therapeutic approach. Therefore, our LNP design focusses on stability and targeting. Stability is achieved by a polyethylene glycol (PEG) coating that protects the LNPs from degradation by the immune system<SupScrollLink label="7"/>. Moreover, we use capsaicin in combination with chitosan to improve the uptake of our construct through their mucus-adhesive properties<SupScrollLink label="8"/>. </p>
</div>
<div className="row align-items-center">
<div className="col">
LAgertemperatur der Parts <LoremShort/>
import PieChart from "../components/Graph";
import PreCyse from "../components/precyse";
import { Section, Subesction } from "../components/sections";
import { symptomdata, SymptomDatensatz } from "../data/symptom-data";
import { drugdata, DrugDatensatz } from "../data/drug-data";
import { useTabNavigation } from "../utils/TabNavigation";
import PrimeEditingComplex from "../components/Complex-svg";
import { useNavigation } from "../utils";
import DescSources from "../sources/description-sources";
import { OneFigure } from "../components/Figures";
export function Description() {
useTabNavigation();
const { goToPagesAndOpenTab, goToPageWithTabAndScroll } = useNavigation();
const { goToPageAndScroll, goToPageWithTabAndCollapsible } = useNavigation();
return (
<div className="row mt-4">
<div className="col">
<Section title="Abstract" id="Abstract">
<p id="obenindescription">We are proud to present <PreCyse />, a next-generation Prime Editing technology, as innovative gene therapy approach for Cystic Fibrosis (CF)
specifically targeting the most common mutation <b>F508del</b> of the CFTR gene. Cystic Fibrosis is a severe disorder that primarily affects the lungs
and for which only short-term symptomatic treatments exist. PreCyse aims to provide long-term relief by delivering a small genetic payload with speed
and precision. Our approach integrates <b>PrimeGuide</b>, a highly optimized Prime Editing system, with <b>AirBuddy</b>, a novel lipid nanoparticle
(LNP) delivery platform. The <b>SORT LNPs</b> used in AirBuddy are optimized for pulmonary delivery, offering precise organ targeting and structural
stability throughout the inhalation process. Small payload size is key for effective delivery and compatibility with viral vectors, which have a
limited capacity. PrimeGuide embodies this vision by utilizing a smaller, more efficient editing complex. Current treatments often require daily
administration whereas PreCyse is currently developed as a monthly applied therapy. In addition, Prime Editing holds the promise to offer a causal cure,
when mutations are corrected in stem cells. Our approach aims to reduce medication frequency while improving patient outcomes.
By lowering costs and improving accessibility, PreCyse aspires to offer an advanced and user-friendly cure for Cystic Fibrosis.</p>
</Section>
<Section title="Our Motivation" id="Our Motivation">
<div className="row align-items-center">
<div className="col" >
<p>Our project started with a personal story. Rather than being driven purely by academic curiosity, our motivation came from someone close to one of our team members — Max Beckmann, a friend who has lived with Cystic Fibrosis (CF) since his birth. Specifically, he carries the F508del mutation, the most common genetic cause of the disease. Seeing the impact of CF on his daily life—frequent treatments and physical strain—made us realize how much more can be done to improve the lives of those affected, which inspired us to pursue this project. </p>
<p>As we explored Cystic Fibrosis further, we were struck by how widespread it is, being the most common genetic disorder in Germany. Approximately 70% of those with CF are specifically affected by the F508del mutation<SupScrollLink label="1" /> . This mutation is the most prevalent and well-studied of the thousands of genetic variations that cause CF, making it an important focus of research and intervention. In fact, about 90% of Europeans and individuals of European descent with CF have at least one F508del allele<SupScrollLink label="2" />. This widespread prevalence highlighted the significance of our project—not just for our friend, but for the thousands of others affected by this mutation across Europe and beyond. </p>
</div>
<div className="col" >
<OneFigure
pic1="https://static.igem.wiki/teams/5247/photos/other/max-bild.webp"
alt1=""
description="Picture from our interview with Max."
num="1 "
/>
</div> {/* */}
</div>
<div className="col">
Trocknung <LoremShort/>
</div>
</div>
<br/>
<p>We are furthermore optimising the LNPs for pulmonary therapy and investigating delivery by nebulisation as a non-invasive method compared to systemic approaches to make the therapy more convenient for patients. For specific targeting, we are focussing on marker proteins of basal cells and ionocytes that produce particularly high levels of CFTR protein and which we want to target with appropriate antibodies<SupScrollLink label="9"/>. Our workflow includes testing our next generation Prime Editing Technology delivered by our optimized LNPs in cell culture lines but also in primary nasal epithelial cells of CF patients to evaluate our optimizations and further improvements in vitro. We can also provide the outlook on the adaptation of the delivery system enabling systemic applications as well. </p>
</section>
</div>
<div className="col">
<section className="section">
<div id="Our-vision"><H2 text="Our vision"></H2> </div>
<p>We are envisioning a potential integration into a broader therapeutic framework involving customized gene editing tools for various genetic disorders, that present similar problems/difficulties to the F508del mutation, as well as other genetic diseases of different causes. This could include collaborations with pharmaceutical companies to develop new treatment modalities for genetic diseases beyond cystic fibrosis, utilizing advanced delivery systems and personalized medicine approaches. </p>
{/* <H2 text="Editing Statistics"/> */}
{/* <PieChart /> */} {/* Render the PieChart component */}
</section>
</div>
{/* Sources */}
<div className="col">
<section className="section">
<div id="References"><H2 text="References"></H2> </div>
<ol>
{/* <!-- Citation num 1--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name">Scotet, V.</span>,
<span property="schema:Name">Gutierrez, H.</span>,
<span property="schema:Name">Farrell, P. </span>
</span>
<span property="schema:name">Newborn Screening for CF across the Globe—Where Is It Worthwhile? </span>
<i property="schema:publisher" typeof="schema:Organization">Int J Neonatal Screen </i>
<b property="issueNumber" typeof="PublicationIssue">6</b>,
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2020">2020</time>).
<a className="doi" href="https://doi.org/10.3390/ijn6010018"> doi: 10.3390/ijn6010018</a>
</li>
{/* <!-- Citation num 2--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-2">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name">Anzalone, A.V.</span>,
<span property="schema:Name">Randolph, P.B.</span>,
<span property="schema:Name">Davis, J.R.</span>,
<span property="schema:Name">Sousa, A.A.</span>,
<span property="schema:Name">Koblan, L.W.</span>,
<span property="schema:Name">Levy, J.M.</span>,
<span property="schema:Name">Newby, G.A.</span>,
<span property="schema:Name">Raguram, A.</span>,
<span property="schema:Name">Liu, D.R. </span>
</span>
<span property="schema:name">Search-and-replace genome editing without double-strand breaks or donor DNA. </span>
<i property="schema:publisher" typeof="schema:Organization">Nature </i>
<b property="issueNumber" typeof="PublicationIssue">574</b>,
<span property="schema:pageBegin"> 589</span>-<span property="schema:pageEnd">594 </span>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2019">2019</time>).
<a className="doi" href="https://doi.org/10.1038/s41586-019-1711-4"> doi: 10.1038/s41586-019-1711-4</a>
</li>
{/* <!-- Citation num 3--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-3">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name">Broad Institute of MIT and Harvard. </span>
</span>
<span property="schema:name">Researchers engineer in vivo delivery system for prime editing, partially restoring vision in mice. </span>
<i property="schema:publisher" typeof="schema:Organization">Phys.org </i>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2024">2024</time>).
</li>
{/* <!-- Citation num 4--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-4">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name">Gaudelli, N.</span>,
<span property="schema:Name">Komor, A.</span>,
<span property="schema:Name">Rees, H.</span>,
<span property="schema:Name">Packer, M.</span>,
<span property="schema:Name">Badran, A.</span>,
<span property="schema:Name">Bryson, D.</span>,
<span property="schema:Name">Liu, D. </span>
</span>
<span property="schema:name">Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. </span>
<i property="schema:publisher" typeof="schema:Organization">Nature </i>
<b property="issueNumber" typeof="PublicationIssue">533</b>,
<span property="schema:pageBegin"> 420</span>-<span property="schema:pageEnd">424 </span>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2016">2016</time>).
<a className="doi" href="https://doi.org/10.1038/nature17946"> doi: 10.1038/nature17946</a>
</li>
{/* <!-- Citation num 5--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-5">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name">OpenEd CUNY. </span>
</span>
<span property="schema:name">RNA Stability and the Role of RNA-Binding Proteins. </span>
<i property="schema:publisher" typeof="schema:Organization">OpenEd CUNY </i>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2024">2024</time>).
</li>
{/* <!-- Citation num 6--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-6">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name">Sahay, G.</span>,
<span property="schema:Name">Alakhova, D.Y.</span>,
<span property="schema:Name">Kabanov, A.V. </span>
</span>
<span property="schema:name">Endocytosis of nanomedicines. </span>
<i property="schema:publisher" typeof="schema:Organization">Journal of Controlled Release </i>
<b property="issueNumber" typeof="PublicationIssue">145</b>,
<span property="schema:pageBegin"> 182</span>-<span property="schema:pageEnd">195 </span>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2010">2010</time>).
<a className="doi" href="https://doi.org/10.1016/j.jconrel.2010.01.036"> doi: 10.1016/j.jconrel.2010.01.036</a>
</li>
{/* <!-- Citation num 7--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-7">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name">Ramachandran, S.</span>,
<span property="schema:Name">Satapathy, S.R.</span>,
<span property="schema:Name">Dutta, T. </span>
</span>
<span property="schema:name">Delivery Strategies for mRNA Vaccines. </span>
<i property="schema:publisher" typeof="schema:Organization">Pharmaceutical Medicine </i>
<b property="issueNumber" typeof="PublicationIssue">36</b>,
<span property="schema:pageBegin"> 11</span>-<span property="schema:pageEnd">20 </span>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2022">2022</time>).
<a className="doi" href="https://doi.org/10.1007/s40290-021-00417-5"> doi: 10.1007/s40290-021-00417-5</a>
</li>
{/* <!-- Citation num 8--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-8">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name">Bandi, S.P.</span>,
<span property="schema:Name">Bhatnagar, S.</span>,
<span property="schema:Name">Venuganti, V.V.K. </span>
</span>
<span property="schema:name">Advanced materials for drug delivery across mucosal barriers. </span>
<i property="schema:publisher" typeof="schema:Organization">Acta Biomaterialia </i>
<b property="issueNumber" typeof="PublicationIssue">119</b>,
<span property="schema:pageBegin"> 13</span>-<span property="schema:pageEnd">29 </span>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2021">2021</time>).
<a className="doi" href="https://doi.org/10.1016/j.actbio.2020.10.031"> doi: 10.1016/j.actbio.2020.10.031</a>
</li>
{/*<!-- Citation num 9--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-9">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name"> Anzalone, A.</span>;
<span property="schema:Name"> Randolph, P.</span>;
<span property="schema:Name"> Davis, J.</span>;
<span property="schema:Name"> Sousa, A.</span>;
<span property="schema:Name"> Koblan, L.</span>;
<span property="schema:Name"> Levy, J.</span>;
<span property="schema:Name"> Chen, P.</span>;
<span property="schema:Name"> Wilson, C.</span>;
<span property="schema:Name"> Newby, G.</span>;
<span property="schema:Name"> Raguram, A.</span>;
<span property="schema:Name"> Liu, D.</span>
</span>
<span property="schema:name">&nbsp;Search-and-replace genome editing without double-strand breaks or donor DNA. </span>
<i property="schema:publisher" typeof="schema:Organization"> Nature</i>
<b property="issueNumber" typeof="PublicationIssue"> 576</b>,&nbsp;
<span property="schema:pageBegin">149–157</span>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2019">2019</time>).
<a className="doi" href="https://doi.org/10.1038/s41586-019-1711-4"> doi: 10.1038/s41586-019-1711-4</a>
</li>
{/*<!-- Citation num 10--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-10">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name"> Doman, J.</span>;
<span property="schema:Name"> Pandey, S.</span>;
<span property="schema:Name"> Neugebauer, M.</span>;
<span property="schema:Name"> An, M.</span>;
<span property="schema:Name"> Davis, J.</span>;
<span property="schema:Name"> Randolph, P.</span>;
<span property="schema:Name"> McElroy, A.</span>;
<span property="schema:Name"> Gao, X.</span>;
<span property="schema:Name"> Raguram, A.</span>;
<span property="schema:Name"> Richter, M.</span>;
<span property="schema:Name"> Everette, K.</span>;
<span property="schema:Name"> Banskota, S.</span>;
<span property="schema:Name"> Tian, K.</span>;
<span property="schema:Name"> Tao, Y.</span>;
<span property="schema:Name"> Tolar, J.</span>;
<span property="schema:Name"> Osborn, M.</span>;
<span property="schema:Name"> Liu, D.</span>
</span>
<span property="schema:name">&nbsp;Phage-assisted evolution and protein engineering yield compact, efficient prime editors. </span>
<i property="schema:publisher" typeof="schema:Organization"> Cell</i>
<b property="issueNumber" typeof="PublicationIssue"> 186</b>,&nbsp;
<span property="schema:pageBegin"> 3983</span>-<span property="schema:pageEnd">4002.e26</span>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2023">2023</time>).
<a className="doi" href="https://doi.org/10.1016/j.cell.2023.07.039"> doi: 10.1016/j.cell.2023.07.039</a>
</li>
{/*<!-- Citation num 11--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-11">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name"> Jinek, M.</span>;
<span property="schema:Name"> Chylinski, K.</span>;
<span property="schema:Name"> Fonfara, I.</span>;
<span property="schema:Name"> Hauer, M.</span>;
<span property="schema:Name"> Doudna, J.</span>;
<span property="schema:Name"> Charpentier, E.</span>
</span>
<span property="schema:name">&nbsp;A programmable dual RNA-guided DNA endonuclease in adaptive bacterial immunity. </span>
<i property="schema:publisher" typeof="schema:Organization"> Science (New York, N.Y.)</i>
<b property="issueNumber" typeof="PublicationIssue"> 337</b>,&nbsp;
<span property="schema:pageBegin">816–821</span>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2012">2012</time>).
<a className="doi" href="https://doi.org/10.1126/science.1225829"> doi: 10.1126/science.1225829</a>
</li>
{/*<!-- Citation num 12--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-12">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name"> Nelson, J.</span>;
<span property="schema:Name"> Randolph, P.</span>;
<span property="schema:Name"> Shen, S.</span>;
<span property="schema:Name"> Everette, K.</span>;
<span property="schema:Name"> Chen, P.</span>;
<span property="schema:Name"> Anzalone, A.</span>;
<span property="schema:Name"> An, M.</span>;
<span property="schema:Name"> Newby, G.</span>;
<span property="schema:Name"> Chen, J.</span>;
<span property="schema:Name"> Hsu, A.</span>;
<span property="schema:Name"> Liu, D.</span>
</span>
<span property="schema:name">&nbsp;Engineered pegRNAs improve prime editing efficiency. </span>
<i property="schema:publisher" typeof="schema:Organization"> Nature Biotechnology</i>
<b property="issueNumber" typeof="PublicationIssue"> 40</b>,&nbsp;
<span property="schema:pageBegin">402–410</span>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2022">2022</time>).
<a className="doi" href="https://doi.org/10.1038/s41587-021-01039-7"> doi: 10.1038/s41587-021-01039-7</a>
</li>
{/*<!-- Citation num 13--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-13">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name"> Sousa, A.</span>;
<span property="schema:Name"> Hemez, C.</span>;
<span property="schema:Name"> Lei, L.</span>;
<span property="schema:Name"> Traore, S.</span>;
<span property="schema:Name"> Kulhankova, K.</span>;
<span property="schema:Name"> Newby, G.</span>;
<span property="schema:Name"> Doman, J.</span>;
<span property="schema:Name"> Oye, K.</span>;
<span property="schema:Name"> Pandey, S.</span>;
<span property="schema:Name"> Karp, P.</span>;
<span property="schema:Name"> McCray, P.</span>;
<span property="schema:Name"> Liu, D.</span>
</span>
<span property="schema:name">&nbsp;Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cells. </span>
<i property="schema:publisher" typeof="schema:Organization"> Nature Biomedical Engineering</i>
<b property="issueNumber" typeof="PublicationIssue"> </b>,&;
<span property="schema:pageBegin">1–15</span>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2024">2024</time>).
<a className="doi" href="https://doi.org/10.1038/s41551-024-01233-3"> doi: 10.1038/s41551-024-01233-3</a>
</li>
{/*<!-- Citation num 14--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-14">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name"> Rodrigues, R.</span>
</span>
<span property="schema:name">&nbsp;Cystic fibrosis and neonatal screening. </span>
<i property="schema:publisher" typeof="schema:Organization"> Cadernos de Saúde Pública</i>
<b property="issueNumber" typeof="PublicationIssue"> 24</b>,&nbsp;
<span property="schema:pageBegin"> 475</span>-<span property="schema:pageEnd">484</span>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2008">2008</time>).
<a className="doi" href="https://doi.org/10.1590/S0102-311X2008001600002"> doi: 10.1590/S0102-311X2008001600002</a>
</li>
{/*<!-- Citation num 15--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-15">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name"> Farrell, P.</span>
</span>
<span property="schema:name">&nbsp;The Impact of the CFTR Gene Discovery on Cystic Fibrosis Diagnosis, Counseling, and Preventive Therapy. </span>
<i property="schema:publisher" typeof="schema:Organization"> Genes</i>
<b property="issueNumber" typeof="PublicationIssue"> 11(4)</b>,&nbsp;
<span property="schema:pageBegin">401</span>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2020">2020</time>).
<a className="doi" href="https://doi.org/10.3390/genes11040401"> doi: 10.3390/genes11040401</a>
</li>
{/*<!-- Citation num 16--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-16">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name"> Lukacs, G.</span>
</span>
<span property="schema:name">&nbsp; CFTR: folding, misfolding and correcting the ΔF508 conformational defect. </span>
<i property="schema:publisher" typeof="schema:Organization"> Trends in molecular medicine</i>
<b property="issueNumber" typeof="PublicationIssue"> 18(2)</b>,&nbsp;
<span property="schema:pageBegin"> 81</span>-<span property="schema:pageEnd">91</span>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2012">2012</time>).
<a className="doi" href="https://doi.org/10.1016/j.molmed.2011.10.003"> doi: 10.1016/j.molmed.2011.10.003</a>
</li>
{/*<!-- Citation num 17--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-17">
<span property="schema:author" typeof="schema:Person">
<span property="schema:Name"> Amico, G.</span>
</span>
<span property="schema:name">&nbsp;Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors. </span>
<i property="schema:publisher" typeof="schema:Organization"> International Journal of Molecular Sciences</i>
<b property="issueNumber" typeof="PublicationIssue"> 20(21)</b>,&nbsp;
<span property="schema:pageBegin">5463</span>
(<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2019">2019</time>).
<a className="doi" href="https://doi.org/10.3390/ijms20215463"> doi: 10.3390/ijms20215463</a>
</li>
</ol>
</section>
</div>
</div>
</div>
);
<p>By focusing on the F508del mutation, we also hope to contribute valuable insights to the global Cystic Fibrosis community. Although this mutation is most common in European populations, it is also found in other regions around the world. Our research could thus help inform treatment strategies and health policies on an international scale. </p>
<p>With several team members focusing their studies on biomedical fields, we began by examining the current landscape of CF treatments. It quickly became clear that, despite recent progress, there is still no cure. Most therapies, such as CFTR modulators, focus on managing symptoms and improving lung function rather than addressing the underlying cause of the disease<SupScrollLink label="3" />{/* ehem6 */}. This realization led us to explore gene-editing technologies, thus leading us to Prime Editing—a next generation gene editing method—captured our attention. </p>
<p>While Prime Editing holds great promise, we found that its application for Cystic Fibrosis, particularly the F508del mutation, had not been fully explored. Recognizing this gap in the research inspired us to take on the challenge of optimizing Prime Editing for this specific mutation. Our mission became clear: we want to contribute to the development of a potential therapeutic approach for Cystic Fibrosis, specifically targeting the F508del mutation with prime editing, and bring us closer to a long-term solution for patients. </p>
</Section>
<Section title="Cystic Fibrosis" id="Cystic Fibrosis">
<Subesction title="Overview" id="Cystic Fibrosis1">
<p data-aos="zoom-y-out" >Cystic Fibrosis (CF) is a common life-limiting genetic disorder, particularly affecting the Caucasian population, with approximately <b>162,400 people worldwide</b> living with the condition<SupScrollLink label="4" />{/* ehem7 */}. Statistically, about <b>one in every 3,300</b> white newborns is born with CF<SupScrollLink label="5" />{/*ehem8*/}. And according to the German Cystic Fibrosis Registry, the average life expectancy for children born with CF in 2021 was around 57 years<SupScrollLink label="6" />{/*ehem9*/}, highlighting the severe and life-shortening nature of the disease. </p>
<p>The modern understanding of CF dates back to 1922 when Dr. Dorothy Andersen, a pediatric specialist, first described the disease and coined the term "Cystic Fibrosis"<SupScrollLink label="7" />{/*ehem10*/}. In Germany, it is commonly known as "Mukoviszidose," derived from the Latin words meaning "mucus" and "viscous"<SupScrollLink label="7" />{/*ehem10*/}, emphasizing the characteristic thick, sticky mucus that defines the condition<SupScrollLink label="8" />{/*ehem11*/}. </p>
<p>Genetic research has identified over 1,700 mutations in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, with the F508del mutation being the most common, affecting about 70% of CF patients. This mutation prevents the proper folding of the CFTR protein, significantly impairing its function<SupScrollLink label="9" />{/*ehem13*/}. </p>
<p>The CFTR protein regulates the flow of chloride ions across the membranes of cells in the lungs, digestive system, and other organs. This ion flow is essential for drawing water into surrounding tissues, which helps maintain the proper hydration and consistency of mucus. In patients with CF, the disruption of this process prevents sufficient water from entering the mucus, making it abnormally thick and sticky. The accumulation of this mucus leads to an obstruction of airways and digestive ducts, resulting in chronic lung infections, inflammation, impaired digestion, and malnutrition<SupScrollLink label="10" />{/*ehem14*/}. </p>
<OneFigure
pic1="https://static.igem.wiki/teams/5247/project-description/lung-ephitel-biorender.png"
num={2}
bg="white"
description="Human lung epithelium with corrected CFTR expression (left) and Cystic Fibrosis (right)."
alt1="Lung ephitelium of human with correct CFTR expression (left) and Cystic Fibrosis (right)."
/>
<Collapsible id="classes-mutations-collapsible" title="Different classes of mutations">
<p>The mutations can be divided into <u>six classes</u><SupScrollLink label="11" />{/*ehem15*/} :</p>
<p><b>Class I</b> mutations prevent the synthesis of CFTR proteins altogether, meaning no channels are produced.</p>
<p><b>Class II</b> mutations, which include the common F508del mutation (responsible for about 85% of cases<SupScrollLink label="11" />{/*ehem16*/}, disrupt the maturation process of the protein. As a result, the defective channels are quickly degraded by the cell.</p>
<p><b>Class III</b> mutations, known as “gating” mutations, reduce the likelihood that the CFTR channel will open correctly, impairing its function.</p>
<p><b>Class IV, V</b> and <b>VI</b> mutations are rare. These mutations result in the production of unstable or inefficient CFTR proteins, which do not function adequately and are produced in insufficient numbers.</p>
</Collapsible>
<p>The prevalence of CF varies globally, with higher concentrations of cases in Europe, North America, and parts of Oceania. This geographic variation underscores the need for regionally tailored healthcare solutions. </p>
<OneFigure
pic1="https://static.igem.wiki/teams/5247/charts-maps/cfper10-000.png"
alt1=""
num="3"
bg="white"
description="Global distribution of cystic fibrosis cases: Countries are color-coded based on the number of reported cases, highlighting regional prevalence patterns."
/>
<p>CF is often diagnosed early through newborn screening programs, which detect elevated levels of immunoreactive trypsinogen (IRT). A positive result typically leads to a sweat test, the gold standard for diagnosing CF, which measures the concentration of chloride in sweat. </p>
<p>Although there is currently no cure for CF, patients must manage the disease throughout their lives, relying on treatments that alleviate symptoms but do not address the root cause. This lifelong management imposes significant financial burdens on affected families and healthcare systems, particularly in regions with a high prevalence of CF<SupScrollLink label="11" />{/*ehem15*/}. In recent years, <b>CFTR modulators</b>, which target the underlying genetic defect, have offered new hope for many patients. </p>
</Subesction>
<Subesction title="The CFTR Protein" id="Cystic Fibrosis2">
<p>The CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) protein is an ion channel that facilitates the movement of chloride ions across epithelial cell membranes<SupScrollLink label="12" />{/*ehem18*/}. This movement is essential for controlling the flow of water in tissues such as the lungs and intestines<SupScrollLink label="13" />{/*ehem19*/}. This increase in ion concentration in the extracellular space draws water out of the cells and into the surrounding mucus or fluid, ensuring it stays thin and mobile<SupScrollLink label="13" />{/*ehem20*/}.</p>
<p>The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein is a specialized protein that plays a crucial role in maintaining the balance of ions and water on the surface of certain cells, particularly in the lungs, pancreas, and other organs. </p>
<H4 text="Structure of CFTR" id="structure-cftr" />
<p>CFTR is a large protein embedded in the cell membrane. It belongs to a family of proteins known as ABC transporters (ATP-Binding Cassette transporters), which typically move molecules across cell membranes<SupScrollLink label="14" />{/*ehem17*/}. CFTR, however, is unique because it functions as an ion channel rather than a transporter<SupScrollLink label="14" />{/*ehem18*/}. </p>
<p>The protein consists of several important regions<SupScrollLink label="15" />: </p>
<ul>
<li><b>Two transmembrane domains (TMDs)</b>: These span the cell membrane and create the channel through which ions can flow.</li>
<li><b>Two nucleotide-binding domains (NBDs)</b>: Located on the cytoplasmic side of the membrane, these domains bind and hydrolyze ATP (adenosine triphosphate). ATP binding and hydrolysis regulate the opening and closing of the chloride channel.</li>
<li><b>Regulatory (R) domain</b>: This domain is unique to CFTR and controls the activity of the protein. It requires phosphorylation by protein kinase A (PKA) to activate the ion channel.</li>
</ul>
<div className="row align-items-center">
<div className="col">
{/* This one this has tp stay a figure and not be a OneFigure */}
<div className="figure-wrapper">
<figure>
<div className="col gif-wrapper">
<img className="CFTR-gif" src="https://static.igem.wiki/teams/5247/fanzor/cftr-wt.gif"></img>
</div>
<figcaption> <b>Animation 1.</b> Model of a functional CFTR protein.</figcaption>
</figure>
</div>
<H4 text="Function of CFTR" id="function-cftr" />
<p>CFTR functions primarily as a chloride ion channel. It is responsible for transporting chloride ions (Cl⁻) across epithelial cell membranes. Here's how it works<SupScrollLink label="12" />{/*ehem18*/}:</p>
<ol>
<li><b>Regulation by phosphorylation</b>: The R domain must first be phosphorylated by PKA to allow channel activation. This phosphorylation is often triggered by cyclic AMP (cAMP), a signaling molecule.</li>
<li><b>Opening the channel</b>: Once the R domain is phosphorylated, ATP binds to the NBDs, causing conformational changes that open the chloride channel.</li>
<li><b>Chloride transport</b>: With the channel open, chloride ions move from inside the cell to the outside. This movement of chloride helps draw water out of the cell, thinning mucus and maintaining proper hydration of the epithelial surfaces.</li>
<li><b>Closing the channel</b>: Hydrolysis of ATP causes the channel to close after a certain period, tightly regulating chloride transport.</li>
</ol>
<p>CFTR plays a critical role in maintaining the fluid balance on the surfaces of tissues such as the airways, digestive tract and sweat glands. By allowing chloride ions to flow out of the cells, CFTR ensures that water follows, preventing the accumulation of thick, sticky mucus.</p>
<H4 text="CFTR in Cystic Fibrosis" id="CFTR-in-cftr" />
<p>In the lungs, this water movement is crucial for maintaining a thin, slippery layer of mucus that can trap and remove particles like dust and bacteria. The mucus is then moved out of the lungs by the action of cilia, tiny hair-like structures on the surface of epithelial cells. When the CFTR protein is defective, as in Cystic Fibrosis, chloride cannot properly exit the cells. This disrupts the osmotic gradient, preventing water from entering the mucus. As a result, the mucus becomes thick and sticky, making it difficult to clear and creating an ideal environment for bacterial infections, which leads to chronic inflammation and lung damage over time.</p>
<p>In the intestines, CFTR regulates fluid secretion into the digestive tract, which is vital for the normal movement of digestive contents. Without proper CFTR function, water movement is reduced, leading to thickened digestive fluids, blockages, and impaired nutrient absorption. This contributes to malnutrition and other digestive complications in Cystic Fibrosis patients. </p>
<p>By correcting the genetic mutations that lead to CFTR malfunction, such as the F508del mutation, we aim to restore the proper balance of chloride and water movement, which is crucial for preventing the buildup of mucus and ensuring normal function in both the respiratory and digestive systems.</p>
</div>
</div>
</Subesction>
<Subesction title="F508del" id="Cystic Fibrosis3">
<p>More than 1,000 mutations in the CFTR gene are responsible for the development of Cystic Fibrosis. The most common variant is the F508del mutation, found in approximately 70% of affected individuals of Caucasian descent in Canada, Northern Europe, and the United States<SupScrollLink label="1" />{/* ehem1 */}. It is estimated that around 90% of people with Cystic Fibrosis in Europe and those of European heritage carry at least one F508del allele<SupScrollLink label="2" />{/* ehem23 */}<sup>,</sup><SupScrollLink label="9" />{/* ehem24 */}. Research suggests that this mutation originated in Western Europe at least 5,000 years ago<SupScrollLink label="2" />{/* ehem23 */}.</p>
<p>The F508del mutation involves the deletion of three nucleotides, "CTT," at position 508, which removes a phenylalanine
residue without causing a frameshift. This deletion impairs the kinetic and thermodynamic folding of the NBD1 domain
<SupScrollLink label="9" />{/* ehem24 */}. As a result, the CFTR protein not only misfolds but also experiences defects in trafficking
and premature degradation, leading to a reduction in its surface expression<SupScrollLink label="16" />{/* ehem25 */}. This specific mutation is particularly severe because it affects both the production and function of CFTR, resulting in a more aggressive disease course. Consequently, patients with the F508del mutation may respond better to CFTR modulators, which target these specific defects in protein folding and function.</p>
<Collapsible id="statistical-distribution-collapsible" title="Statistical distribution of F508del mutations">
<p>In 2023, a comprehensive analysis was conducted to assess the distribution of mutations in the CFTR gene associated with Cystic Fibrosis (CF) worldwide. Data was sourced from two reputable databases: the <a href="https://cftr.iurc.montp.inserm.fr/cgi-bin/variant_list.cgi" title="CFTR-database-1" >CFTR Mutation Database</a> and the <a href="https://cftr2.org/mutations_history" title="CFTR-database-2" >CFTR2 Database</a>. </p>
<p>The results indicate the following distribution of CFTR mutation types and their frequencies in percent: </p>
<div className="row align-items-center">
<div className="col" >
<ul>
<li><b>Insertions (ins)</b>: 0.00088%</li>
<li><b>Deletions (del)</b>: 72.64%</li>
<li><b>Substitutions (subs)</b>: 23.84%</li>
<li><b>Insertions/Deletions (indel)</b>: 0,00485%</li>
<li><b>Other mutations</b>: 0,00370%</li>
</ul>
</div>
<div className="col" >
<PieChart />{/* Render the PieChart component */}
</div>
</div>
</Collapsible>
<p>Overall, the statistical distribution of CFTR mutations reveals significant variations in mutation types and their frequencies worldwide, with deletions (72.64%) being the most common mutation type. This underscores the need for continued research and monitoring of these genetic variations to improve patient care and treatment strategies. CF not only affects the directly affected organs, but also many other areas of the body that are indirectly affected by the extent of the disease, e.g. through the condition of diseased organs. </p>
<div className="row">
<div className="col">
</div>
<div className="col"></div>
</div>
</Subesction>
<Subesction title="Symptoms" id="Cystic Fibrosis4">
<p>Since the CFTR gene is expressed in nearly all tissues of the human body, Cystic Fibrosis affects as a metabolic disease a wide range of vital organs.</p>
<Collapsible id="symptoms-collapsible" title="How the symptoms affect different parts of the body" >
<TabButtonRow data={symptombuttonrowdata} opentype="meditabs" closing="" />
<ButtonRowTabs data={symptombuttonrowdata} cla="meditabs" />
</Collapsible>
</Subesction>
<Subesction title="Diagnosis" id="Cystic Fibrosis5">
<p>With Cystic Fibrosis being a hereditary disease, the diagnostic methods have evolved significantly. Early diagnosis is crucial, as it
allows for timely interventions that can improve the quality of life and longevity for CF patients<SupScrollLink label="37" />{/* ehem58 */}.
With advancements in screening and diagnostic tools, many individuals are diagnosed shortly after birth, enabling early management of
the disease.</p>
<p>Cystic Fibrosis can be diagnosed through a variety of methods, often starting in infancy or even before birth. The most common diagnostic test
is the newborn screening, which involves a blood test that checks for elevated levels of a protein called immunoreactive trypsinogen
(IRT). Elevated IRT levels can indicate potential CF, prompting further testing<SupScrollLink label="31" />{/* ehem61 */}. </p>
<Collapsible id="newborn-screening-collapsible" title="Newborn screening">
<p>Newborn screening for Cystic Fibrosis (CF) has been a major advancement in early detection and management, leading to significantly
improved patient outcomes. This practice, which started in the late 1960s, became more widespread in the 1970s. The screening
typically involves a blood test within the first few days of life, measuring immunoreactive trypsinogen (IRT), a marker that is
elevated in newborns with CF. Elevated IRT levels prompt further genetic testing to identify CFTR mutations<SupScrollLink label="39" />{/* ehem62 */}.
If mutations are found, a sweat chloride test is often conducted to confirm the diagnosis. </p>
<p>Many countries, including the United States, Canada, the United Kingdom, Australia, and several European nations, have implemented
newborn screening programs for CF. However, a survey of CF screening in Europe revealed that the implementation of such programs varies
widely, with some countries adopting more comprehensive protocols than others. Early diagnosis through
screening offers significant benefits, such as improved growth, better lung function, and overall enhanced health outcomes
<SupScrollLink label="40" />{/* ehem64 */}. The discovery of the CFTR gene has further refined diagnostic techniques and underscored the crucial role of newborn screening in the early detection and management of CF. </p>
<p>Technological advancements and improved medical procedures have greatly transformed the diagnosis of Cystic Fibrosis.
While newborn screening has revolutionized early detection and treatment, traditional methods such as the sweat test and
symptom observation continue to play a vital role, particularly in regions where screening programs are not yet widely
available.</p>
</Collapsible>
<p>Another widely used method is the sweat test, which measures the concentration of chloride in a person's sweat. CF patients
typically have higher-than-normal chloride levels due to defective CFTR protein function. While the sweat test is non-invasive and reliable for
indicating CF, it is limited in scope. For definitive diagnosis and to guide specific treatments, a genetic analysis is usually required
to identify the exact CFTR mutation, such as the F508del mutation<SupScrollLink label="41" />{/* ehem66 */}.</p>
<Collapsible id="sweat-test-collapsible" title="Sweat test">
<p>Traditionally, Cystic Fibrosis (CF) has been diagnosed using the sweat test, which measures chloride levels in sweat. A
chloride level below 40 mmol/L (millimoles of chloride per litre of sweat) is considered normal and unlikely to indicate CF.
Levels between 40 and 60 mmol/L require further investigation, while levels above 60 mmol/L strongly suggest the presence of CF<SupScrollLink label="41" />{/* ehem65 */}.</p>
<p>This quick and painless test has been the gold standard for CF diagnosis for many years. Despite its accuracy, the sweat test requires specialized lab personnel and can be difficult to perform on newborns. While diagnosing CF based on symptoms can be useful, it is not always reliable, particularly in mild or atypical cases.</p>
</Collapsible>
</Subesction>
<Subesction title="Treatment" id="Cystic Fibrosis6">
<p>Current Cystic Fibrosis treatments focus on managing symptoms, slowing disease progression, and improving quality of
life. Since there is still no cure for CF, treatment is typically lifelong and involves multiple approaches, including medications,
physical therapy, and dietary adjustments<SupScrollLink label="42" />{/* ehem66 */}. </p>
<p>The primary goal of CF treatment is to clear the thick mucus from the lungs to prevent infections and improve
breathing. Airway clearance techniques, such as chest physiotherapy, are often used alongside inhaled medications, like
bronchodilators and mucolytics, to thin the mucus and open the airways<SupScrollLink label="43" />{/* ehem69 */}<sup>,</sup><SupScrollLink label="44" />{/* ehem70 */}.
Antibiotics are frequently prescribed to treat or prevent lung infections caused by trapped bacteria in the
airways<SupScrollLink label="45" />{/* ehem71 */}.</p>
<p>One of the most significant advances in CF treatment has been the development of CFTR modulators, which target the underlying protein
dysfunction caused by mutations in the CFTR gene<SupScrollLink label="44" />{/* ehem70 */}<sup>,</sup><SupScrollLink label="46" />{/* ehem72 */}.
These drugs, such as ivacaftor, lumacaftor, and elexacaftor, work by improving the function of the defective CFTR protein, particularly
in patients with specific mutations like F508del<SupScrollLink label="46" />{/* ehem24 */}. While CFTR modulators can dramatically
improve lung function and overall health in many patients, they are not effective for all CFTR mutations and often are very
expensive<SupScrollLink label="47" />{/* ehem73 */}.</p>
<p>Digestive enzyme supplements are essential for CF patients who suffer from pancreatic insufficiency, helping them to absorb nutrients
from food<SupScrollLink label="22" />{/* ehem68 */}. Additionally, high-calorie diets and vitamins are recommended to support growth and maintain
body weight<SupScrollLink label="22" />{/* ehem68 */}.</p>
<p>Although current treatments can significantly improve quality of life and life expectancy, managing CF remains a daily challenge for
patients. Continued research into gene therapy and other innovative treatments offers hope for more
permanent solutions in the future.</p>
<Collapsible id="drugs-collapsible" title="Different types of drugs" >
<TabButtonRow data={medibuttonrowdata} opentype="symptabs" closing="" />
<ButtonRowTabs data={medibuttonrowdata} cla="symptabs" />
</Collapsible>
<H4 text="CF treatment with gene therapy"></H4>
<p>While mentioned medications have improved the quality of life for numerous CF patients, they only manage symptoms rather than cure the disease. Moreover, most of them are expensive and not world-wide accessible. Our research is focused on the development of a gene therapy that targets the underlying cause of CF by correcting the defective CFTR gene. <PreCyse /> aims to halt disease progression and reduce the treatment burden for patients.</p>
</Subesction>
</Section>
<Section title="Our Approach" id="Approach">
<Subesction title="Mechanism" id="Approach1">
<p>The development of an improved Prime Editing complex holds great promise for advancing gene editing technologies. Our enhanced system, Prime Guide, addresses key limitations of conventional Prime Editing by focusing on four main areas: editing efficiency, precision, size, and safety. Prime Guide has been designed to target the F508del mutation in Cystic Fibrosis with high accuracy, while minimizing off-target effects. By optimizing the pegRNA, reverse transcriptase, and nickase components, we aim to deliver precise and efficient genetic modifications.</p>
<InfoBox title="Prime Editing" id="prime-editing">
<details>
<summary>Prime editing is a new method of gene editing based on an RNA-Protein complex. It was developed by a group of
researchers revolving around Professor David Liu from Harvard University in 2019.<SupScrollLink label="55" />{/*ehem15*/} </summary>
<p></p>
<p><b>How does Prime Editing work?</b></p>
<p>Prime Editing builds on the well-known CRISPR technology, offering a more precise and controlled approach to DNA modification.
Traditional CRISPR-Cas9 methods typically involve creating double-strand breaks in DNA, which can be repaired by the cell in ways that
might introduce unintended mutations. Prime Editing, by contrast, circumvents this issue by using a more refined method that avoids
double strand breaks altogether<SupScrollLink label="55" />{/* ehem91 */}.</p>
<p>At the heart of Prime Editing is a fusion protein, which combines two key components: a modified Cas9 enzyme, known as a "nickase,"
and a
reverse transcriptase enzyme. The nickase is responsible for making a single strand cut in the DNA, unlike the traditional Cas9,
which cuts both strands. This single strand cut minimizes the risk of unintended mutations or large-scale DNA damage. The reverse
transcriptase attached to the nickase then modifies the DNA at the targeted site by incorporating new genetic information.</p>
<p>To guide this process, Prime Editing uses a specialized RNA molecule known as prime editing guide RNA (pegRNA). This pegRNA serves
two functions: it directs the Cas9 nickase to the specific location on the genome, and it carries a template for the desired DNA
modification. Now, let’s go through the process in more detail, referencing the image above.<SupScrollLink label="56"/></p>
<ol>
<li><b>DNA Nicking</b>: In the first step (top left in the image), the Cas9 nickase, guided by the pegRNA, binds to the target
genomic DNA and creates a single-strand break, or "nick," at the precise location. This is a key difference from standard CRISPR,
where both DNA strands are cut, increasing the risk of unwanted mutations.</li>
<li><b>Primer Binding and Reverse Transcription</b>: Once the DNA is nicked, the primer binding site (PBS) on the pegRNA hybridizes
with the exposed single-stranded DNA, as shown in the middle of the image. This alignment allows the reverse transcriptase (RT)
enzyme, also fused to the nickase, to begin copying the edit into the target DNA. The reverse transcriptase uses the template
encoded within the pegRNA to create a complementary DNA sequence (depicted as the new sequence in the image), ensuring the corrected
genetic sequence is accurately inserted into the genome.</li>
<li><b>Flap Formation and Equilibration</b>: The process continues as the reverse transcriptase copies the new genetic sequence into
the DNA strand, creating what is called a "3' flap" (as shown in the bottom part of the image). This flap contains the newly edited
sequence. At this point, there is an equilibration between the new flap (which encodes the intended edit) and the unedited 5' flap,
which still contains the original, unmodified DNA sequence. The cell's natural mechanisms typically degrade the unedited 5' flap,
favoring the integration of the 3' flap encoding the edit.</li>
<li><b>Flap Resolution and Final Editing</b>: In some cases, an additional nick (seen in the PE3/PE5 systems in the image) is
introduced in the non-target DNA strand to promote repair and favor the incorporation of the edit. This step increases the efficiency
of Prime Editing by ensuring that the newly edited strand is preferentially used during the cell's DNA repair process.
The mismatch repair (MMR) system of the cell also plays a role in determining whether the edit is retained or reverted to the
original sequence. For systems like PE4 and PE5, inhibition of the mismatch repair system (e.g., by MLH1dn) further promotes the
integration of the desired edit.</li>
<li><b>Final outcome</b>: Once the unedited flap is degraded and the new sequence is integrated, the cell completes the repair,
and the edit becomes permanently incorporated into the DNA. As shown in the diagram, the result is a successful genetic modification,
where the new, corrected sequence replaces the original faulty sequence.</li>
</ol>
{/* This figure has to stay this way */}
<figure>
<img className="gif-wrapper" src="https://static.igem.wiki/teams/5247/project-description/prime-editing-animation-10fps.gif" />
<figcaption>
<b>Animation 2. </b>
Illustration of the Prime Editing process and its possible outcomes.
</figcaption>
</figure>
<p>Overall, there are many different Prime Editing systems with a variety of components and complexity, starting from PE2 up to PE7. Possible edits could integrate substitutions, inserts and deletions in the range of one base up to hundreds of nucleotides, with gradually decreasing editing efficiency. Therefore Prime Editing technology allows targeted modifications of specific genes. </p>
</details>
</InfoBox>
<p>However, the Prime Editing complex is relatively large, posing challenges for therapeutic delivery<SupScrollLink label="60"/>{/* ehem3 */}. Additionally, Prime Editing has been shown to be relatively inefficient in terms of gene editing rates, which could limit its therapeutic utility<SupScrollLink label="62"/>{/* ehem4 */}. Our project aims to enhance the Prime Editing approach by miniaturizing its components and enhancing its efficiency, as well as precision. </p>
<p>As shown in the image, we developed two potential configurations for Prime Guide, each using a different nickase: one based on the Fanzor (nSpuFz1) nickase and the other on a CasX (nPlmCasX) nickase. Both configurations are designed to improve the precision and stability of the Prime Editing system. The pegRNA scaffold, reverse transcriptase (PE6c), and primer binding site (PBS/RTT) work together in both systems to introduce precise edits, with the La(1-193) enhancing stability and function.</p>
<div className="figure-wrapper">
<figure>
<div className="row">
<div className="col">
<img className="img" src="https://static.igem.wiki/teams/5247/project-description/primeguide.png" />
</div>
<div className="col"><PrimeEditingComplex /></div>
</div>
<figcaption>
<b>Figure 4. </b>
Illustration of our newly designed Prime Editors, "PrimeGuide".
</figcaption>
</figure>
</div>
<p>To develop our innovative Prime Editing system, Prime Guide, we worked closely with several leading experts in the field. Among them were Mattijs
Bulcaen, Makato Saito, Dr. Hammer, Jan-Phillipp Gerhard and Prof. Kristian Müller, whose insights helped guide our decisions. Prime Guide
is a highly specialized Prime Editing complex, designed to target the F508del mutation in Cystic Fibrosis with precision and efficiency. </p>
<p>Our Prime Guide system consists of carefully selected components, each optimized for its role. For the nickase, we chose between SpuFz1 and CasX
nickases due to their smaller size and structural advantages, which suggest increased stability for the pegRNA within the Prime Editing
complex. Smaller nickases also provide benefits in terms of overall efficiency and ease of delivery, aligning with the compact design
we aimed for.</p>
<Collapsible id="fanzorcas-collapsible" title="Advantages of Fanzor/PlmCasX over Cas9">
<p>From the start of our project we have been examining the established Prime Editing complex, known for its effectiveness
but also for several limitations, including its relatively large size and structural vulnerabilities. A key component
of this complex is the Cas9 nickase, an enzyme that selectively cuts one of the two DNA strands at a precise location.
This nickase was originally engineered by introducing mutations into the Cas9 endonuclease, which typically cuts both DNA
strands. By disabling one of the two active sites, the Cas9 nickase was designed to nick only one strand, a function essential
to the success of the Prime Editing process<SupScrollLink label="55" />{/* ehem92 */}. </p>
<p>Our aim was to improve the Prime Editing complex, not only by reducing its size but also by enhancing its stability. To achieve
this, we sought alternative endonucleases that are smaller and possess other desirable properties. Our strategy involved
identifying endonucleases with suitable characteristics and then developing methods to mutate them into nickases, allowing
them to selectively cut a single DNA strand. CasX and Fanzor emerged as promising candidates, offering structural advantages
beyond their smaller size. </p>
<p>In Cas9-based systems, the spacer region of the guide RNA (gRNA)—the part that binds to the target DNA—is located at the 5' end
of the RNA-protein complex. However, in CasX and Fanzor, the spacer is positioned at the 3' end<SupScrollLink label="57" />{/* ehem93 */}<sup>,
</sup><SupScrollLink label="58" />{/* ehem94 */}. This reversal offers several benefits: the 3' end of the RNA is typically more
susceptible to degradation by RNases, which can compromise the stability and effectiveness of the Prime Editing complex. In CasX and
Fanzor, however, the 3’ terminus is positioned at the spacer enclosed by the protein, potentially protecting from RNase degradation. </p>
<p>Additionally, this reversed architecture alters the positioning of the reverse transcription template (RTT) and primer binding site (PBS)
on the pegRNA. In Cas9-based systems, the RTT is located at the 3' end of the pegRNA, which leaves it more exposed and increases the risk of
reverse transcription continuing past the intended stop point. This "scaffold read-through" effect can result in the synthesis of unintended
DNA sequences, leading to undesired mutations or genomic alterations at the target site<SupScrollLink label="55" />{/* ehem95 */}, potentially compromising the
safety of the Prime Editing process. In CasX and Fanzor systems, however, the RTT is positioned at the 5' end of the pegRNA, while the spacer is
located near the 3' end and is closely bound to the protein. This reversed layout helps ensure that reverse transcription stops precisely at
the end of the RTT sequence, significantly reducing the risk of unintended extensions and improving the precision and reliability of the editing process.</p>
<p>By incorporating these smaller, more stable nickases into the Prime Editing complex, we aim to reduce its overall size while maintaining
or even enhancing its functionality and reliability. </p>
</Collapsible>
<p>In terms of the pegRNA, we opted for a pegRNA, including a 16-base primer binding site (PBS) and a 30-base reverse transcription
template (RTT), with no silent edits and a structural motif, the tevopreQ1. After extensive screening using a reporter system, this
pegRNA demonstrated the highest performance, leading us to select it as the best candidate for further development. While other
pegRNAs also showed promise, pegRNA_PEAR_04 was ultimately chosen for its superior results in our testing.</p>
<Collapsible id="pegRNA-genau-collapsible" title="Optimization of the pegRNA">
<p><b>Stability improvement: tevopreQ1 extension</b></p>
<p>The pegRNA was specifically optimized to enhance its stability in the cellular environment. To achieve this, a structural motif
known as tevopreQ1 was added to the basic pegRNA structure. This motif was selected based on its known ability to improve RNA
stability by preventing degradation. By integrating tevopreQ1, the goal was to extend the half-life of the pegRNA, allowing it
to remain functional in cells for a longer duration, thus improving the likelihood of successful gene edits. This stabilizing
addition was particularly valuable in the context of CFTR gene editing, where higher RNA stability could lead to better editing
outcomes.</p>
<p><b>Precision enhancement: Spacer selection</b></p>
<p>A major focus during the optimization of the pegRNA was the careful design of the spacer sequence, which plays a crucial role in
guiding the editing complex to the correct genomic location. Multiple spacer sequences were designed and tested via a software,
with the aim of minimizing off-target effects that can lead to unintended genetic changes. Through expert consultations and
theoretical modeling, a rational design strategy was employed to select a spacer sequence that would enhance the precision of
the editing process. This precision is especially important for therapeutic applications, such as in CFTR gene editing, where
unintended edits could have harmful consequences.</p>
<p><b>Improving Editing Efficiency: PBS and RTT length adjustments with Silent Edits</b></p>
<p>To maximize editing efficiency, various combinations of primer binding site (PBS) and reverse transcriptase template (RTT) lengths
were evaluated. The RTT, which provides the template for the desired genetic change, was carefully optimized, including the
introduction of silent edits—changes in the RTT that do not alter the protein sequence but can improve the editing process.
Both shortened and extended versions of the PBS and RTT were tested in combinations with each other, with and without these
silent edits, to identify the optimal configuration that would result in the highest editing efficiency. This step-by-step
screening process allowed for the selection of the most efficient pegRNA for targeting the CFTR gene, ensuring that the system
could achieve high levels of successful edits with minimal unintended consequences.</p>
</Collapsible>
<p>For the reverse transcriptase, we selected the PE6c variant, which has shown to provide the best editing efficiency and a more compact
structure compared to alternatives. Its advanced development stage and ability to offer high precision and editing performance made it
the ideal choice for Prime Guide. </p>
<p>Together, these components form a highly optimized Prime Editing system that balances size, stability, and efficiency. Our aim with
Prime Guide is to create a robust and precise solution for correcting the F508del mutation in Cystic Fibrosis, building on the
guidance from our expert collaborators and extensive testing of each individual component.</p>
<H4 text="Our PreCyse cassette" id="PreCyse-cassette" />
<p>We have developed our PrimeGuide, an optimized version of the Prime Editing system, designed to enhance editing efficiency, precision,
and versatility. As part of our continued efforts to improve and streamline the Prime Editing workflow, we introduce to you the
PreCyse-Cassette—a universal plasmid backbone specifically tailored for any Prime Editing system.</p>
<p>The PreCyse-Cassette is engineered to provide maximum flexibility for the construction of the Prime Editing systems. It includes BsaI
und SapI cloning sites, allowing easy insertion and exchange of essential components like a nickase and reverse transcriptase,
fundamental for Prime Editing. Additionally, it incorporates a cloning site for the guide RNA, ensuring seamless integration and
adaptation to various target sequences.</p>
<p>Moreover, the PreCyse-Cassette contains several advanced features designed to enhance system performance. The architecture of this
cassette is based on a combination of the PE4 and PE7 systems, providing the presence of the LA motif and MLH1dn. Thus allowing an
increased functionality and editing efficiency, while the CMV and T7 promoters ensure high expression levels across different systems.
These features make the cassette universally applicable to a wide range of Prime Editing contexts, enabling users to effortlessly
clone their desired components—nickase, reverse transcriptase, and guide RNA—without the need for complex modifications.</p>
<p>With this PreCyse-Cassette, researchers can easily set up and test their Prime Editing systems, bypassing much of the laborious cloning
work traditionally associated with these setups. The cassette provides an efficient and versatile platform for experimenting with and
refining Prime Editing applications, forming the ideal backbone for PrimeGuide and beyond.</p>
<OneFigure
pic1="https://static.igem.wiki/teams/5247/thaw/precyse-plasmid.webp"
alt1=""
description="Schematic diagram of the designed plasmid containing our PreCyse cassette"
num="5"
/>
</Subesction>
<Subesction title="Delivery" id="Approach2">
<div className='row align-items-center'>
<div className='col'>
<OneFigure
pic1="https://static.igem.wiki/teams/5247/delivery/sort-lnp-ohne-beschriftung.webp"
alt1=""
description="3D Figure of our optimized SORT LNP called AirBuddy."
num="6"
/>
</div>
<div className='col'>
<p>We optimized LNPs as a robust delivery system to transport larger therapeutic cargo, such as Prime Editing mRNA, to lung
epithelial cells via inhalation. LNPs were chosen over other delivery systems, like Adeno-associated viruses (AAVs), due to
their superior cargo capacity and reduced immunogenicity. Our goal was to create a spray-dried lung-specific LNP named</p>
<figure>
<img className="gif-wrapper" src="https://static.igem.wiki/teams/5247/delivery/airbuddy.webp" />
</figure>
<img src="" style={{ maxHeight: "80pt" }} />
<p>capable of efficiently delivering of our Prime Editing components, referred to as PrimeGuide, to lung tissues through
inhalation. This approach is designed to advance precision medicine by ensuring targeted delivery with minimal off-target
effects.</p>
</div>
</div>
<Collapsible id="Col1" open={false} title="LNPs explained">
<H4 text="What are LNPs?" id="text" />
<p>Lipid nanoparticles, short LNPs, are small, spherical structures made of lipids that serve as delivery vehicles for therapeutic
molecules, such as RNA, DNA, or drugs. They protect their cargo from degradation, enhance cellular uptake, and are widely used in
mRNA vaccines and gene therapy due to their efficiency and biocompatibility.</p>
<H4 text="LNPs and their impact on modern medicine" id="text" />
<p>LNPs are an advanced delivery system designed to transport therapeutic molecules like RNA, DNA or proteins into the cells. These
nanoparticles are tiny spheres made of lipids that form a protective shell around the cargo. The size of LNPs typically ranges from
50 to 200 nm in diameter, making them incredibly small - about 1,000 times thinner than a human hair<SupScrollLink label="59" />{/* ehem1 */}. </p>
<p>Overall, LNPs represent a significant advancement in drug delivery technology. LNPs offer exceptionally high drug-loading capacities,
making them highly effective for delivering substantial amounts of therapeutic agents in a single dose. Their advanced design allows
for the encapsulation of a large payload, which enhances the efficacy of treatments and reduces the frequency of administration<SupScrollLink label="60"/>{/* ehem3 */}. By
encapsulating and protecting therapeutic agents like mRNA, LNPs enhance the stability, targeted delivery, and effectiveness of
treatments. Their ability to be tailored for specific delivery needs, such as targeting particular organs or overcoming physiological
barriers, makes them a powerful tool in modern medicine<SupScrollLink label="60" />{/*ehem3*/}.</p>
<H4 text="Protection of cargo" id="text" />
<p> The primary function of LNPs is to shield the therapeutic agents they carry, such as mRNA, from degradation and facilitate their
delivery into cells. mRNA is a critical component in many modern vaccines and therapies, but it is highly susceptible to breaking
down before it can reach its target within cells. LNPs address this challenge by encapsulating the mRNA, thus protecting it from
harmful enzymes, like RNases and environmental conditions<SupScrollLink label="61" />{/* ehem2 */}. </p>
<H4 text="Delivery assurance" id="text" />
<p>LNPs come in various types tailored for different therapeutic needs. Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers
(NLCs) enhance drug stability and solubility, while Liposomes, with their bilayer structure, are versatile for encapsulating both
hydrophilic and hydrophobic drugs. Cationic LNPs are ideal for gene delivery due to their positive charge, whereas anionic and neutral
LNPs offer reduced interaction and lower toxicity, respectively<SupScrollLink label="60"/>{/* ehem3 */}. </p>
<p>To enhance their effectiveness, LNPs are designed with specific components. For instance, the Nebulized Lung Delivery 1 (NLD1)
nanoparticle, a particular type of LNP, includes a combination of lipids and polymers that stabilize the mRNA and allow it to be
delivered efficiently. This formulation includes small lipid particles that encapsulate the mRNA and can maintain stability for
several days under proper storage conditions<SupScrollLink label="61"/>.</p>
<H4 text="Role of surface modifications in targeting" id="text" />
<div className='row align-items-center'>
<div className='col'>
<OneFigure
pic1="https://ars.els-cdn.com/content/image/1-s2.0-S1773224724002156-gr3_lrg.jpg"
alt1="Aufnahme LNP"
num={7}
description={<span> Endosomal escape vs degradation of LNP cargo at endocytosis.</span>}
/>
</div>
<div className='col'>
<p>LNPs are pivotal not only for shielding mRNA but also for ensuring its efficient delivery into target cells. They
facilitate cellular uptake through endocytosis, where the cell membrane engulfs the nanoparticle. LNPs are acclaimed
for their high drug-loading capacities, which greatly enhance their therapeutic effectiveness. However, the success of
this delivery hinges on effective endosomal escape. Ideally, LNPs release their mRNA payload into the cytoplasm after
escaping from endosomes. If this escape process is inefficient, the mRNA can be degraded by lysosomes, which poses a
significant challenge for mRNA vaccines and therapies<SupScrollLink label="62"/>{/* ehem4 */}.</p>
</div>
</div>
<p>A crucial advancement in LNP technology involves the use of pH-sensitive cationizable lipids. These lipids remain neutral
at physiological pH but become cationic in the acidic environment of endosomes. This shift in charge helps dissociate the nanoparticles and
disrupt the endosomal membrane, enhancing the likelihood of successful endosomal escape<SupScrollLink label="63"/>{/* ehem5 */}. </p>
<p>Moreover, the surface of LNPs can be customized to improve targeting. For instance, incorporating specific lipids or modifying the surface with
charged groups can direct the delivery of mRNA to targeted organs like the lungs or spleen<SupScrollLink label="64" />{/* ehem6 */}.
Additionally, LNPs can be engineered with targeting ligands or antibodies to precisely direct their payload to specific cell types, further
enhancing their therapeutic efficacy<SupScrollLink label="65" />{/* ehem7 */}. Another approach can be chitosan-based nanoparticles have been
explored for their ability to adhere to mucus and enhance drug delivery through the respiratory tract. These nanoparticles can penetrate through
the mucus layer to reach the lung tissues more effectively<SupScrollLink label="66" />{/*ehem8*/}. This versatility in design is essential for
optimizing the delivery and effectiveness of LNP-based therapies.</p>
</Collapsible>
<Collapsible id="Col2" open={false} title="Challenges of working with LNPs">
<p>Maintaining the stability of LNPs throughout formulation, storage, and delivery is critical, as factors like temperature changes, pH shifts, or
mechanical stress can affect their integrity<SupScrollLink label="67" />{/* ehem1 */}<sup>,</sup><SupScrollLink label="68" />{/* ehem2 */}. Equally
important is ensuring efficient encapsulation of the genetic material, as any inefficiency can lead to degradation of the therapeutic cargo or inadequate
delivery to the target cells. Once inside the body, LNPs face the challenge of cellular uptake and successful endosomal escape<SupScrollLink label="69"/>{/* ehem3 */}<sup>,</sup><SupScrollLink label="62"/>{/* ehem4 */}.
If they cannot escape the endosome after entering the cells, there is a risk that the genetic material will be degraded in the lysosomes, limiting the
efficacy of the treatment. In addition, the formulation must minimize immunogenicity and toxicity, particularly with repeated dosing, which is often
necessary for chronic diseases<SupScrollLink label="68" />{/* ehem2 */}<sup>,</sup><SupScrollLink label="69"/>{/* ehem3 */}. Achieving this sensitive
balance is crucial for maximizing the therapeutic potential of LNPs
in gene delivery.</p>
<p>While these are general difficulties in the use of LNPs for gene therapy, further challenges arise when administering the LNPs via inhalation into the lungs,
due to the unique environment and anatomy of the respiratory system.</p>
<H4 text="Challenges of inhalated lung-specific LNPs" id="chall2" />
<p>These challenges range from formulation and particle size to overcoming biological barriers and maintaining consistent dosing, all of which
impact the overall efficacy of the therapy. </p>
<p>When transforming LNP formulations into inhalable particles, even greater attention must be paid to stability than is already the case. During
processes like nebulization or spray-drying, LNPs are exposed to strong <strong>mechanical stress</strong> such as shear forces during aerosolization
that can damage the LNP and thus their ability to protect and deliver genetic material effectively<SupScrollLink label="70"/>{/* ehem5 */}. Ensuring that the
LNPs maintain their structure throughout this transformation while remaining suitable for aerosol delivery is critical to the success of the therapy.</p>
<p>The <strong>size</strong> of the nanoparticles is another important factor. For successful lung delivery, LNPs should be smaller than 2
µm<SupScrollLink label="71" />{/* ehem6 */}. If the particles are too large, there is a risk that they will get stuck in the upper airways not able to reach the target cells; if they are too small, they may be exhaled before reaching the deeper lung tissue. The right particle size is crucial for the LNPs to reach the alveoli, where they can provide the greatest therapeutic impact.</p>
<p>Another major challenge is overcoming the lungs' natural <strong>protective barriers</strong>. The airways are lined with mucus and surfactants, which
help to defend against pathogens, but also make it difficult for LNPs to be transported. In diseases such as Cystic Fibrosis, the thickened mucus presents
an even greater obstacle, making it more difficult for the LNPs to reach the target cells<SupScrollLink label="70"/>{/* ehem5 */}.
The development of LNPs that can penetrate these barriers is essential for the success of gene therapy. </p>
<p>Finally, inhaled administration leads to fluctuations in the consistency of the <strong>dosage</strong>. Unlike intravenous administration, where
dosing can be strictly controlled, the results of inhalation are influenced by factors such as the patient's breathing pattern, lung capacity and
inhalation technique. These variables can affect how much of the LNP formulation actually reaches the lungs, complicating efforts to maintain a consistent
therapeutic dose over time, which is a reasonable price to pay when you consider that inhalation is a non-invasive form of therapy compared to systemic
therapy via injections into the bloodstream</p>
<p>All these challenges complicate the work with LNPs and present scientists with a great challenge, which makes working with LNPs even more important to
find solutions.</p>
</Collapsible>
<br />
<div id="airbuddy-hook" className='row align-items-center'>
<p>To optimize AirBuddy for pulmonary delivery, we collaborated extensively with several experts, including <a onClick={() => goToPagesAndOpenTab('weber', '/human-practices')}>Prof. Weber,
Dr. Große-Onnebrink</a> and <a onClick={() => goToPagesAndOpenTab('kolonkofirst', '/human-practices')}>Dr. Kolonko</a> as medical experts,
<a onClick={() => goToPagesAndOpenTab('kristian', '/human-practices')}>Prof. Dr. Müller</a>, <a onClick={() => goToPagesAndOpenTab('radukic', '/human-practices')}>Dr. Radukic</a>,
<a onClick={() => goToPagesAndOpenTab('moorlach', '/human-practices')}>Benjamin Moorlach</a> and the <a onClick={() => goToPagesAndOpenTab('biophysik', '/human-practices')}>Physical and Biophysical Chemistry working group</a>
as academic experts from Bielefeld University and FH Bielefeld as well as <a onClick={() => goToPagesAndOpenTab('corden', '/human-practices')}>Corden Pharma</a> and <a onClick={() => goToPagesAndOpenTab('rnhale', '/human-practices')}>RNhale</a> as industrial experts.
Throughout the <a onClick={() => goToPageWithTabAndScroll({ tabId: 'tab-delivery', path: '/engineering', scrollToId: "delivery-header" })}>development process</a>, we tested two commercially available kits: the
<strong>Cayman Chemical LNP Exploration Kit (LNP-102)</strong> and the <strong>Corden Pharma LNP Starter Kit #2</strong>. While the Cayman kit
showed good non-lung-specific transfection efficiency, the Corden Pharma formulation also proved not to be the right approach. Building on this,
we integrated the <strong>SORT LNP</strong> method based on Wang's research<SupScrollLink label="71" />{/* ehem1 */}, making our nanoparticles lung-specific.
Additionally, we employed the <strong>chitosan-complexation of the therapeutic cargo</strong> to improve the stability of our LNP, ensuring that it
withstands the inhalation process without degradation. Moreover, further stabilization approaches including the employment of the <strong>spray-drying
technique</strong> in cooperation with RNhale<SupScrollLink label="72" />{/* ehem2 */} are in the pipeline. This improved stability is crucial for the efficient
delivery of mRNA into lung epithelial cells, where PrimeGuide can effectively perform genome editing.</p>
<OneFigure
pic1="https://static.igem.wiki/teams/5247/delivery/big-plan-inhalation-teil-del.webp"
alt1=""
description="Schematic representation our LNP-based drug delivery system."
num="8"
/>
</div>
<p>To evaluate the <strong>delivery efficiency</strong>, we transfected HEK293 and CFBE41o- cells using fluorescent cargo and quantified the results
through flow cytometry analysis. We also ensured that AirBuddy meets the necessary standards for safety and efficacy since we conducted extensive
<a onClick={() => goToPageAndScroll('In-Depth Characterization of LNPsH', '/materials-methods')}> characterization of the LNPs </a>using physicochemical
techniques such as Zeta potential analysis, Dynamic Light Scattering (DLS), Scanning Electron Microscopy (SEM), and Cryogenic Electron Microscopy (cryo-EM).
These methods confirmed the stability and optimal size distribution of the nanoparticles. Furthermore, <strong>cytotoxicity assessments</strong>
including MTT and proliferation assays demonstrated that our LNPs are biocompatible despite the incorporation of <a onClick={() => goToPageWithTabAndCollapsible({ tabId: 'tab-delivery', path: '/engineering', collapseId: "Col1" })}>PEG</a>
and other ambivalent components. These findings reinforce AirBuddy's potential as a safe and effective tool for pulmonary delivery, with broad
implications for gene therapies targeting lung diseases.</p>
</Subesction>
</Section>
<Section title="Our Achievement" id="Our Achievement">
<p>We have successfully demonstrated a <b>proof of concept</b> for our gene therapy approach targeting Cystic Fibrosis. In initial experiments, HEK cells carrying a 3-base deletion analogous to the <i>F508del</i> mutation were transfected with our prime editing complex. The results met our expectations, confirming the viability of our approach for precise gene correction. Based on these findings, we optimized the prime editing complex, leading to the creation of <b>PrimeGuide</b>, a more compact and efficient editing tool. </p>
<p>Central to our <b>delivery system</b> is <b>AirBuddy</b>, a lung-specific lipid nanoparticle designed to stabilize and protect the prime editing complex during transport to lung epithelial cells. <b>AirBuddy</b> ensures that the protein complex is delivered specifically to lung cells, enhancing the efficiency of the gene-editing process. By modifying the lipid nanoparticle with protective features, we achieved increased stability, ensuring effective delivery to the target cells. </p>
<p>We further optimized the prime editing fusion protein, <b>PrimeGuide</b>, to streamline its components, resulting in a smaller and more efficient prime editing complex. This improvement significantly enhances the precision of the gene editing process, reducing off-target effects and increasing the overall success of mutation correction. </p>
<p>In subsequent experiments, <b>HEK293 and CFBE41o- cells</b> carrying the CFTR <i>F508del</i> mutation were successfully <b>transfected</b> with the optimized prime editing complex. Our results indicated successful correction of the mutation, confirming the potential of our approach for treating Cystic Fibrosis. </p>
<p>Additionally, we explored <b>downstream applications</b>. Primary cell cultures were treated with lipid nanoparticles to introduce a reporter RNA and Patch Clamp measurements were explored as a validation method.</p>
</Section>
<Section title="Our Vision" id="Our Vision">
<p>At <b>PreCyse</b>, we envision a future where gene therapy for Cystic Fibrosis (CF) is as simple and user-friendly as using an inhaler. Our goal is to develop a fully integrated Prime Editing system, <b>PrimeGuide</b>, delivered via a cutting-edge lipid nanoparticle (LNP) platform, <b>AirBuddy</b>. The therapy would allow patients to inhale the therapeutic complex, targeting the underlying genetic mutation that causes CF—specifically, the F508del mutation in the CFTR gene. </p>
<p>The core of our vision is to create a highly efficient and safe Prime Editing complex, referred to as Prime Guide, that is delivered directly into lung epithelial cells. This complex will be packaged as mRNA into LNPs, with an optimal ratio of the Prime Editing components and its guide RNA (pegRNA). Once inside the cell, the mRNA will be translated, forming the active Prime Editing complex, which then translocates into the nucleus using nuclear localization sequences. There, the complex will precisely edit the genome to correct the F508del mutation. </p>
<p>To ensure safety, we are working on developing a robust mechanism that regulates the Prime Editing complex at the mRNA level. One concept we are exploring is using the XBP1 intron<SupScrollLink label="73" />{/* ehem96 */}, which responds to cellular stress signals. Additionally, in the future, we aim to develop more mutation-specific control mechanisms, such as RNA riboswitches that activate the editing complex only in the presence of the target mutation, offering an even greater level of precision and safety. </p>
<p>The long-term vision for PreCyse is to provide a gene therapy that can be administered through inhalation, much like an asthma spray. The patient would simply inhale the LNPs, which then deliver the therapeutic mRNA to the lungs. This approach offers a user-friendly and minimally invasive treatment that could suppress the symptoms of CF for several months. By correcting the mutation in the top layers of lung epithelial cells, where mucus buildup is most problematic, we could offer relief from symptoms over an extended period. However, since these epithelial cells naturally regenerate over time, the therapy would need to be reapplied periodically, likely every few months, balancing long-lasting effects with the need for occasional re-administration. </p>
<p>Ultimately, our vision is to create a therapeutic approach that not only offers a cure that is safe and efficient but also maximizes convenience for the patient. With an easy-to-use inhaler, patients could administer their treatment with minimal disruption to their daily lives, inhaling the gene therapy in just a few breaths, leaving the rest of the process to the science we've built into PreCyse. By reducing the frequency of administration and simplifying the delivery method, we aim to make gene therapy for Cystic Fibrosis both accessible and practical for patients around the world. </p>
<OneFigure
pic1="https://static.igem.wiki/teams/5247/delivery/big-plan-inhalation-del-mech.webp"
num={9}
description="Illustration of our path from final product to prime editing in lung epithelial cells."
alt1="Illustration of our path from final product to prime editing in lung epithelial cells."
/>
</Section>
<Section title="References" id="References">
<DescSources />
</Section>
</div>
</div>
);
}
let medibuttonrowdata =[
let medibuttonrowdata = [
{
node: createDrugSteckbrief(drugdata[0]),
buttonname: "Modulators",
cssname: "Med-First",
main: true
},
{
node: createDrugSteckbrief(drugdata[1]),
buttonname: "Mucolytics",
cssname: "Mucolytics"
},
{
node: createDrugSteckbrief(drugdata[2]),
buttonname: "Antibiotics",
cssname: "Antibiotics"
},
{
node: createDrugSteckbrief(drugdata[3]),
buttonname: "Enzymes",
cssname: "Enzymes"
},
]
let symptombuttonrowdata = [
{
node: createSymptomSteckbrief(symptomdata[0]),
buttonname: "Pancreas",
cssname: "Symp-First",
main: true
},
{
node: createSymptomSteckbrief(symptomdata[1]),
buttonname: "Intestines",
cssname: "intestines"
},
{
node: createSymptomSteckbrief(symptomdata[2]),
buttonname: "Liver",
cssname: "liver"
},
{
node: createSymptomSteckbrief(symptomdata[3]),
buttonname: "Sexual glands",
cssname: "Sexual glands"
},
{
node: createSymptomSteckbrief(symptomdata[4]),
buttonname: "Lungs",
cssname: "lungs"
},
{
node: createSymptomSteckbrief(symptomdata[5]),
buttonname: "Skeletal System",
cssname: "Skeletal System"
},
{
node: <div>About</div>,
buttonname: "About",
cssname: "First"
node: createSymptomSteckbrief(symptomdata[6]),
buttonname: "Skin",
cssname: "skin"
},
{
node: <h2>Modulators</h2>,
buttonname: "Modulators",
cssname: "modulators"
{
node: createSymptomSteckbrief(symptomdata[7]),
buttonname: "Nasal mucosa",
cssname: "Nasal mucosa"
},
{
node: <h2>Inhalations</h2>,
buttonname: "Inhalations",
cssname: "inhalations"
node: createSymptomSteckbrief(symptomdata[8]),
buttonname: "Brain",
cssname: "brain"
},
]
function createSymptomSteckbrief(data: SymptomDatensatz) {
let examplelist: JSX.Element[] = [];
for (let index = 0; index < data.introduction.length; index++) {
examplelist.push(
<li key={index}>{data.introduction[index]}</li>
)
}
return (
<div>
<H4 id={`${data.name}-btn`} text={data.name} />
<div className="row">
<div className="col-2">
<div className="symptom-img-wrapper">
<img src={data.picture} className="symptom-img" />
</div>
</div>
<div className="col">
<ul>{examplelist}</ul>
</div>
</div>
</div>
)
}
function createDrugSteckbrief(data: DrugDatensatz) {
let examplelist: JSX.Element[] = [];
for (let index = 0; index < data.examples.length; index++) {
let absaetze: JSX.Element[] = []
for (let i = 0; i < data.examples[index].text.length; i++) {
absaetze.push(
<li key={i}>{data.examples[index].text[i]}</li>
)
}
examplelist.push(
<div key={index + 500} className="drug">
<H4 text={data.examples[index].title} />
<ul key={index}>{absaetze}</ul>
</div>
)
}
return (
<div>
<H4 id={`${data.name}-btn`} text={data.name} />
<div className="row">
<div className="col-2">
<div className="symptom-img-wrapper">
<img src={data.picture} className="symptom-img" />
</div>
</div>
<div className="col">
{data.introduction}
</div>
</div>
<div className="col">
{examplelist}
</div>
</div>
)
}
\ No newline at end of file
src/contents/design.tsx deleted 100644 → 0
View file @ 5f3933d7
import { useEffect } from "react";
import { useLocation } from "react-router-dom";
import { openFromOtherPage } from "../components/Buttons";
export function Design() {
const location = useLocation();
useEffect(() => {
const params = new URLSearchParams(location.search);
const collapseId = params.get('collapseId');
const tabId = params.get('tab');
// Scroll to the section specified by collapseId
if (collapseId) {
const collapseElement = document.getElementById(collapseId);
if (collapseElement) {
const elementTop = collapseElement.getBoundingClientRect().top + window.pageYOffset;
const offset = window.innerHeight / 2 - collapseElement.offsetHeight / 2;
const scrollPosition = elementTop - offset;
window.scrollTo({
top: scrollPosition,
behavior: 'smooth',
});
}
}
// Open the tab specified by tabId
if (tabId) {
openFromOtherPage(tabId)({ currentTarget: document.getElementById(tabId)! });
}
}, [location.search]);
return (
<>
<div className="row mt-4">
<div className="col-lg-8">
</div>
</div>
</>
);
}
\ No newline at end of file